<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10468591</article-id><article-id pub-id-type="pmcid-ver">PMC10468591.1</article-id><article-id pub-id-type="pmcaid">10468591</article-id><article-id pub-id-type="pmcaiid">10468591</article-id><article-id pub-id-type="pmid">37662903</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1221008</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Cell-targeted vaccines: implications for adaptive immunity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ung</surname><given-names initials="T">Trevor</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2335603"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rutledge</surname><given-names initials="NS">Nakisha S.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiss</surname><given-names initials="AM">Adam M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2391990"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Esser-Kahn</surname><given-names initials="AP">Aaron P.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/846968"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Deak</surname><given-names initials="P">Peter</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2230557"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Pritzker School of Molecular Engineering, University of Chicago</institution>, <addr-line>Chicago, IL</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Chemical and Biological Engineering Department, Drexel University</institution>, <addr-line>Philadelphia, PA</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Ali M Harandi, University of Gothenburg, Sweden</p></fn><fn fn-type="edited-by"><p>Reviewed by: Manfred B. Lutz, Julius Maximilian University of W&#252;rzburg, Germany; Lukas Heger, University Hospital Erlangen, Germany</p></fn><corresp id="fn001">*Correspondence: Peter Deak, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:pd562@drexel.edu">pd562@drexel.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427662</issue-id><elocation-id>1221008</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-09-05 19:25:18.067"><day>05</day><month>09</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Ung, Rutledge, Weiss, Esser-Kahn and Deak</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ung, Rutledge, Weiss, Esser-Kahn and Deak</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-14-1221008.pdf"/><abstract><p>Recent advancements in immunology and chemistry have facilitated advancements in targeted vaccine technology. Targeting specific cell types, tissue locations, or receptors can allow for modulation of the adaptive immune response to vaccines. This review provides an overview of cellular targets of vaccines, suggests methods of targeting and downstream effects on immune responses, and summarizes general trends in the literature. Understanding the relationships between vaccine targets and subsequent adaptive immune responses is critical for effective vaccine design. This knowledge could facilitate design of more effective, disease-specialized vaccines.</p></abstract><kwd-group><kwd>vaccine</kwd><kwd>innate immunity</kwd><kwd>targeted vaccines</kwd><kwd>cell targeting</kwd><kwd>adaptive immunity</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases
</institution><institution-id institution-id-type="doi">10.13039/100006492</institution-id></institution-wrap></funding-source></award-group><funding-statement>This work was supported by NIH T32 Fellowship, T32 AI153020 (PD and NR) and Margaret Q Landenberger Research Foundation Grant (PD).</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="306"/><page-count count="20"/><word-count count="11959"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Vaccines and Molecular Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Vaccines are one of the most valuable human health technologies in terms of lives saved. From Edward Jenner&#8217;s variolation experiments with cowpox in the 18<sup>th</sup> century, to Jonas Salk&#8217;s efforts to develop inactivated whole pathogen vaccines for polio, vaccine research has produced some of the most important medical breakthroughs in history. For a vaccine to stimulate an immune response against a specific pathogen, it must contain antigens related to that pathogen. First generation vaccines generally consist of live or attenuated/inactivated whole pathogens. Despite their historical success and widespread adoption, whole pathogen vaccines pose safety concerns as they contain extraneous and potentially harmful pathogen components. They may also replicate or revert to their pathogenic form (<xref rid="B1" ref-type="bibr">1</xref>). Subunit vaccines instead contain only the minimal components of the pathogen, such as a recombinant protein, required to stimulate an immune response. These technologies have improved the safety profile of vaccines (<xref rid="B2" ref-type="bibr">2</xref>). However, subunit vaccines are inherently less potent than whole pathogen vaccines at stimulating immune responses. Because of this limitation, they generally contain additional immunostimulatory molecules, known as adjuvants, to develop protective immunity (<xref rid="B2" ref-type="bibr">2</xref>). Other recent vaccine technologies include viral vector and nucleic acid-based vaccines, which encode for pathogenic antigens and induce antigen production in the cells of the vaccine recipient. In the case of viral vector vaccines, additional immune stimulation is provided through mimicry of natural infection, while in nucleic acid vaccines, innate immune stimulation is generated by components of the nucleic acid delivery system or by incorporation of additional adjuvants (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). These technologies have been employed against pathogens including the Zika virus, and more recently, SARS-CoV-2 (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p><p>A common feature of these emerging vaccine technologies is that they seek to improve and optimize immune responses through the choice of antigen or adjuvant, thereby tuning downstream adaptive immune responses. While the choice of antigen and adjuvant strongly influence the immune response, the type of cells that respond to, or are even targeted by the vaccine are critical to immune responses (<xref rid="B7" ref-type="bibr">7</xref>&#8211;<xref rid="B9" ref-type="bibr">9</xref>). This review will focus on this emerging role in vaccine research: the selective targeting of innate immune cells.</p><p>The immune system can be broadly separated into two categories: innate and adaptive immunity. Innate immune cells have evolved to recognize, bind, and capture pathogens. They play a crucial role in initiating the pathogen-specific immune response. Pathogen associated molecular patterns (PAMPs) are molecular motifs common to bacteria and viruses that bind to pattern recognition receptors (PRRs). PRRs are ubiquitously expressed on innate and other immune cell types (<xref rid="B8" ref-type="bibr">8</xref>). PAMP-PRR binding triggers inflammatory signaling, which typically results in pathogen phagocytosis, antigen presentation, and activation of innate immune cells (<xref rid="B10" ref-type="bibr">10</xref>). Vaccine adjuvants take advantage of this interaction, using PAMPs or mimicking their structure to mimic pathogen-associated immune activation in innate immune cells (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Innate immune cells that capture antigens and are activated by pathogens or adjuvants can be broadly classified as antigen-presenting cells (APCs). APCs serve as the bridge between innate and adaptive immune responses by processing antigens and presenting them to T cells. Presentation of pathogen-specific antigens to CD4<sup>+</sup> &#8220;helper&#8221; T cells in the presence of appropriate innate immune signaling (e.g. PRR activation) initiates an adaptive immune response. APCs and CD4<sup>+</sup> T cells further signal to na&#239;ve T cells and B cells, generating pathogen-specific CD8<sup>+</sup> &#8220;killer&#8221; T cells as well as B cell maturation and neutralizing antibody responses. The initialization of adaptive immunity is a critical function of innate immune cells, making them attractive targets for vaccines (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>The vaccine-induced adaptive immune response can vary widely based on the specific spatiotemporal patterns of PRR activation and innate immune stimulation. Several reviews have extensively commented on how the choice of adjuvant and PRR stimulation modulates the type of adaptive immune response (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). Broadly, adaptive immune responses can be categorized based on the CD4<sup>+</sup> T cell activity: conventional Th1, Th2, Th17 and T follicular helper (Tfh) cells, and regulatory T cell (Treg) subtypes (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>) (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). Each response profile can be characterized by distinct cytokines released from APCs and T cells, which in turn, modulate downstream cellular and humoral responses. Generally, Th1 responses, characterized by IFN-&#947; and IL-12 signaling, generate CD8<sup>+</sup> cytotoxic T cell responses and protect against intracellular pathogens (type 1 immunity). Th2 responses, characterized by IL-4, IL-5, and IL-13 signaling, generate antigen-specific antibodies, recruit granulocytes, and protect against parasites (type 2 immunity). Th17 responses, characterized by IL-17 signaling, generate inflammatory responses at mucosal membranes and protect against extracellular bacteria and fungi (type 3 immunity). Tfh cell responses, characterized by IL-21 signaling, assist and modulate the B cell response (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Treg responses are characterized by secretion of immunosuppressive factors such as TGF-&#946;, IL-10, and IL-35 (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Tregs limit immune responses towards antigens, such as self- and dietary antigens, to prevent autoimmunity and aberrant inflammatory responses, and also participate in the resolution of immune responses to pathogens (<xref rid="B20" ref-type="bibr">20</xref>). While Tregs can also be induced alongside conventional T cells during vaccination (<xref rid="B21" ref-type="bibr">21</xref>), the focus of this review is on the conventional T cell responses that are required for adaptive immunity towards pathogens. Specific responses are desired against different diseases &#8211; for example, in viral infections, a Th1 response is more favorable (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B22" ref-type="bibr">22</xref>). Thus, there is great interest in tuning T cell responses during vaccination. While refining adjuvant formulations can modulate cytokine production to exert a degree of control over CD4<sup>+</sup> T cell responses, this is still an emerging field of research (<xref rid="B23" ref-type="bibr">23</xref>). An additional and underutilized &#8220;lever&#8221; for controlling T cell responses to vaccines is modulating which innate immune cells act as APCs, capturing and presenting antigen to T cells (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Here we will discuss the types of innate immune cells that have been targeted, the targeting systems employed, and their downstream effect on adaptive immune responses (see <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S1</bold>
</xref> for comprehensive list of all targeting strategies referenced).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Summary of potential receptor targets for vaccines, the cells targeted and the potential variations in adaptive immune responses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1221008-g001.jpg"/></fig></sec><sec id="s2"><label>2</label><title>Innate immune cell subsets</title><p>The innate immune system can be broadly categorized into compartments based on their primary function: leukocyte killer cells, granulocytes, and phagocytic cells. Leukocyte killer cells, such as natural killer cells (NK cells), directly attack and lyse infected host cells, and are generally involved in viral infections and cancer (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Granulocytes such as neutrophils, basophils, mast cells, and eosinophils, contain large depots of cytotoxic molecules in granules that can be released into circulation upon activation, and are generally involved in parasitic and allergic responses (<xref rid="B28" ref-type="bibr">28</xref>). Phagocytic cells such as macrophages, monocytes, and dendritic cells, phagocytose pathogens and present them to na&#239;ve T cells to initialize an adaptive immune response (<xref rid="B29" ref-type="bibr">29</xref>). While each subset may be involved in vaccine-induced immune responses, phagocytic cells are the primary focus of this review, as these are the primary APCs involved in T cell responses. Furthermore, phagocytic cells can also be classified into further subsets, which are discussed below.</p><sec id="s2_1"><label>2.1</label><title>Dendritic cells</title><p>Dendritic cells (DCs) present the most attractive target for vaccines due to their increased capabilities for antigen presentation, lymph node migration, and T cell stimulation, compared to other APCs (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Dendritic cells are canonically identified by their expression of the integrin CD11c and major histocompatibility complex class II (MHC II), as well as characteristic dendrite projections that appear when the cells are fully matured (<xref rid="B30" ref-type="bibr">30</xref>). DCs can be broadly classified based on their cell origin: conventional DCs (cDCs) arise from myeloid progenitor cells, plasmacytoid DCs (pDCs) have been reported to arise from both myeloid and lymphoid progenitors, and monocyte-derived DCs (moDCs) arise from monocytes after inflammatory stimulus (<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>). Additionally, human pDCs have limited expression of CD11c (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>). These subsets will be discussed specifically later in this review. In this section, we will only discuss strategies that broadly target all DCs.</p><p>Receptors that have been used for pan-DC targeting include CD11c, MHC II, CD40, GM-CSFR (CD116), and FLT3 (CD135) (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Here, &#8220;pan-DC&#8221; indicates a receptor has been used to target all DCs, but not necessarily for DC-specific targeting. Some of these receptors are expressed on other immune cells and are thus not DC-specific (e.g. macrophages may express CD11c and MHC II while B cells also express MHC II and CD40) (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). However, given the increased capacity of DCs for antigen presentation compared to other APCs (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>), vaccines targeting these markers have attributed the immunological outcomes to DC targeting. Several vaccines have targeted pan-DC markers to improve T cell responses. A CD11c-targeting DNA vaccine, which produces anti-CD11c single chain variable fragments (scFvs) fused to tumor-associated antigens, produced strong anti-tumor CD8<sup>+</sup> T cell responses in mice (<xref rid="B45" ref-type="bibr">45</xref>). Similarly, liposomes bearing anti-CD11c scFvs, and containing the model antigen ovalbumin (OVA) and either lipopolysaccharide (LPS) or IFN-&#947; as adjuvant, improved anti-tumor CD8<sup>+</sup> T cell responses and slowed progression of OVA-bearing tumors (<xref rid="B46" ref-type="bibr">46</xref>). CD11c can also be targeted using peptide ligands. A peptide derived from ICAM-4, a natural ligand for CD11c, has been used to target nanocarriers to DCs, but in the context of delivering tolerogenic compounds (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Other peptide ligands for pan-DC targeting can be generated by phage display, although the cell-specific targets may be unknown. Liu et&#160;al. generated DC-targeting peptides using phage display against splenic DCs (<xref rid="B49" ref-type="bibr">49</xref>). The resultant peptides were used to target silica-based nanoparticles containing OVA and cytosine phosphoguanine (CpG) to DCs, improving CD8<sup>+</sup> T cell responses against OVA-bearing tumors (<xref rid="B49" ref-type="bibr">49</xref>). Puth et&#160;al. used a similar phage display strategy against CD11c<sup>+</sup> cells (<xref rid="B50" ref-type="bibr">50</xref>). The resultant peptides were used to target a recombinant protein, consisting of tumor antigens and flagellin as an adjuvant, to DCs. This elicited strong anti-tumor T cell responses and slowed tumor progression (<xref rid="B50" ref-type="bibr">50</xref>). This indicates targeting antigen to DCs through CD11c can effectively produce antigen-specific CD8<sup>+</sup> T cells.</p><p>Cruz et&#160;al. compared immune responses between DC targeting with PLGA nanoparticles using two pan-DC markers, CD11c and CD40 (<xref rid="B51" ref-type="bibr">51</xref>). Anti-CD11c or anti-CD40 monoclonal antibodies (mAb) were adsorbed on PLGA nanoparticles containing OVA and two adjuvants, polyinosinic:polycytidylic acid (poly I:C), and resiquimod (R848). Both CD40- and CD11c-targeting nanoparticles improved CD8<sup>+</sup> T cell cytokine production and cytolytic activity to similar degrees, compared to non-targeting nanoparticles (<xref rid="B51" ref-type="bibr">51</xref>). However, Castro et&#160;al. compared the T cell responses after vaccination with OVA directly conjugated to anti-CD11c or anti-MHC II antigen-binding fragments (Fabs) (<xref rid="B52" ref-type="bibr">52</xref>). With Fab-antigen conjugates, CD11c targeting elicited better CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses compared to MHC II targeting (<xref rid="B52" ref-type="bibr">52</xref>). Taken together, this suggests that the magnitude of the T cell response can depend on the choice of pan-DC marker, but that the targeting method can reinforce or negate any differences observed by targeting one marker over the other.</p><p>Targeting pan-DC markers can also benefit antibody responses. Wang et&#160;al. immunized mice with hamster anti-mouse CD11c and goat anti-hamster secondary antibodies, generating immune complexes targeting CD11c (<xref rid="B53" ref-type="bibr">53</xref>). This strategy rapidly increased anti-goat IgG levels over time and improved anti-goat serum titers compared to an isotype control. A limitation of this study is that T cell responses were not tracked (<xref rid="B53" ref-type="bibr">53</xref>). Additionally, the formation of immune complexes is known to trigger phagocytosis and innate immune cell activation through the complement system, which is known to trigger antibody responses (<xref rid="B54" ref-type="bibr">54</xref>). Pugholm et&#160;al. showed that immunizing mice with rat anti-mouse CD11c antibodies alone increased anti-rat IgG production (<xref rid="B55" ref-type="bibr">55</xref>). This suggests CD11c targeting alone, even in the absence of immune complex formation, can contribute to an increase in antibody levels. Braathen et&#160;al. generated DNA vaccines which produced hemagglutinin (HA) from influenza fused to scFvs against CD11c, CD40, and MHC II (<xref rid="B56" ref-type="bibr">56</xref>). Targeting CD11c and MHC II produced the highest magnitude of IgG of all the pan-DC markers. A study from White et&#160;al. similarly showed that targeting <italic toggle="yes">via</italic> anti-CD11c or anti-CD40 Fabs markedly raised antibody titers compared to MHC II Fabs (<xref rid="B57" ref-type="bibr">57</xref>). Overall, targeting pan-DC markers increased overall antibody titers, and CD11c seems to elicit the highest magnitude of IgG. These studies did not assess T cell functionality, nor the epitope diversity or affinity of these antibodies. However, the choice of pan-DC marker could influence the IgG subclass produced. Braathen et&#160;al. showed that CD11c and MHC II targeting produced equal amounts of IgG1 and IgG2, while GM-CSFR targeting resulted in an IgG1-biased response, and CD40 or FLT3 targeting resulted in an IgG2-biased response (<xref rid="B56" ref-type="bibr">56</xref>). Since IgG1 and IgG2 are associated with Th2 and Th1 responses, respectively (<xref rid="B58" ref-type="bibr">58</xref>), this suggests that the choice of pan-DC targeting marker can influence the type of adaptive response.</p><p>DCs may also be broadly targeted <italic toggle="yes">via</italic> scavenger receptors, which recognize a broad range of ligands including both endogenous and pathogenic molecules, and are thus involved in homeostasis and immune responses (<xref rid="B59" ref-type="bibr">59</xref>). The scavenger receptor, CD206 (also known as mannose receptor (MR)), is a C-type lectin receptor (CLR) that recognizes pathogen glycoproteins, and is expressed on immature DCs (<xref rid="B60" ref-type="bibr">60</xref>&#8211;<xref rid="B63" ref-type="bibr">63</xref>). Wilson et&#160;al. designed a targeted glyco-adjuvant consisting of a random copolymer of mannose and TLR7 agonist (<xref rid="B64" ref-type="bibr">64</xref>). When conjugated to an antigen, the mannose allows delivery to DCs <italic toggle="yes">via</italic> CD206 and activation <italic toggle="yes">via</italic> TLR7. The glyco-adjuvant improved the magnitude of the antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cell response, as well as the magnitude and epitope coverage of the IgG response. CD206 has also been targeted <italic toggle="yes">via</italic> antigens conjugated to sulfated glycans, and Singh et&#160;al. showed that such targeting was able to induce both CD8<sup>+</sup> T cell responses and a Th1-skewed CD4<sup>+</sup> T cell response (<xref rid="B65" ref-type="bibr">65</xref>). He et&#160;al. showed that targeting of humanized CD206 with antigen-mAb conjugates in a transgenic mouse model also improved both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, demonstrating the ability to target human CD206 (<xref rid="B66" ref-type="bibr">66</xref>). However, in humans CD206 has only been observed on moDCs, limiting its use for human pan-DC targeting (<xref rid="B67" ref-type="bibr">67</xref>). Additionally, CD206 and other scavenger receptors that recognize glycosylated proteins are widely expressed on other innate immune cell subsets, including macrophages (<xref rid="B68" ref-type="bibr">68</xref>). While CD206 targeting may broadly benefit adaptive immune responses, the lack of selective targeting makes it difficult to attribute these outcomes to DCs.</p><p>Overall, targeting of pan-DC markers generally improves both cellular and humoral immunity in vaccination. The choice of targeting marker remains an understudied method by which specific adaptive immune responses may be generated. At present, it seems the choice of pan-DC target and its effect on adaptive immune bias are overshadowed by the model antigen studied, the delivery vehicle, and the presence, absence, or type of adjuvant. Furthermore, lack of specificity of the receptor should be considered. Receptors such as CD11c, CD206, CD40 and MHC II are also expressed on other innate immune subsets, such as macrophages and B cells, and thus off-target or additive effects of vaccines targeting these receptors should be studied.</p><sec id="s2_1_1"><label>2.1.1</label><title>Conventional dendritic cells</title><p>Conventional dendritic cells (cDCs) are the most common DC subset (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B69" ref-type="bibr">69</xref>). cDCs can be identified based on their location: lymphoid resident cDCs sample antigens through draining lymph, while peripheral cDCs traffic to lymph nodes after capturing antigen. Within lymphoid tissues, such as lymph nodes, they can then present antigen to and activate na&#239;ve T cells. As with all DCs, cDCs commonly express CD11c and MHC II, but these markers also arise in pDCs, and on macrophages at lower levels (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>CD24 and CD26 are potential pan-cDC surface targets, but are also present on a wide variety of immune and stromal cell types (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B75" ref-type="bibr">75</xref>). Antibody targeting of these receptors have been used in contexts outside vaccination, and could potentially enable a platform to target cDCs (<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B77" ref-type="bibr">77</xref>). However, given their expression in other tissues, they may not provide selective targeting of cDCs.</p><p>Other cDC markers are used to delineate the two subsets of cDCs, conventional type 1 and type 2 DCs (cDC1s and cDC2s). There are two important clarifications for cDC subtypes. First, while expression of transcription factors and surface molecules is a widely accepted method of classification, recent research has shown heterogeneity in these populations, especially during active infection (<xref rid="B78" ref-type="bibr">78</xref>). Furthermore, recent single cell sequencing studies suggest other categories of cDCs, particularly in humans, with nuanced lineages and functions (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>). As we are focusing on receptor targeting and consequences on downstream effector responses, rather than the intricacies of innate immune classification, here we will rely on established cDC1 and cDC2 markers and briefly overlook newer paradigms of classification for simplicity.</p><p>With regard to vaccine design; cDC1s and cDC2s function differently when activating T cells, making them potential targets for vaccines which can modulate T cell responses (<xref rid="B43" ref-type="bibr">43</xref>). In mice, cDC1s are generally associated with type 1 immune responses, including cross-presentation of exogenous or cell-associated antigen on major histocompatibility complex class I (MHC I). As a result, cDC1s primarily facilitate CD8<sup>+</sup> T cell responses and release Th1-biasing cytokines (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>). cDC2s are generally associated with type 2 and type 3 immune responses, including capturing soluble antigen. As a result, cDC2s primarily facilitate CD4<sup>+</sup> T cell and antibody responses (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B81" ref-type="bibr">81</xref>&#8211;<xref rid="B84" ref-type="bibr">84</xref>). However these delineations are less strict in human cDCs, and under certain conditions human cDC1s can facilitate type 2 immune responses, while conversely human cDC2s can facilitate CD8<sup>+</sup> T cell and type 1 immune responses (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>). The next sections will discuss cDC1 and cDC2 targeting in detail.</p><sec id="s2_1_1_1"><label>2.1.1.1</label><title>Conventional type 1 dendritic cells</title><p>cDC1s are typically identified by their expression of CD8&#945; in mice, and CD141 (BDCA3) in humans (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B87" ref-type="bibr">87</xref>). cDC1 targeted vaccines are often intended to invoke type 1 immune responses, particularly for the generation of antiviral or anti-tumor immunity (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B88" ref-type="bibr">88</xref>). Receptors that have been used for cDC1 targeting include XCR1, DEC-205 (CD205), Clec9a (DNGR1), Clec12a, Treml4, CD36, LOX1, and Fc&#947;R (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B88" ref-type="bibr">88</xref>&#8211;<xref rid="B105" ref-type="bibr">105</xref>).</p><p>XCR1 is a receptor for the chemokine XCL1, which plays a role in cDC1 recruitment (<xref rid="B106" ref-type="bibr">106</xref>). XCR1 has been targeted by DNA vaccines encoding XCL1-antigen fusion proteins. It has been shown to generate strong CD8<sup>+</sup> T cell responses, as well as Th1-biased CD4<sup>+</sup> T cell and IgG2 antibody responses against OVA and viral antigens (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B107" ref-type="bibr">107</xref>). DEC-205, Clec9a, and Clec12a are CLRs, which similar to CD206, broadly participate in pathogen recognition, endocytosis, and antigen uptake (<xref rid="B95" ref-type="bibr">95</xref>). T cell and antibody responses to CLR targeting are strongly dependent on the inflammatory context. Recombinant anti-DEC-205 and anti-Clec12a mAb-antigen conjugates have been shown to raise strong antigen-specific CD8<sup>+</sup> T cell responses in the presence of adjuvant or inflammation (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). DEC-205 targeting in human DCs also generates both antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses (<xref rid="B108" ref-type="bibr">108</xref>&#8211;<xref rid="B110" ref-type="bibr">110</xref>). Meixlsperger et&#160;al. showed that this response required maturation of CD141<sup>+</sup> DCs (<xref rid="B109" ref-type="bibr">109</xref>), a marker associated with cDC1s in humans. However, under steady state or low-inflammatory conditions, targeting DEC-205 and Clec12a raises weak or even tolerogenic responses (<xref rid="B93" ref-type="bibr">93</xref>&#8211;<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B97" ref-type="bibr">97</xref>). Additionally, DEC-205 and Clec12a are not entirely cDC1 specific. DEC-205 is also expressed at low levels on cDC2s in mice (<xref rid="B93" ref-type="bibr">93</xref>), but it is broadly expressed in DCs in humans (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B96" ref-type="bibr">96</xref>). Clec12a, meanwhile, is also expressed on pDCs in mice but broadly on DCs in humans (<xref rid="B97" ref-type="bibr">97</xref>). Thus, interpretation of the immune responses resulting from DEC-205 or Clec12a targeting can be confounded by adjuvant effects and differential specificity of these receptors for cDC1s between species.</p><p>The last CLR of interest for cDC1, Clec9a, has a high specificity for both mouse and human cDC1s (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>). Clec9a naturally binds F-actin-myosin complexes associated with dying cells, and its activation is associated with phagosomal rupture and cross-presentation of antigens to CD8<sup>+</sup> T cells (<xref rid="B113" ref-type="bibr">113</xref>). Studies comparing Clec9a and DEC-205 targeting in mice <italic toggle="yes">via</italic> mAb-antigen conjugates showed that despite raising similar CD8<sup>+</sup> T cell responses, Clec9a targeting induced better protection in an influenza challenge model (<xref rid="B93" ref-type="bibr">93</xref>). In addition, Clec9a targeting elicited antibody and Tfh responses in both mice and non-human primates (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). However, there are conflicting studies on whether or not adjuvant is required to produce Tfh and antibody responses resulting from Clec9a targeting (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B115" ref-type="bibr">115</xref>&#8211;<xref rid="B117" ref-type="bibr">117</xref>). In human DCs, Clec9a targeting was highly specific for CD141<sup>+</sup> DCs (<xref rid="B96" ref-type="bibr">96</xref>). Additionally, when Clec9a was targeted with tumor antigens and poly I:C as adjuvant, anti-tumor CD8<sup>+</sup> T cell responses were stronger than DEC-205 targeting (<xref rid="B96" ref-type="bibr">96</xref>). Taken together, Clec9a targeting of cDC1s has the potential to improve both cellular and humoral responses in vaccination, like targeting the pan-DC receptor CD11c.</p><p>Several other non-CLR scavenger receptors have been targeted on cDC1s. TREML4 is a receptor that mediates uptake of apoptotic or necrotic cells, and is primarily associated with cDC1s (<xref rid="B89" ref-type="bibr">89</xref>). Anti-TREML4 mAb-antigen conjugates can generate antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cell immunity to tumor and viral antigens (<xref rid="B90" ref-type="bibr">90</xref>), or antigen-specific tolerance (<xref rid="B91" ref-type="bibr">91</xref>), when targeted in the presence or absence of external adjuvant. CD36 is a scavenger receptor that has high specificity for mouse CD8&#945;<sup>+</sup> DCs (<xref rid="B98" ref-type="bibr">98</xref>). In a comparative study between anti-CD36 and anti-DEC-205 scFv-antigen conjugates, CD36 targeting was able to induce CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, even in the absence of adjuvant (<xref rid="B98" ref-type="bibr">98</xref>). LOX1 is another scavenger receptor that recognizes heat shock proteins (Hsp), is involved in cross presentation, and has high specificity for CD8&#945;<sup>+</sup> DCs (<xref rid="B102" ref-type="bibr">102</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B118" ref-type="bibr">118</xref>). LOX1 targeting <italic toggle="yes">via</italic> antigen fused to anti-LOX1 mAbs or Hsp-60 induced strong CD8<sup>+</sup> T cell responses, and to a lesser extent, CD4<sup>+</sup> T cell responses (<xref rid="B102" ref-type="bibr">102</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B118" ref-type="bibr">118</xref>). Altogether, while these studies show that TREML4, CD36, and LOX1 are potential cDC1 targets and can raise both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses after vaccination, bias towards Th1 or Th2 responses generated by activation of these receptors is unclear or understudied. Comparing vaccines targeting these receptors to other targets such as XCR1, with a more well-defined Th1 bias, could help evaluate if targeting these receptors can induce a bias towards type 1 or type 2 immune responses.</p><p>Another family of receptors that have been used to target cDC1s is the Fc-gamma receptor (Fc&#947;R). It is important to consider the differences between murine and human Fc&#947;Rs, as well as the fact that Fc&#947;R isoforms have activating or inhibitory downstream signaling (<xref rid="B119" ref-type="bibr">119</xref>&#8211;<xref rid="B122" ref-type="bibr">122</xref>). Activating isoforms contain immunoreceptor tyrosine-based activation motifs (ITAMs) while inhibitory isoforms contain immunoreceptor tyrosine-based inhibition motifs (ITIMs) (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Murine DCs express the activating isoforms Fc&#947;RI, Fc&#947;RIII, Fc&#947;RIV, and the inhibitory isoform Fc&#947;RIIb, while human DCs express the activating isoforms Fc&#947;RI, Fc&#947;RIIa/c, and the inhibitory isoform Fc&#947;RIIb (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B121" ref-type="bibr">121</xref>). Fc&#947;RIV is not found in human DCs, while Fc&#947;RIIa/c are not found in murine DCs (<xref rid="B121" ref-type="bibr">121</xref>). These species-specific isoforms are preferentially expressed by cDCs both in mice and humans (<xref rid="B119" ref-type="bibr">119</xref>). Lehmann et&#160;al. showed that mAb-antigen conjugates targeting Fc&#947;RIIb, Fc&#947;RIII, and Fc&#947;RIV on murine DCs were preferentially taken up by CD8&#945;<sup>+</sup> DCs compared to CD8&#945;<sup>-</sup> DCs, suggesting some cDC1 targeting ability (<xref rid="B105" ref-type="bibr">105</xref>). However, the shared expression of these isoforms with cDC2s and pDCs may limit cDC1-specific targeting, and Fc&#947;RIIb has also been used to target murine pDCs (which will be discussed in a later section). Lehmann et&#160;al. observed CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses when targeting both Fc&#947;RIV and Fc&#947;RIIb (<xref rid="B105" ref-type="bibr">105</xref>). However, long-lasting T cell responses were dependent on the presence of adjuvant rather than the isoform targeted, suggesting targeting of activating or inhibitory isoforms alone has minimal effect. Additionally, CD8<sup>+</sup> T cell responses were only induced by CD8&#945;<sup>+</sup> DCs while CD4<sup>+</sup> T cell responses were induced primarily by CD8&#945;<sup>-</sup> DCs. Similarly, Flinsenberg et&#160;al. used IgG-coupled antigen to broadly target Fc&#947;R on human DCs, and showed that while cDC2s took up more antigen, cDC1s generated a stronger CD8<sup>+</sup> T cell response, likely due to the increased capability of cDC1s for cross-presentation (<xref rid="B101" ref-type="bibr">101</xref>). While this suggests Fc&#947;R targeting can improve CD8<sup>+</sup> T cell responses, the lack of Fc&#947;R specificity for cDC1s should be considered, as well as any adjuvant effects.</p><p>cDC1s have often been targeted for their cross-presenting capabilities and to raise type 1 immune responses. Receptors with clear specificity for cDC1s, such as XCR1, have been associated with strong effector T cell response against viral antigens and tumors (<xref rid="B123" ref-type="bibr">123</xref>). Alternatively, markers with less clear selectivity for cDC1 show increased type 1 immune responses, but less clear type 1 bias, which may be a result of the lack of receptor selectivity. This hypothesis is further supported by the fact that cDC1s show strong MHC I and cross-presentation of exogenous antigen, facilitating formation of type 1 responses (<xref rid="B124" ref-type="bibr">124</xref>). Yu et&#160;al. have reported that human lung cDC1s are able to generate type 2 immune responses (<xref rid="B85" ref-type="bibr">85</xref>). However, this may be tissue-dependent, as the responses were dependent on induction of OX40L on cDC1s by the epithelial cytokine TSLP (<xref rid="B85" ref-type="bibr">85</xref>). Overall, it is likely that targeting cDC1 takes advantage of this cross-presentation and therefore is more suitable for generating anti-viral and anti-tumoral type 1 skewed immune responses.</p></sec><sec id="s2_1_1_2"><label>2.1.1.2</label><title>Conventional type 2 dendritic cells</title><p>cDC2s are typically identified by expression of CD11b and lack of CD8&#945; in mice, or by CD1c (BDCA1) in humans, while CD172a (SIRP&#945;) is used as a marker for both humans and mice (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Receptors that have been used for cDC2 targeting include DCIR (Clec4a), GM-CSFR (CD116), CCR1/3/5, TLR5, Dectin-1 (Clec7a), Dectin-2 (Clec6a), DC-SIGN (CIRE/CD209), FIRE, and MGL (Clec10a/CD301) (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B125" ref-type="bibr">125</xref>&#8211;<xref rid="B134" ref-type="bibr">134</xref>).</p><p>While there are 4 murine isoforms of the CLR DCIR (DCIR1-4), the isoform DCIR2 is found specifically on CD8&#945;<sup>-</sup> cDCs and is the most specific receptor for mouse cDC2s (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B125" ref-type="bibr">125</xref>&#8211;<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B135" ref-type="bibr">135</xref>&#8211;<xref rid="B138" ref-type="bibr">138</xref>). Anti-DCIR2 mAb-conjugates preferentially induced antigen presentation on MHC II, CD4<sup>+</sup> T cell activation, and antibody generation, particularly in comparison to cDC1-targeting anti-DEC-205 mAb-conjugates (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B130" ref-type="bibr">130</xref>). However, these responses were highly dependent on the presence of an adjuvant or inflammatory stimulus (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B128" ref-type="bibr">128</xref>). Surprisingly, DCIR2 targeting induced both CD8<sup>+</sup> T cell responses and IgG2 production, and induced equal protection in a tumor challenge model compared to DEC-205 targeting (<xref rid="B128" ref-type="bibr">128</xref>). This suggests that, while cDC2s are generally associated with CD4<sup>+</sup> T cell and antibody responses, they can also participate in type 1 immune responses. Humans express a single DCIR isoform with closest homology to murine DCIR1 and DCIR2 (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Klechevsky et&#160;al. showed that targeting of DCIR <italic toggle="yes">via</italic> mAb-antigen conjugates efficiently induced cross-presentation in human DCs and generation of CD8<sup>+</sup> T cell responses, with and without adjuvant (<xref rid="B139" ref-type="bibr">139</xref>). However, DCIR is broadly present on human DC subtypes including pDCs (<xref rid="B136" ref-type="bibr">136</xref>&#8211;<xref rid="B139" ref-type="bibr">139</xref>), limiting the ability of DCIR to be considered a cDC2-specific target in humans. An additional consideration for vaccine targeting <italic toggle="yes">via</italic> DCIR is that both mouse and human DCIR contain ITIM domains, and targeting DCIR in the absence of adjuvant has been used to elicit tolerogenic responses (<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). Despite this, the work done by Lehmann et&#160;al. targeting activating and inhibitory isoforms of Fc&#947;R and the work by Klechevsky et&#160;al. targeting DCIR altogether suggest that targeting ITIM-containing receptors will not necessarily lead to inhibition of immune responses, but instead may depend on whether or not targeting occurs in an inflammatory or steady-state context (<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B139" ref-type="bibr">139</xref>).</p><p>Braathen et&#160;al. and Lys&#233;n et&#160;al. compared the effect of cDC2 targeting through DNA vaccines expressing recombinant proteins with antigen and GM-CSF, CCL3-HA, or flagellin (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B129" ref-type="bibr">129</xref>). GM-CSFR is a receptor for GM-CSF, a cytokine which participates in DC differentiation (<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B143" ref-type="bibr">143</xref>). CCL3 is a ligand for CCR1/3/5, which are expressed widely on DCs, including cDC2s (<xref rid="B129" ref-type="bibr">129</xref>). TLR5 is a receptor that recognizes flagellin, which is preferentially expressed on CD11b<sup>+</sup> DCs compared to other APCs (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B145" ref-type="bibr">145</xref>). In a standard subcutaneous or intramuscular vaccination, it could be argued that the flagellin fusion proteins preferentially target cDC2s given the limited TLR5 expression in major APC subsets that reside in these tissues (<xref rid="B144" ref-type="bibr">144</xref>). Likewise, while GM-CSFR and CCR1/3/5 are also not specific to cDC2s, fusion proteins targeting antigens to these receptors preferentially bound cDC2s for all constructs, suggesting some cDC2 targeting ability (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B129" ref-type="bibr">129</xref>). More interesting is the downstream effect of GM-CSFR and CCR1/3/5 targeting; each fusion protein influenced the IgG subclass, with GM-CSF producing an IgG1 bias, CCL3 producing an IgG2 bias, and flagellin producing equal IgG1 and IgG2 (<xref rid="B56" ref-type="bibr">56</xref>). While it is tempting to conclude that both type 1 and type 2 immune responses can be generated by targeting cDC2s expressing these receptors, the lack of specificity for cDC2 should be considered, as both TLR5 and CCR1/3/5 are upregulated in, but not limited to, cDC2s.</p><p>Dectin-1 and Dectin-2 are CLRs which are commonly associated with CD8&#945;<sup>-</sup> and CD1c<sup>+</sup> DCs, suggesting cDC2 expression in mice and humans (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B146" ref-type="bibr">146</xref>). In mice, subcutaneous vaccinations where Dectin-1 or Dectin-2 mAbs were conjugated to antigens and formulated with poly I:C as adjuvant resulted in equal CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>). Meanwhile, when Dectin-1 was targeted <italic toggle="yes">via</italic> intravenous vaccination, a CD4<sup>+</sup> T cell response was generated instead (<xref rid="B131" ref-type="bibr">131</xref>). Carter et&#160;al. hypothesized that the balanced CD8<sup>+</sup> and CD4<sup>+</sup> T cell response was due to Langerhans cells, APCs that reside in the skin which express both Dectin-1 and DEC-205 (<xref rid="B146" ref-type="bibr">146</xref>). They suggested that during subcutaneous vaccination, Langerhans cells captured and presented antigen to both CD8<sup>+</sup> and CD4<sup>+</sup> T cells, while during intravenous administration, Dectin-1 expressing cDC2s preferentially captured and presented antigen to CD4<sup>+</sup> T cells (<xref rid="B131" ref-type="bibr">131</xref>). In humans, Lundberg et&#160;al. reported a larger proportion of CD141<sup>+</sup> DCs expressing Dectin-1 and Dectin-2 compared to CD1c<sup>+</sup> DCs, suggesting Dectin-1 and Dectin-2 may be more highly expressed on human cDC1s (<xref rid="B147" ref-type="bibr">147</xref>). A caveat of this study is that the DCs studied were isolated from peripheral blood of mostly allergic patients, although expression patterns of Dectin-1 and Dectin-2 did not vary significantly between allergic and healthy patients (<xref rid="B147" ref-type="bibr">147</xref>). Additionally, while this study was performed on human DCs, the work by Lundberg et&#160;al. and Carter et&#160;al. highlight the difficulty of identifying cDC2-specific receptors in humans and mice, and subsequent interpretation of the effects on downstream immune responses. Pugholm et&#160;al. showed that targeting of Dectin-1 and Dectin-2 could also raise antibody responses in the absence of adjuvant (<xref rid="B55" ref-type="bibr">55</xref>). These results are consistent with pan-DC targeting strategies that raised antibody responses, as well as the ability of adjuvants to raise robust humoral and cellular immunity.</p><p>DC-SIGN is another CLR commonly found on CD8&#945;<sup>-</sup> and CD11b<sup>+</sup> DCs in mice, suggesting preferential expression on cDC2s (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>). Corbett et&#160;al. immunized mice with rat anti-mouse DC-SIGN (mDC-SIGN) antibodies and showed significantly increased anti-rat IgG even in the absence of adjuvant (<xref rid="B133" ref-type="bibr">133</xref>). Schetters et&#160;al. further showed that targeting mDC-SIGN <italic toggle="yes">via</italic> mAb-antigen conjugates in the presence of adjuvant could also generate CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, consistent with previous studies targeting Dectin-1 and Dectin-2 (<xref rid="B134" ref-type="bibr">134</xref>). The targeted portion of the mDC-SIGN receptor may also play a role in determining T cell responses, as Tacken et&#160;al. showed that antibodies targeting the neck region of mDC-SIGN, rather than the carbohydrate recognition domain which is common to all CLRs, improved DC cross-presentation (<xref rid="B148" ref-type="bibr">148</xref>). The putative human analog of mDC-SIGN, hDC-SIGN, has only been observed on moDCs but not human peripheral DCs (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B149" ref-type="bibr">149</xref>), suggesting hDC-SIGN may not be useful for cDC2-specific targeting in humans. FIRE (F4/80-like receptor) is a surface glycoprotein that is found on CD8&#945;<sup>-</sup> DCs in mice, but its functions are not currently known (<xref rid="B150" ref-type="bibr">150</xref>). Corbett et&#160;al. showed that similar to mDC-SIGN, immunizing mice with rat anti-FIRE antibodies significantly raised anti-rat IgG in the absence of adjuvant (<xref rid="B133" ref-type="bibr">133</xref>), indicating similar downstream functions as DC-SIGN targeting; however further research is required to fully investigate these claims.</p><p>MGL (macrophage galactose-type lectin) is an additional CLR found on DCs and macrophages in both mice and humans, which is preferential to cDC2 (<xref rid="B151" ref-type="bibr">151</xref>&#8211;<xref rid="B154" ref-type="bibr">154</xref>). Two isoforms exist in mice; the isoform MGL1 (CD301a) is found on macrophages while the isoform MGL2 (CD301b) is found on CD8&#945;<sup>-</sup> cDCs (<xref rid="B153" ref-type="bibr">153</xref>&#8211;<xref rid="B155" ref-type="bibr">155</xref>). Humans express a single isoform of MGL that is most homologous to MGL2, and is found primarily on CD1c<sup>+</sup> DCs, suggesting MGL is a potential target for cDC2s (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B155" ref-type="bibr">155</xref>). Although to date, no studies have targeted MGL in vaccination, Heger et&#160;al. and Eggink et&#160;al. generated targeting peptides for MGL based off the endogenous ligand MUC-1, or identified <italic toggle="yes">via</italic> phage display (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B155" ref-type="bibr">155</xref>). Heger et&#160;al. showed that a glycosylated MUC-1 peptide preferentially bound human cDC2s <italic toggle="yes">in vitro</italic> (<xref rid="B153" ref-type="bibr">153</xref>). Heger et&#160;al. also noted that administration of the MUC-1 peptide enhanced DC cytokine secretion in combination with the adjuvant R848, consistent with previous reports that ligation of MGL augments TLR-induced DC cytokine secretion (<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B153" ref-type="bibr">153</xref>). While Eggink et&#160;al. did not assess the targeting ability of their MGL-targeting peptides, they similarly showed that MGL-targeting peptides induced DC maturation and cytokine secretion in human DCs and modestly improved survival in tumor-bearing mice (<xref rid="B155" ref-type="bibr">155</xref>). Together, these studies suggest that not only is MGL a potential cDC2-specific target, but that targeting of MGL alone or in the presence of adjuvant can benefit vaccine responses and warrants further investigation.</p><p>Vaccines targeting cDC2s generate a breadth of responses, in contrast to cDC1 targeting. Depending on the targeted receptor, type 1- or type 2-skewed immune responses have been observed. In some cases, even tolerogenic responses have been observed, when cDC2s were targeted <italic toggle="yes">via</italic> DCIR2 in the absence of adjuvant (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). Additionally, Bourdely et&#160;al. showed that human CD1c<sup>+</sup> DCs could prime CD8<sup>+</sup> T cells. CD1c normally marks cDC2s in humans, suggesting that cDC2s can also raise type 1 immune responses. However, these cells also expressed CD163 and were proposed to be a new subset of DCs, as they also expressed monocyte markers (<xref rid="B86" ref-type="bibr">86</xref>). Indeed, a complicating factor is that the markers for cDC2 are much more widely expressed on other innate immune cells, limiting the selectivity of cDC2 targeting. Therefore, it is unknown if the variety of responses are due to poor receptor selectivity, or intrinsic to cDC2 targeting. With that said, the data provided herein provide compelling evidence that targeting cDC2-related receptors can generate enhanced antibody and type 2 immune responses compared to cDC1 targeting.</p></sec></sec><sec id="s2_1_2"><label>2.1.2</label><title>Plasmacytoid dendritic cells</title><p>pDCs are a small subset of DCs that circulate through the blood and are specialized for viral recognition and response. They express TLRs which recognize foreign nucleic acid, such as TLR7 and TLR9, and rapidly secrete type I and type III interferons (IFNs) in response to infection (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>). pDCs are typically identified by expression of B220 (CD45R), Ly6C, Siglec-H, and BST2 (CD317) in mice, BDCA2 (CD303), BDCA4 (CD304), and CD123 (IL-3R) in humans, and CD45RA in both (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Receptors that have been used for pDC targeting include PDC-TREM, Siglec-H, BST2, DEC-205, DCIR, BDCA2, and Fc&#947;RII (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B158" ref-type="bibr">158</xref>&#8211;<xref rid="B164" ref-type="bibr">164</xref>).</p><p>The main pDC receptors studied for targeted vaccination are PDC-TREM, Siglec-H, and BST2. PDC-TREM is a pDC-specific receptor that triggers type I IFN production (<xref rid="B165" ref-type="bibr">165</xref>). Siglec-H is a pDC-specific receptor that functions as an endocytic receptor, but unlike other receptors in the Siglec family, it does not bind sialic acids (<xref rid="B162" ref-type="bibr">162</xref>). Pugholm et&#160;al. showed that immunization with rat anti-PDC-TREM without adjuvant was able to raise anti-rat IgG, while anti-Siglec-H was unable to raise an antibody response (<xref rid="B55" ref-type="bibr">55</xref>). Targeting of Siglec-H by mAb-antigen conjugates without adjuvant led to a tolerogenic CD4<sup>+</sup> T cell response (<xref rid="B163" ref-type="bibr">163</xref>), but in the presence of adjuvant a CD8<sup>+</sup> T cell response was generated (<xref rid="B162" ref-type="bibr">162</xref>). BST2 is a receptor that prevents virion dissemination by binding virion lipid membranes (<xref rid="B166" ref-type="bibr">166</xref>). BST2 identifies pDCs under homeostatic conditions, but is upregulated on most cells during viral infection and inflammation (<xref rid="B167" ref-type="bibr">167</xref>). Similarly, targeting of BST2 by mAb-antigen conjugates in the presence of adjuvant generated a CD8<sup>+</sup> T cell response and IgG2 production, suggesting a Th1 response (<xref rid="B164" ref-type="bibr">164</xref>). However, CD8<sup>+</sup> T cell responses from pDC targeting is thought to occur through antigen transfer to cDC1s and not directly from pDC-T cell interactions (<xref rid="B168" ref-type="bibr">168</xref>). Taken together, this suggests that while PDC-TREM targeting can raise antibody responses without adjuvant, Siglec-H and BST2 targeting require adjuvant and potentially other DC subsets to generate humoral and T cell responses.</p><p>Due to their availability in blood, pDCs are more extensively studied in humans than other DC subsets. Human pDCs have been targeted <italic toggle="yes">via</italic> DEC-205, DCIR, BDCA-2, and Fc&#947;RII (<xref rid="B158" ref-type="bibr">158</xref>&#8211;<xref rid="B161" ref-type="bibr">161</xref>). Tel et&#160;al. demonstrated that when PLGA nanoparticles containing OVA and R848 were targeted to pDCs <italic toggle="yes">via</italic> these receptors, CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses were generated (<xref rid="B158" ref-type="bibr">158</xref>). Human pDC-generated immune responses are likely dependent on the presence of adjuvant, as targeting and ligation of DCIR and BDCA2 alone can suppress DC activation (<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>). To this end, Sepulveda-Toepfer et&#160;al. generated an &#945;Fc&#947;RII-CpG conjugate that was shown to target and activate human pDCs (<xref rid="B161" ref-type="bibr">161</xref>); however, its efficacy in a vaccine formulation has yet to be assessed. Additionally, the presence of Fc&#947;RII on other immune cells such as cDC1s and its previous use as a cDC1 target, as well as the activating and inhibitory isoforms of this receptor, should be considered (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B119" ref-type="bibr">119</xref>&#8211;<xref rid="B122" ref-type="bibr">122</xref>). Overall, the literature indicates that targeting pDCs can generate type 1 immune responses, but the response can vary depending on the targeted receptor and on the presence of adjuvant. More research is required to fully establish the effects of pDC targeting during vaccination.</p></sec><sec id="s2_1_3"><label>2.1.3</label><title>Other DC subsets</title><p>Formulations administered <italic toggle="yes">via</italic> subcutaneous and intramuscular injection routes will encounter other types of cDCs that should be considered in the design of effective vaccines. Under steady state conditions, cDCs can be further classified into tissue resident and migratory subsets. This classification is determined on if they primarily reside in local tissue environments or are primed to sample antigens from local tissues and migrate to nearby lymphoid tissues (<xref rid="B69" ref-type="bibr">69</xref>). DC phenotypes can further vary by tissue location, such as lung and intestinal DCs. The classification and functions of these tissue-resident DCs have been reviewed extensively elsewhere (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B169" ref-type="bibr">169</xref>&#8211;<xref rid="B172" ref-type="bibr">172</xref>); this review is focused on APCs in lymphoid tissues. In lymphoid tissues, migratory cDCs express more DC maturation markers, and have higher levels of MHC II and lower levels of CD11c compared to resident cDCs under homeostatic conditions (<xref rid="B31" ref-type="bibr">31</xref>). However, under inflammatory conditions, where both resident and migratory DCs will mature, this classification no longer holds (<xref rid="B31" ref-type="bibr">31</xref>). Instead, lymphoid resident and migratory cDC1s can be identified by expression of CD8&#945; or CD103, respectively (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Semmrich et&#160;al. showed that targeting CD103<sup>+</sup> DCs <italic toggle="yes">via</italic> mAb-antigen conjugates raised both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses in the presence of adjuvant (<xref rid="B173" ref-type="bibr">173</xref>). In the absence of adjuvant, a tolerogenic response resulted (<xref rid="B173" ref-type="bibr">173</xref>). CD103 is an integrin that plays a role in tissue residence for a wide variety of cell types, including T cells (<xref rid="B174" ref-type="bibr">174</xref>), and thus is a non-specific target for migratory cDC1s. However, the immunogenic response is consistent with the importance of CD103<sup>+</sup> DCs in generating CD8<sup>+</sup> T cell responses (<xref rid="B175" ref-type="bibr">175</xref>). The contrasting immunogenic and tolerogenic responses are further consistent with the targeting of cDC1s <italic toggle="yes">via</italic> receptors such as DEC-205, where the presence of adjuvant determines the immunogenic or tolerogenic nature of the response (<xref rid="B93" ref-type="bibr">93</xref>&#8211;<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B97" ref-type="bibr">97</xref>). No markers have yet been identified to distinguish lymphoid resident and migratory cDC2s. Further delineation of resident and migratory DCs and their functions have been reviewed in depth (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B169" ref-type="bibr">169</xref>); however in the context of targeted vaccines, DCs present at the site of vaccination that are primed to migrate prior to antigen encounter should be considered and further studied.</p><p>One unique tissue-resident class of DCs are the Langerhans cells (LCs). LCs are specialized, skin-resident, immature APCs that reside in the skin and can be identified by the presence of cytoplasmic organelles, known as Birbeck granules (<xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B181" ref-type="bibr">181</xref>). They are also distinguished by the expression of CD207 (Langerin) (<xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B181" ref-type="bibr">181</xref>). While Langerhans cells share common features of DCs, including the characteristic dendrite projections and expression of CD11c and MHC II, they arise from macrophage progenitors and monocytes (<xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B180" ref-type="bibr">180</xref>, <xref rid="B181" ref-type="bibr">181</xref>). Thus, while LCs have been classically considered to be a DC subset, some have proposed considering LCs as a macrophage subset (<xref rid="B179" ref-type="bibr">179</xref>, <xref rid="B181" ref-type="bibr">181</xref>). Furthermore, studies have observed CD207-expressing DCs that are distinct from LCs, making CD207 a less reliable LC target (<xref rid="B177" ref-type="bibr">177</xref>, <xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B180" ref-type="bibr">180</xref>). Regardless, as LCs exist in the skin and encounter vaccine antigens delivered subcutaneously, some studies have investigated targeting vaccines to LCs or CD207<sup>+</sup> DCs (<xref rid="B182" ref-type="bibr">182</xref>). Li et&#160;al. targeted LCs using mannose ligands, which bind CD207, conjugated to melanoma antigens. In this study, poor induction of a CD8<sup>+</sup> T cell response compared to untargeted antigen was observed (<xref rid="B183" ref-type="bibr">183</xref>). Bellmann et&#160;al. conjugated viral proteins to anti-CD207 or anti-DEC-205 mAbs and directly compared their efficacy in promoting T cell responses in human <italic toggle="yes">ex vivo</italic> skin models (<xref rid="B184" ref-type="bibr">184</xref>). Similarly, the CD207-targeted vaccines were ineffective in generating CD8<sup>+</sup> or CD4<sup>+</sup> T cell responses, while the DEC-205-targeted formulation generated a moderate T cell response as reported by others (<xref rid="B184" ref-type="bibr">184</xref>). These results are consistent with previous findings that dermal DCs, and not LCs, are the primary drivers of immune responses in skin (<xref rid="B185" ref-type="bibr">185</xref>). Despite these findings, Carter et&#160;al. hypothesize that Th1-biased immune responses are driven by Langerhans cells in the skin (<xref rid="B131" ref-type="bibr">131</xref>). They show that CD8<sup>+</sup> T cell responses are enhanced when targeting cDC2s <italic toggle="yes">via</italic> Dectin-1, which is also expressed by LCs, after subcutaneous injection (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B146" ref-type="bibr">146</xref>). Given the clear challenges in classifying migratory and resident DCs in the skin, further investigation is required to understand the relative contributions of dermal DCs and Langerhans cells in vaccine-mediated immunity after subcutaneous injection.</p></sec></sec><sec id="s2_2"><label>2.2</label><title>Monocytes and monocyte-derived DCs</title><p>Monocytes circulate through lymphoid and peripheral tissues, and are recruited to sites of inflammation where they differentiate into monocyte-derived dendritic cells (moDCs) or macrophages (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Monocytes are typically identified by expression of CD14, CD16 (Fc&#947;RIII), CD88, M-CSFR (CD115), F4/80, CD11b, CX3CR1, and Ly6C in mice, and by CD14, CD16, CD88, and CD89 in humans (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B186" ref-type="bibr">186</xref>&#8211;<xref rid="B189" ref-type="bibr">189</xref>). Huang et&#160;al. demonstrated that monocytes loaded <italic toggle="yes">ex vivo</italic> with tumor antigens and transferred into tumor-bearing mice were able to generate anti-tumor CD8<sup>+</sup> T cell responses and suppress tumor growth (<xref rid="B190" ref-type="bibr">190</xref>). However, Huang et&#160;al. also suggested that monocytes themselves have poor antigen presentation capabilities, and that they instead transfer antigen to endogenous APCs for T cell activation (<xref rid="B190" ref-type="bibr">190</xref>). <italic toggle="yes">In vivo</italic>, monocytes have been targeted <italic toggle="yes">via</italic> CD11b and Ly6C (<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B192" ref-type="bibr">192</xref>). Lee et&#160;al. used a tetrazine-transcyclooctene (TCO) click chemistry strategy to deliver chemotherapeutics to tumor-recruited monocytes. In this study, they first administered TCO-modified anti-CD11b mAbs and then treated with tetrazine-modified mesoporous silica nanoparticles (<xref rid="B191" ref-type="bibr">191</xref>). However, CD11b appears on other innate immune cells, and its specificity for monocytes is a limitation of this study. <italic toggle="yes">In vivo</italic> monocyte targeting has also been used for treatment of inflammatory and autoimmune disorders (<xref rid="B38" ref-type="bibr">38</xref>). In one example of this approach, Veiga et&#160;al. delivered IL-10-encoding mRNA to Ly6C<sup>+</sup> leukocytes for colitis treatment using lipid nanoparticles (LNPs) bearing a Ly6C scFv targeting moiety (<xref rid="B192" ref-type="bibr">192</xref>). However, to date, no <italic toggle="yes">in vivo</italic> targeting of monocytes specifically for vaccine delivery have been reported.</p><p>After inflammatory stimulus, monocytes may differentiate into moDCs, and are identified by expression of monocyte markers as well as CD11c, MHC II, CD206, CD24, CD172a (SIRP&#945;), DC-SIGN, and CD64 (Fc&#947;RI) (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Like monocyte targeting, to date, <italic toggle="yes">in vivo</italic> targeting of moDCs for vaccination has not been reported. However, Segura et&#160;al. showed that moDCs could generate Th17 responses <italic toggle="yes">ex vivo</italic> (<xref rid="B39" ref-type="bibr">39</xref>). As Th17 responses play a critical role in effective vaccination against extracellular bacteria including <italic toggle="yes">M. tuberculosis</italic>, <italic toggle="yes">S. pneumonia</italic>, <italic toggle="yes">B. pertussis</italic>, and <italic toggle="yes">H. pylori</italic> (<xref rid="B193" ref-type="bibr">193</xref>), further research in this area is warranted.</p></sec><sec id="s2_3"><label>2.3</label><title>Macrophages</title><p>In addition to DCs, macrophages are a critical APC involved in adaptive immune responses. Macrophages reside in lymphoid and peripheral tissues, are generally responsible for phagocytosis of pathogens and cellular debris, and can present antigens <italic toggle="yes">via</italic> MHC molecules (<xref rid="B194" ref-type="bibr">194</xref>&#8211;<xref rid="B196" ref-type="bibr">196</xref>). Macrophages are typically identified by the expression of CD11b, F4/80 (mouse)/EMR1 (human), MHC II, CD18 (MAC-1), and CD68 (<xref rid="B197" ref-type="bibr">197</xref>&#8211;<xref rid="B200" ref-type="bibr">200</xref>). It is important to note that, while macrophages can arise from circulating monocytes during inflammation, tissue resident macrophages also arise during embryonic development and are maintained locally (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B201" ref-type="bibr">201</xref>, <xref rid="B202" ref-type="bibr">202</xref>). Thus, tissue resident and circulating macrophages may not share common monocyte markers. Furthermore, macrophages can exhibit tissue-specific marker expression, similar to DCs (<xref rid="B198" ref-type="bibr">198</xref>, <xref rid="B201" ref-type="bibr">201</xref>). We will focus on broad macrophage targeting, as well as specific macrophage phenotypes that can potentially improve vaccine responses, in this review.</p><p>Due to their phagocytic activity, macrophages can be passively targeted with micro- or nanoscale carriers. The size, charge, and morphology of micro/nanocarriers affect macrophage uptake. In general, carriers between 100 nm to 3 &#181;m are preferentially taken up by macrophages, highly charged carriers (positive or negative) are preferentially taken up compared to near neutral charges, and spherical carriers are preferentially taken up compared to cylindrical or rod-shaped carriers (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B204" ref-type="bibr">204</xref>). It should further be noted that the physicochemical properties of these carriers play a key role in downstream responses (<xref rid="B205" ref-type="bibr">205</xref>). Active targeting of murine macrophages has been achieved using anti-mouse F4/80 Fab-decorated PLA nanoparticles (<xref rid="B206" ref-type="bibr">206</xref>). In one study, Laroui et&#160;al. administered these nanoparticles orally to deliver siRNA which inhibited TNF-&#945; production in colonic macrophages for the treatment of colitis (<xref rid="B206" ref-type="bibr">206</xref>). While this study specifically sought to invoke a response in the colon, this strategy may be adaptable for pan-macrophage targeting by using alternative routes of administration or modified particle formulations.</p><sec id="s2_3_1"><label>2.3.1</label><title>M1/M2 macrophage polarization</title><p>Macrophages are often classified into &#8220;pro-inflammatory&#8221; M1 and &#8220;anti-inflammatory&#8221; M2 phenotypes; M1 macrophages express high levels of MHC II, CD40, CD80, CD86, and TLR4, while M2 macrophages express CD163, CD206, MARCO (CD204), Dectin-1 (Clec7a), and DC-SIGN (CD209) (<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>). However, these phenotypes are no longer considered discrete states but rather a spectrum, as macrophages may switch from one phenotype to another or simultaneously express markers that define M1 and M2 states (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B201" ref-type="bibr">201</xref>, <xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>). M1 macrophage targeting has generally focused on polarization towards M2, particularly for applications in treating inflammatory diseases (<xref rid="B209" ref-type="bibr">209</xref>). Conversely, M2 targeting has focused on polarization towards M1 or specific M2 depletion. Such targeted responses are of value for cancer therapy, as tumor-associated macrophages (TAMs) are phenotypically similar to M2 macrophages (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B210" ref-type="bibr">210</xref>), and increased levels of M2 TAMs are associated with poor outcomes (<xref rid="B203" ref-type="bibr">203</xref>). However, since &#8220;repolarization&#8221; strategies often focus on bulk macrophage populations and given the plasticity of the M1/M2 spectrum, specific M1/M2 targeting has, to date, been rare.</p><p>We highlight here some examples of macrophage targeting, which have primarily been used for macrophage reprogramming. Jain et&#160;al. demonstrated reprogramming of M1 macrophages to M2 using IL-10 encoding DNA loaded into alginate nanoparticles bearing tuftsin peptide, which broadly enhances phagocytosis by macrophages (<xref rid="B211" ref-type="bibr">211</xref>, <xref rid="B212" ref-type="bibr">212</xref>). Farajzadeh et&#160;al. and Tran et&#160;al. demonstrated reprogramming by delivering M2-polarizing therapeutics in hyaluronic acid-based nanoparticles, which bind CD44, a marker overexpressed on macrophages (<xref rid="B213" ref-type="bibr">213</xref>, <xref rid="B214" ref-type="bibr">214</xref>). However, both these strategies rely on pan-macrophage marker targeting strategies, rather than targets that achieve M1 or M2-specific delivery.</p><p>Alvarado-Vasquez et&#160;al. reprogrammed M1 macrophages to M2 by delivering CD163 encoding plasmids <italic toggle="yes">via</italic> a mannose-grafted polyethyleneimine (PEI) nanoparticle, targeting CD206 (<xref rid="B215" ref-type="bibr">215</xref>). Conversely, Zhu et&#160;al. targeted M2 TAMs using a mannose-grafted PLGA nanoparticle (<xref rid="B216" ref-type="bibr">216</xref>), demonstrating the difficulty of M1/M2 target specificity. Similarly, although Dectin-1 is considered a M2 marker, &#946;-1,3-D-glucan nanoparticles targeting Dectin-1 have been used to deliver TNF-&#945;-suppressing siRNAs to pro-inflammatory macrophages (<xref rid="B217" ref-type="bibr">217</xref>, <xref rid="B218" ref-type="bibr">218</xref>). However, Cieslewicz et&#160;al. demonstrated specific targeting of M2 TAMs, generating a M2-specific targeting peptide by phage display against M2 macrophages to deliver pro-apoptotic peptides (<xref rid="B210" ref-type="bibr">210</xref>). This targeting ability and specific depletion could be improved by multivalency (<xref rid="B219" ref-type="bibr">219</xref>). Lee et&#160;al. also demonstrated M2-specific targeting and depletion using melittin, an amphiphilic peptide derived from honey bee venom, after conjugation to pro-apoptotic peptides (<xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>). M2 TAMs are also known to overexpress folate receptor beta (FR&#946;), and its natural ligand, folic acid, may be used for M2 TAM targeting (<xref rid="B222" ref-type="bibr">222</xref>). Hattori et&#160;al. and Tie et&#160;al. demonstrated that folate-decorated liposomes were able to target M2 TAMs, while Nagai et&#160;al. demonstrated M2 TAM targeting using an FR&#946; ScFv (<xref rid="B223" ref-type="bibr">223</xref>&#8211;<xref rid="B225" ref-type="bibr">225</xref>). Due to the focus of the field being on altering M1/M2 phenotype switching or M2 depletion, rather than targeting native M1 or M2 macrophages, the effect of M1/M2 targeting on adaptive immune responses remaining an open question and an opportunity for future research.</p></sec><sec id="s2_3_2"><label>2.3.2</label><title>CD169<sup>+</sup> macrophages</title><p>Another macrophage subset with implications for targeted vaccines is CD169<sup>+</sup> macrophages. CD169 (Siglec-1) is a sialic acid binding receptor expressed on macrophages from lymphoid tissues (<xref rid="B226" ref-type="bibr">226</xref>). CD169<sup>+</sup> macrophages share the common macrophage markers except for F4/80, which is only expressed on some CD169<sup>+</sup> macrophages (<xref rid="B207" ref-type="bibr">207</xref>). CD169 is expressed on marginal zone macrophages in the spleen, and subcapsular sinus macrophages in the lymph node (<xref rid="B207" ref-type="bibr">207</xref>). These macrophages line the barrier between draining blood or lymph and lymphocytes, and can capture draining antigens, suggesting they could play a critical role as vaccine targets. However, CD169<sup>+</sup> macrophages themselves are poorly phagocytic; rather than presenting antigen, they shuttle intact antigens to B cell follicles to generate antibody responses (<xref rid="B227" ref-type="bibr">227</xref>, <xref rid="B228" ref-type="bibr">228</xref>). Alternatively, CD169<sup>+</sup> macrophages have been shown to transfer antigen to cDC1s to generate CD8<sup>+</sup> T cell responses, suggesting they are important for all immune responses (<xref rid="B229" ref-type="bibr">229</xref>). Because of their selective expression in lymphoid tissues and role in coordinating both B and T cell responses, CD169<sup>+</sup> macrophages may be a desirable target for targeted vaccines.</p><p>While targeting CD169<sup>+</sup> macrophages is a new concept in vaccine design, a few studies have demonstrated the potential of this approach in mice. van Dinther et&#160;al. showed that targeting of OVA to CD169<sup>+</sup> macrophages using anti-CD169 mAb-antigen conjugates resulted in anti-tumor CD8<sup>+</sup> T cell responses and slowed progression of OVA-bearing tumors (<xref rid="B230" ref-type="bibr">230</xref>). Nijen Twilhaar et&#160;al. targeted CD169<sup>+</sup> macrophages using the liposomes decorated with the ganglioside GM3, a natural ligand for CD169. GM3 liposomes loaded with OVA peptides were able to raise both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses (<xref rid="B231" ref-type="bibr">231</xref>). Edgar et&#160;al. instead targeted CD169<sup>+</sup> macrophages with liposomes decorated with a synthetic glycan that binds CD169, termed CD169L (<xref rid="B232" ref-type="bibr">232</xref>, <xref rid="B233" ref-type="bibr">233</xref>). CD169L liposomes loaded with OVA alone generated CD4<sup>+</sup> T cell responses. However, when a mix of TLR7 agonist-loaded and OVA-loaded CD169L liposomes were used, both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses were generated, suggesting that CD169 targeting can be used to modulate CD8<sup>+</sup> and CD4<sup>+</sup> T cell ratios (<xref rid="B233" ref-type="bibr">233</xref>). In CD169<sup>-/-</sup> mice, both T cell responses were diminished, indicating the dependence of these responses on CD169. Interestingly, Lisk et&#160;al. showed the antibody production of TLR adjuvant-based vaccines was diminished in CD169<sup>-/-</sup> mice, suggesting the importance of CD169 in TLR-based vaccines (<xref rid="B234" ref-type="bibr">234</xref>). Overall, given the importance of CD169<sup>+</sup> macrophages in shuttling antigen into lymph nodes, targeting them may represent a useful strategy in improving cellular and humoral responses to vaccines.</p></sec></sec><sec id="s2_4"><label>2.4</label><title>Granulocytes</title><p>Granulocytes are a critical component of the innate immune response against pathogens. These cells, which include neutrophils, eosinophils, basophils, and mast cells, release inflammatory molecules that both directly neutralize pathogens and inform downstream adaptive responses. In addition, granulocytes have been observed to exhibit APC-like characteristics, such as the expression of MHC II and costimulatory markers, under inflammatory conditions. This concept has been extensively reviewed by others (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B235" ref-type="bibr">235</xref>&#8211;<xref rid="B238" ref-type="bibr">238</xref>). Granulocytes can inform a wide range of adaptive immune responses. For example, neutrophils can generate Th1 and Th17 biases, while eosinophils and basophils can generate a Th2 bias (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B239" ref-type="bibr">239</xref>, <xref rid="B240" ref-type="bibr">240</xref>). While the functions and consequences of granulocytes as APCs require further research, they are an understudied aspect of innate immunity with respect to targeted vaccines. Here we will discuss targeting strategies for granulocytes that may potentially be applied to targeted vaccine design.</p><sec id="s2_4_1"><label>2.4.1</label><title>Neutrophils</title><p>Neutrophils comprise most circulating granulocytes. They are recruited to sites of inflammation by chemokines and cytokines, where they release reactive oxygen species (ROS) and immunostimulatory molecules (<xref rid="B238" ref-type="bibr">238</xref>). They may also form neutrophil extracellular traps (NETs), web-like structures of DNA that trap and kill pathogens (<xref rid="B241" ref-type="bibr">241</xref>, <xref rid="B242" ref-type="bibr">242</xref>). Neutrophils are typically identified by their expression of CD11b and Ly6G (Gr-1) (<xref rid="B241" ref-type="bibr">241</xref>, <xref rid="B242" ref-type="bibr">242</xref>). Targeting of neutrophils has been widely studied for the treatment of inflammatory and autoimmune diseases rather than vaccination. Wang et&#160;al. and Zhang et&#160;al. showed that albumin nanoparticles can passively target activated neutrophils; however, this targeting effect was dependent on nanoparticle opsonization and inflammation-driven upregulation of Fc&#947;RII and Fc&#947;RIII on neutrophils (<xref rid="B243" ref-type="bibr">243</xref>, <xref rid="B244" ref-type="bibr">244</xref>). Active targeting of neutrophils has been accomplished using both antibody and peptide ligands. Vij et&#160;al. used PLGA nanoparticles conjugated to an anti-Ly6G/6C antibody to deliver anti-inflammatory drugs to neutrophils (<xref rid="B245" ref-type="bibr">245</xref>). A limitation of this targeting strategy is that Ly6C is not specific to neutrophils and could also target other innate immune cells, such as monocytes and monocyte-derived cells. Cruz et&#160;al. developed a liposome which used Ly6G Fabs for neutrophil-specific targeting in order to deliver drugs that modulate neutrophil activity (<xref rid="B246" ref-type="bibr">246</xref>). Further specificity was conferred by adding a peptide derived from &#945;1-antitrypsin, the natural ligand for neutrophil elastase, a surface protein exclusively expressed on activated neutrophils (<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B247" ref-type="bibr">247</xref>). Volz et&#160;al. generated a neutrophil-specific targeting peptide by phage display which binds CD177, a neutrophil-specific activation marker. This CD177-targeting peptide was used to deliver PLGA nanoparticles to neutrophils containing immunomodulatory molecules (<xref rid="B248" ref-type="bibr">248</xref>).</p><p>For targeted vaccines, almost no studies have directly measured the response of targeting vaccines to neutrophils. It is known that alum based vaccines recruits neutrophils to injection sites and other large positively charged nanocarriers also induce neutrophil recruitment, which is especially helpful for generation of antibacterial Th1/Th17 responses (<xref rid="B239" ref-type="bibr">239</xref>, <xref rid="B240" ref-type="bibr">240</xref>, <xref rid="B249" ref-type="bibr">249</xref>, <xref rid="B250" ref-type="bibr">250</xref>). It may be possible that neutrophils assist in this Th1/Th17 response, but further research is required to determine how targeting neutrophils effects vaccination efficacy.</p></sec><sec id="s2_4_2"><label>2.4.2</label><title>Eosinophils, basophils, and mast cells</title><p>Eosinophils, basophils, and mast cells comprise the remaining populations of granulocytes. They are generally involved in Th2 responses, and release immunostimulatory molecules upon activation. Eosinophils are activated by IL-5 in response to allergy or parasitic infections, while basophils and mast cells degranulate in response to crosslinking of surface-bound IgE and activation of the high-affinity Fc receptor for IgE (Fc&#1013;R1) (<xref rid="B238" ref-type="bibr">238</xref>). Eosinophils are typically identified by expression of CD11b, CCR3, and Siglec-F (mouse)/Siglec-8 (human) (<xref rid="B251" ref-type="bibr">251</xref>). Basophils and mast cells share the markers CD11b, IL3Ra (CD123), Fc&#1013;R1, and CD203c (ENPP-3), with basophils additionally expressing CD49b and mast cells additionally expressing c-kit (CD117) (<xref rid="B252" ref-type="bibr">252</xref>, <xref rid="B253" ref-type="bibr">253</xref>).</p><p>Eosinophils, basophils, and mast cells have generally been targeted for the treatment of allergic diseases. Siglec-F/Siglec-8 is a common eosinophil target, and Siglec-8 antibody targeting for eosinophil depletion has been used in clinical trials to treat eosinophilic disorders (<xref rid="B254" ref-type="bibr">254</xref>). For targeted delivery to eosinophils, Nycholat et&#160;al. developed synthetic glycans that bind both Siglec-F/Siglec-8, and showed that liposomes decorated with these glycans effectively trafficked to eosinophils <italic toggle="yes">in vivo</italic> (<xref rid="B255" ref-type="bibr">255</xref>). In humans, basophils and mast cells express Siglec-3 (CD33) (<xref rid="B256" ref-type="bibr">256</xref>), and Duan et&#160;al. showed that liposomes decorated with a synthetic glycan targeting Siglec-3 were able to target human mast cells in a CD33-transgenic mouse model (<xref rid="B257" ref-type="bibr">257</xref>, <xref rid="B258" ref-type="bibr">258</xref>). Targeting of basophils and mast cells can also be achieved through the exclusively expressed membrane-associated protein CD203c. Gold nanoparticles functionalized with anti-CD203c antibodies were shown to bind human basophil and mast cells <italic toggle="yes">in vitro</italic>; however, <italic toggle="yes">in vivo</italic> targeting has yet to be demonstrated with this system (<xref rid="B259" ref-type="bibr">259</xref>, <xref rid="B260" ref-type="bibr">260</xref>). As with neutrophils, these granulocytes are also understudied for their participation in vaccination responses, particularly vaccines engineered for type 2 immune responses.</p></sec></sec><sec id="s2_5"><label>2.5</label><title>Lymph node targeting and non-innate immune cell targeting</title><p>A crucial factor in vaccine design is lymphatic targeting. Lymph is composed of draining interstitial fluid, carrying antigens and immune cells to the lymph nodes as a constant form of immune surveillance. Lymph nodes are therefore critical sites for coordination of both antibody and T cell responses, and targeting immune cell subsets that reside in, or traffic to, lymph nodes are potent methods to improve vaccine-induced immunity.</p><p>Typical strategies for broad lymphatic delivery include nanoparticles and albumin &#8220;hitchhiking&#8221; (<xref rid="B261" ref-type="bibr">261</xref>&#8211;<xref rid="B265" ref-type="bibr">265</xref>). Size is one of the primary determinants of lymphatic entry, and nanomaterials on the scale of 100 nm preferentially drain from the interstitium and into lymphatics (<xref rid="B264" ref-type="bibr">264</xref>, <xref rid="B266" ref-type="bibr">266</xref>). Albumin is an abundant protein that constantly circulates through blood, exits into the interstitium, then drains into the lymph <italic toggle="yes">via</italic> active transcellular or passive paracellular mechanisms before returning to blood circulation (<xref rid="B263" ref-type="bibr">263</xref>). Thus, albumin-binding or albumin-complexed therapeutics may also access lymphatics. Strategies for broad lymphatic targeting have been extensively reviewed (<xref rid="B261" ref-type="bibr">261</xref>&#8211;<xref rid="B265" ref-type="bibr">265</xref>); this review will focus on active targeting of specific lymph-node associated cells for vaccine-induced immunity.</p><p>Many of the innate immune cell subsets described in this review are present in lymph nodes, and active targeting may be paired with lymphatic delivery to achieve lymph node cell-specific targeting. However, several other types of cells coordinate with these innate immune cells to generate vaccine-induced immune responses. For example, while the main function of B cells is their adaptive immune response, particularly their differentiation into antibody-producing cells and the generation of humoral responses, B cells are also professional APCs capable of presenting antigens as peptide-MHC complexes (<xref rid="B44" ref-type="bibr">44</xref>). Additionally, lymph node stromal cells (LNSCs) provide the architecture and support required for innate and adaptive immune cell responses, and they can also play critical immunomodulatory roles themselves. While the subsets and functions of LNSCs have been extensively reviewed elsewhere (<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B247" ref-type="bibr">247</xref>), here we will focus on two LNSC subsets: follicular dendritic cells (FDCs) and lymphatic endothelial cells (LECs). While B cells, FDCs, and LECs do not belong to the innate immune cell compartment, this section will discuss both the ability of these cells to improve adaptive immune responses for vaccination and methods of targeting these cells.</p></sec><sec id="s2_6"><label>2.6</label><title>B cells</title><p>While one of the main functions of B cells is their adaptive immune response, mainly their differentiation into antibody-producing cells and the generation of humoral responses, B cells are also professional APCs, capable of presenting antigens as peptide-MHC II complexes (<xref rid="B44" ref-type="bibr">44</xref>). B cells are typically identified by their expression of CD19, CD20, B220, MHC II, and CD21/35 (CR1/2) (<xref rid="B44" ref-type="bibr">44</xref>). As B cells reside in lymphoid tissues, they also provide a measure of lymph node targeting.</p><p>B cells are organized into follicles within lymphoid tissues and may be passively targeted with vaccine nanoformulations. Nanoformulations on the scale of 100 nm preferentially drain to lymph nodes, where they may directly access B cell follicles or be transferred into follicles by CD169<sup>+</sup> subcapsular sinus macrophages in a CD21/35-dependent manner (<xref rid="B227" ref-type="bibr">227</xref>, <xref rid="B228" ref-type="bibr">228</xref>, <xref rid="B261" ref-type="bibr">261</xref>, <xref rid="B267" ref-type="bibr">267</xref>). Shen et&#160;al. demonstrated that iron nanoparticles were rapidly opsonized by complement component 3b (C3b), allowing nanoparticles to be taken up by B cells <italic toggle="yes">via</italic> CD21/35 (<xref rid="B268" ref-type="bibr">268</xref>). Thus, while nanocarrier targeting of B cells is considered &#8220;passive&#8221; targeting, from another viewpoint, intentional complement opsonization of nanocarriers and uptake <italic toggle="yes">via</italic> CD21/35 could be considered an &#8220;active&#8221; targeting approach. Using this principle, Shimizu et&#160;al. used polyethylene glycol (PEG)-decorated (PEGylated) liposomes to induce a weak anti-PEG IgM response (<xref rid="B269" ref-type="bibr">269</xref>&#8211;<xref rid="B271" ref-type="bibr">271</xref>). Upon administration of a second, PEGylated liposome loaded with antigen, liposomes were opsonized with IgM and complement proteins, allowing B cell uptake and adaptive immune responses toward the antigen (<xref rid="B269" ref-type="bibr">269</xref>&#8211;<xref rid="B271" ref-type="bibr">271</xref>). Further chemical modification of PEG to contain terminal hydroxyl groups, which engage the complement system, allowed for B cell targeting with PEGylated liposomes in a single injection (<xref rid="B272" ref-type="bibr">272</xref>).</p><p>Since B cells initiate humoral responses after binding antigens with their B cell receptors (BCRs), antigens themselves may be considered a form of antigen-specific B cell targeting. Multivalent antigen display on nanocarriers has also been shown to enhance BCR crosslinking, improving humoral responses (<xref rid="B261" ref-type="bibr">261</xref>). Temchura et&#160;al. demonstrated that calcium phosphate (CaP) nanoparticles coated with antigens and adjuvants were able to target and activate B cells <italic toggle="yes">in vitro</italic> (<xref rid="B273" ref-type="bibr">273</xref>). <italic toggle="yes">In vivo</italic> B cell targeting led to CD4<sup>+</sup> T cell and humoral responses (<xref rid="B274" ref-type="bibr">274</xref>). Moyer et&#160;al. demonstrated that antigens adsorbed to aluminum hydroxide (alum), which acts as both a nanocarrier and adjuvant, was taken up by and strongly activated B cells <italic toggle="yes">in vivo</italic> (<xref rid="B275" ref-type="bibr">275</xref>). The alum-adsorbed antigen formulation enhanced antibody levels relative to non-adsorbed antigens. It is important to consider that in both these cases, the targeted B cells were transgenic, antigen-specific cells. This makes it difficult to assess if BCR targeting is generalizable to other antigens and endogenous antigen-specific B cells. Despite this, taken together these studies indicate that nanocarrier targeting and multivalent antigen display are effective strategies for B cell-targeted vaccines.</p><p>B cells may also be actively targeted <italic toggle="yes">via</italic> their surface receptors CD19 and MHC II. CD19 is a membrane protein that reduces the threshold for BCR activation (<xref rid="B276" ref-type="bibr">276</xref>, <xref rid="B277" ref-type="bibr">277</xref>). Yan et&#160;al. compared the targeting of B cells <italic toggle="yes">via</italic> anti-CD19 and anti-IgM mAb-antigen conjugates. Both CD19 targeting and IgM targeting were able to deliver antigens to B cells and induced T cell activation <italic toggle="yes">in vivo</italic> (<xref rid="B278" ref-type="bibr">278</xref>). Ma et&#160;al. and Ding et&#160;al. further showed that targeting tumor antigens to B cells <italic toggle="yes">via</italic> CD19 induced strong antibody responses, and both CD8<sup>+</sup> and CD4<sup>+</sup> cell responses, which were able to suppress tumor growth (<xref rid="B279" ref-type="bibr">279</xref>, <xref rid="B280" ref-type="bibr">280</xref>). Instead of targeting CD19, Andersen et&#160;al. and Hinke et&#160;al. targeted B cells <italic toggle="yes">via</italic> MHC II using DNA vaccines that expressed multivalent HA fused to anti-MHC II scFvs. MHC II targeting improved antibody and Tfh responses compared to non-targeting formulations, while multivalency improved for protection against flu challenge compared to single antigen formulations, likely through increased BCR crosslinking (<xref rid="B281" ref-type="bibr">281</xref>, <xref rid="B282" ref-type="bibr">282</xref>). Although MHC II is also expressed on other APCs, limiting B cell-specific targeting, Andersen et&#160;al. showed that DC presentation was not required for the magnitude of antibodies produced by B cell targeting in their vaccine (<xref rid="B281" ref-type="bibr">281</xref>). Taken together, targeting B cells in a vaccination is a promising approach for the induction of strong antibody responses. Further study is required to understand the relative contributions of B cell targeting to T cell responses, such as CD4<sup>+</sup> Tfh and type 2 immune responses, and cellular-biased T cell responses, such as CD8<sup>+</sup> T cell responses, in vaccination.</p></sec><sec id="s2_7"><label>2.7</label><title>Lymph node stromal cells</title><p>Lymph node stromal cells (LNSCs) provide the architecture and support required for innate and adaptive immune cell responses, but also play critical immunomodulatory roles themselves. While the subsets and functions of LNSCs have been extensively reviewed elsewhere (<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B247" ref-type="bibr">247</xref>), here we will focus on two LNSC subsets, follicular dendritic cells (FDCs) and lymphatic endothelial cells (LECs).</p><sec id="s2_7_1"><label>2.7.1</label><title>Follicular dendritic cells</title><p>Despite sharing a name with DCs, follicular dendritic cells (FDCs) are a functionally distinct cell subset with a key role in adaptive immunity. FDCs arise from mesenchymal, rather than hematopoietic progenitors, only sharing the characteristic dendrite morphology (<xref rid="B283" ref-type="bibr">283</xref>, <xref rid="B284" ref-type="bibr">284</xref>). FDCs are a rare population that reside in the B cell follicles, but do not process antigen. Instead, FDCs retain antigens in native form <italic toggle="yes">via</italic> immune complexes for presentation to germinal center B cells (<xref rid="B283" ref-type="bibr">283</xref>&#8211;<xref rid="B286" ref-type="bibr">286</xref>). B cells with high-affinity, antigen-specific BCRs bind retained antigen, and receive survival signals from FDCs, a critical process known as affinity maturation (<xref rid="B283" ref-type="bibr">283</xref>&#8211;<xref rid="B286" ref-type="bibr">286</xref>). Thus, vaccines targeting FDCs may be able to generate robust humoral responses.</p><p>FDCs are typically identified by expression of gp38 (PDPN) and CD21/35 (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B286" ref-type="bibr">286</xref>). Given their location in B cell follicles, targeting strategies that utilize opsonization and CD21/35 binding for B cell targeting may also be applicable to FDCs. Zhang et&#160;al. showed that both 15-50 nm-sized and 50-100 nm-sized antigen-conjugated gold nanoparticles were able to leverage lymphatic transport and traffic to lymph nodes (<xref rid="B287" ref-type="bibr">287</xref>). However, 50-100 nm-sized nanoparticles preferentially accumulated on FDCs due to increased C3b opsonization and CD21/35 binding (<xref rid="B287" ref-type="bibr">287</xref>). Mattsson et&#160;al. and Schussek et&#160;al. showed that a CD21/35-binding adjuvant derived from cholera toxin bound to FDCs, and strongly potentiated antibody and Tfh responses (<xref rid="B288" ref-type="bibr">288</xref>, <xref rid="B289" ref-type="bibr">289</xref>). Aung et&#160;al. demonstrated that FDCs could be targeted with antigens fused to anti-CD35 ScFvs (<xref rid="B290" ref-type="bibr">290</xref>). After vaccination, targeted antigen was retained on FDCs longer, and significantly increased antigen-specific IgG, compared to a non-targeted control (<xref rid="B290" ref-type="bibr">290</xref>). Given the importance of FDCs to mature antibody production and humoral immune responses, further research on antigen targeting to FDCs is warranted.</p></sec><sec id="s2_7_2"><label>2.7.2</label><title>Lymphatic endothelial cells</title><p>LECs line the lymphatic vessels and lymph nodes. As a result, they are poised to interact with antigens and immune cells as they enter lymphatic circulation. LECs are capable of antigen capture and presentation to T cells (<xref rid="B291" ref-type="bibr">291</xref>&#8211;<xref rid="B298" ref-type="bibr">298</xref>). Under steady-state conditions, LECs are also known to generate long-lived memory CD8<sup>+</sup> T cells that can differentiate into effector cells after re-challenge (<xref rid="B294" ref-type="bibr">294</xref>). Under inflammatory conditions such as viral infections, antigen persistence in LECs has been observed in a mechanism distinct from FDC retention (<xref rid="B291" ref-type="bibr">291</xref>&#8211;<xref rid="B293" ref-type="bibr">293</xref>). This persistence enhanced memory CD8<sup>+</sup> T cell responses against infections. Thus, vaccines targeting LECs may be able to generate robust memory T cell responses.</p><p>LECs are typically identified by expression of gp38 (PDPN), CD31, LYVE1, and VEGFR3 (<xref rid="B299" ref-type="bibr">299</xref>, <xref rid="B300" ref-type="bibr">300</xref>). While no LEC-targeting vaccine formulations have been reported, Guo et&#160;al. demonstrated that LEC-targeting magnetic nanoparticles for magnetic resonance imaging (MRI), functionalized with anti-LYVE-1 mAbs, were able to target LECs <italic toggle="yes">in vitro</italic> (<xref rid="B301" ref-type="bibr">301</xref>). Wu et&#160;al. further showed that magnetic nanoparticles functionalized with both anti-LYVE-1 and anti-gp38 mAbs were able to target LECs <italic toggle="yes">in vivo</italic> (<xref rid="B302" ref-type="bibr">302</xref>). While targeting systems exist, further research will also be required to show how selectively targeting vaccines to LECs affects adaptive responses.</p></sec></sec></sec><sec sec-type="discussion" id="s3"><label>3</label><title>Discussion</title><p>This review presents the numerous strategies for vaccine targeting of specific cell subsets and the implications on adaptive immune responses. Through compiling these studies, several trends could be observed. For example, general targeting of cDC1 regardless of receptor generated stronger CD8<sup>+</sup> T cell responses compared to other cell types. However, cDC1s did not exclusively generate CD8<sup>+</sup> T cell responses, as targeting of receptors such as Clec9a could result in humoral and Tfh responses. Neither were CD8<sup>+</sup> T cell responses exclusive to cDC1s, as cDC2s could additionally generate CD8<sup>+</sup> T cell responses in addition to CD4<sup>+</sup> T cell responses. The type of CD4<sup>+</sup> T cell response also varied widely depending on the target receptor, although the relatively fewer number of cDC2-specific receptors should be considered in interpreting these results. Immune cells such as monocytes, macrophages, B cells, neutrophils, and other granulocytes have been targeted in a wide variety of therapeutics, but their roles as target cells in vaccine delivery are still poorly defined. However, the fundamental hypothesis that the cells that first encounter vaccine material impacts adaptive immunity, is confirmed by a large body of literature. This review also presents stromal cells, such as FDCs and LECs, as new opportunities for targeted vaccine research that could potentially generate long-lived humoral and cellular responses.</p><p>It is important to note that there are other design considerations for cell targeted vaccines not discussed in this review, including immune responses against targeting constructs and anti-carrier immunity, off-target effects, and cell receptor disruption. For example, in murine studies, the targeting antibodies utilized are often of rat or hamster origin, which can lead to an anti-antibody host response due to non-self immune recognition (<xref rid="B303" ref-type="bibr">303</xref>&#8211;<xref rid="B305" ref-type="bibr">305</xref>). Repeated administration, which may be required in some vaccine schedules, can result in either immunogenic or tolerogenic responses toward these antibodies, but also toward any carrier molecules (<xref rid="B306" ref-type="bibr">306</xref>). Anti-host antibodies have been used as a readout for immunological outcomes of targeted vaccines after injection of the targeting antibody alone. However, when antibodies or other biologics are used to target antigens to specific cells, it is necessary to decouple the immune reactions to the antigen versus the targeting component. This could be accomplished by analyzing antigen-specific cellular and humoral responses. In human and clinical studies, these issues are often pre-empted by using chimeric, humanized, or fully human antibodies that reduce the risk of anti-antibody responses (<xref rid="B303" ref-type="bibr">303</xref>&#8211;<xref rid="B306" ref-type="bibr">306</xref>). However, the potential for non-antigen specific immune responses should still be considered. Another important consideration is the potential for cell signaling after engagement of a target molecule. For example, some target receptors (e.g. Fc&#947;Rs, DCIR) contain ITAMs or ITIMs, or are costimulatory molecules (e.g. CD40), which may induce or restrict downstream immune responses. In the case of Fc&#947;R, no differences in immune responses were observed between targeting of activating or inhibitory isoforms (<xref rid="B105" ref-type="bibr">105</xref>). However, to fully understand the immunological effects of targeted vaccines, it is critical to evaluate if the targeting method can induce any agonistic or antagonistic effects after ligation of the target receptor, which may alter an immune response. Some targets are ITAM and ITIM-independent (e.g. DEC-205), or may have pleiotropic effects depending on if they are targeted under inflammatory or steady state conditions (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Lastly, while some receptors are highly specific to a cell subtype, many receptors mentioned in this review are present on many innate immune cell types, and targeting these receptors can lead to off-target cellular activation and impact vaccine efficacy.</p><p>Here we have shown how control over innate immune response can be achieved by targeting vaccines to specific cellular subsets or surface markers. This body of literature will be useful for the design of next generation vaccines which carefully match desired adaptive immune response to specific diseases.</p></sec><sec sec-type="author-contributions" id="s4"><title>Author contributions</title><p>The idea for this review was conceived by PD. PD generated the figure. PD, TU, AMW and NSR contributed to reviewing literature, formatting the article, writing of the text and critique of the text. APE-K provided intellectual oversight, review, and critique of the article. All authors contributed to the article and approved the submitted version.</p></sec></body><back><sec sec-type="COI-statement" id="s6"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s7"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s8"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1221008/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2023.1221008/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyle</surname><given-names>P</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Self-adjuvanting lipopeptide vaccines</article-title>. <source>Curr Med Chem</source> (<year>2008</year>) <volume>15</volume>:<page-range>506&#8211;16</page-range>. doi: <pub-id pub-id-type="doi">10.2174/092986708783503249</pub-id><pub-id pub-id-type="pmid">18289006</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyle</surname><given-names>PM</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Modern subunit vaccines: development, components, and research opportunities</article-title>. <source>ChemMedChem</source> (<year>2013</year>) <volume>8</volume>:<page-range>360&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cmdc.201200487</pub-id><pub-id pub-id-type="pmid">23316023</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></name></person-group>. <article-title>A guide to vaccinology: from basic principles to new developments</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>:<fpage>83</fpage>&#8211;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></name></person-group>. <article-title>Making innate sense of mRNA vaccine adjuvanticity</article-title>. <source>Nat Immunol</source> (<year>2022</year>) <volume>23</volume>:<page-range>474&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-022-01168-4</pub-id><pub-id pub-id-type="pmid">35354958</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>P-Y</given-names></name></person-group>. <article-title>Zika virus vaccine: progress and challenges</article-title>. <source>Cell Host Microbe</source> (<year>2018</year>) <volume>24</volume>:<page-range>12&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2018.05.021</pub-id><pub-id pub-id-type="pmcid">PMC6112613</pub-id><pub-id pub-id-type="pmid">30008291</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>KA</given-names></name></person-group>. <article-title>mRNA vaccines for infectious diseases: principles, delivery and clinical translation</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>:<page-range>817&#8211;38</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id><pub-id pub-id-type="pmid">34433919</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeway</surname><given-names>CA</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Innate immune recognition</article-title>. <source>Annu Rev Immunol</source> (<year>2002</year>) <volume>20</volume>:<fpage>197</fpage>&#8211;<lpage>216</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.20.083001.084359</pub-id><pub-id pub-id-type="pmid">11861602</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Pattern recognition receptors and inflammation</article-title>. <source>Cell</source> (<year>2010</year>) <volume>140</volume>:<page-range>805&#8211;20</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pashine</surname><given-names>A</given-names></name><name name-style="western"><surname>Valiante</surname><given-names>NM</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>JB</given-names></name></person-group>. <article-title>Targeting the innate immune response with improved vaccine adjuvants</article-title>. <source>Nat Med</source> (<year>2005</year>) <volume>11</volume>:<page-range>S63&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm1210</pub-id><pub-id pub-id-type="pmid">15812492</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name></person-group>. <article-title>Recognition of pathogen-associated molecular patterns by TLR family</article-title>. <source>Immunol Lett</source> (<year>2003</year>) <volume>85</volume>:<fpage>85</fpage>&#8211;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0165-2478(02)00228-6</pub-id><pub-id pub-id-type="pmid">12527213</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>E</given-names></name><name name-style="western"><surname>Leitner</surname><given-names>W</given-names></name></person-group>. <article-title>Adjuvants in the driver&#8217;s seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators</article-title>. <source>Vaccines</source> (<year>2014</year>) <volume>2</volume>:<page-range>252&#8211;96</page-range>. doi: <pub-id pub-id-type="doi">10.3390/vaccines2020252</pub-id><pub-id pub-id-type="pmcid">PMC4494256</pub-id><pub-id pub-id-type="pmid">26344620</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>:<page-range>454&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id><pub-id pub-id-type="pmid">33824489</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A</given-names></name><name name-style="western"><surname>Seder</surname><given-names>RA</given-names></name></person-group>. <article-title>Vaccine adjuvants: putting innate immunity to work</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>33</volume>:<fpage>492</fpage>&#8211;<lpage>503</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schijns</surname><given-names>V</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A</given-names></name><name name-style="western"><surname>Barjaktarovi&#263;</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Bouzalas</surname><given-names>I</given-names></name><name name-style="western"><surname>Brimnes</surname><given-names>J</given-names></name><name name-style="western"><surname>Chernysh</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Modulation of immune responses using adjuvants to facilitate therapeutic vaccination</article-title>. <source>Immunol Rev</source> (<year>2020</year>) <volume>296</volume>:<page-range>169&#8211;90</page-range>. doi: <pub-id pub-id-type="doi">10.1111/imr.12889</pub-id><pub-id pub-id-type="pmcid">PMC7497245</pub-id><pub-id pub-id-type="pmid">32594569</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>JS</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>R</given-names></name><name name-style="western"><surname>Watson</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HL</given-names></name></person-group>. <article-title>An introduction to immunology and immunopathology</article-title>. <source>Allergy Asthma Clin Immunol</source> (<year>2018</year>) <volume>14</volume>:<fpage>49</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id><pub-id pub-id-type="pmid">30263032</pub-id><pub-id pub-id-type="pmcid">PMC6156898</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnaswamy</surname><given-names>JK</given-names></name><name name-style="western"><surname>Als&#233;n</surname><given-names>S</given-names></name><name name-style="western"><surname>Yrlid</surname><given-names>U</given-names></name><name name-style="western"><surname>Eisenbarth</surname><given-names>SC</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name></person-group>. <article-title>Determination of T follicular helper cell fate by dendritic cells</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2169</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02169</pub-id><pub-id pub-id-type="pmid">30319629</pub-id><pub-id pub-id-type="pmcid">PMC6170619</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>F</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name></person-group>. <article-title>T follicular helper cell subsets and the associated cytokine IL-21 in the pathogenesis and therapy of asthma</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2918</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02918</pub-id><pub-id pub-id-type="pmid">31921177</pub-id><pub-id pub-id-type="pmcid">PMC6923700</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name></person-group>. <article-title>CD4 T helper cell subsets and related human immunological disorders</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>:<fpage>8011</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21218011</pub-id><pub-id pub-id-type="pmid">33126494</pub-id><pub-id pub-id-type="pmcid">PMC7663252</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annunziato</surname><given-names>F</given-names></name><name name-style="western"><surname>Romagnani</surname><given-names>C</given-names></name><name name-style="western"><surname>Romagnani</surname><given-names>S</given-names></name></person-group>. <article-title>The 3 major types of innate and adaptive cell-mediated effector immunity</article-title>. <source>J Allergy Clin Immunol</source> (<year>2015</year>) <volume>135</volume>:<page-range>626&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2014.11.001</pub-id><pub-id pub-id-type="pmid">25528359</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>P</given-names></name><name name-style="western"><surname>Goel</surname><given-names>PN</given-names></name><name name-style="western"><surname>Greene</surname><given-names>MI</given-names></name></person-group>. <article-title>Regulatory T cells: regulation of identity and function</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>750542</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.750542</pub-id><pub-id pub-id-type="pmid">34675933</pub-id><pub-id pub-id-type="pmcid">PMC8524049</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniel</surname><given-names>C</given-names></name><name name-style="western"><surname>Wennhold</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Von Boehmer</surname><given-names>H</given-names></name></person-group>. <article-title>Enhancement of antigen-specific Treg vaccination in <italic toggle="yes">vivo</italic>
</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2010</year>) <volume>107</volume>:<page-range>16246&#8211;51</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1007422107</pub-id><pub-id pub-id-type="pmcid">PMC2941325</pub-id><pub-id pub-id-type="pmid">20805478</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kurt-Jones</surname><given-names>EA</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group>. <article-title>Pattern recognition receptors and the innate immune response to viral infection</article-title>. <source>Viruses</source> (<year>2011</year>) <volume>3</volume>:<page-range>920&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.3390/v3060920</pub-id><pub-id pub-id-type="pmcid">PMC3186011</pub-id><pub-id pub-id-type="pmid">21994762</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>I</given-names></name><name name-style="western"><surname>Garg</surname><given-names>R</given-names></name><name name-style="western"><surname>van Drunen Littel-van den Hurk</surname><given-names>S</given-names></name></person-group>. <article-title>Selection of adjuvants for vaccines targeting specific pathogens</article-title>. <source>Expert Rev Vaccines</source> (<year>2019</year>) <volume>18</volume>:<page-range>505&#8211;21</page-range>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2019.1604231</pub-id><pub-id pub-id-type="pmcid">PMC7103699</pub-id><pub-id pub-id-type="pmid">31009255</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesfaye</surname><given-names>DY</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Bogen</surname><given-names>B</given-names></name><name name-style="western"><surname>Fossum</surname><given-names>E</given-names></name></person-group>. <article-title>Targeting conventional dendritic cells to fine-tune antibody responses</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1529</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01529</pub-id><pub-id pub-id-type="pmid">31333661</pub-id><pub-id pub-id-type="pmcid">PMC6620736</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohn</surname><given-names>L</given-names></name><name name-style="western"><surname>Delamarre</surname><given-names>L</given-names></name></person-group>. <article-title>Dendritic cell-targeted vaccines</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>255</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00255</pub-id><pub-id pub-id-type="pmid">24910635</pub-id><pub-id pub-id-type="pmcid">PMC4039009</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S</given-names></name><name name-style="western"><surname>Lal</surname><given-names>G</given-names></name></person-group>. <article-title>The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>1124</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2017.01124</pub-id><pub-id pub-id-type="pmid">28955340</pub-id><pub-id pub-id-type="pmcid">PMC5601256</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>J</given-names></name><name name-style="western"><surname>Ridgley</surname><given-names>LA</given-names></name><name name-style="western"><surname>Bodman-Smith</surname><given-names>M</given-names></name></person-group>. <article-title>How to train your dragon: harnessing gamma delta T cells antiviral functions and trained immunity in a pandemic era</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>666983</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.666983</pub-id><pub-id pub-id-type="pmid">33854516</pub-id><pub-id pub-id-type="pmcid">PMC8039298</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><name name-style="western"><surname>Lor&#233;</surname><given-names>K</given-names></name></person-group>. <article-title>Granulocytes: new members of the antigen-presenting cell family</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>1781</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2017.01781</pub-id><pub-id pub-id-type="pmid">29321780</pub-id><pub-id pub-id-type="pmcid">PMC5732227</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuijs</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>BN</given-names></name></person-group>. <article-title>Professional and &#8216;Amateur&#8217; Antigen-presenting cells in type 2 immunity</article-title>. <source>Trends Immunol</source> (<year>2019</year>) <volume>40</volume>:<fpage>22</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2018.11.001</pub-id><pub-id pub-id-type="pmid">30502024</pub-id><pub-id pub-id-type="pmcid">PMC7610811</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></name><name name-style="western"><surname>Briere</surname><given-names>F</given-names></name><name name-style="western"><surname>Caux</surname><given-names>C</given-names></name><name name-style="western"><surname>Davoust</surname><given-names>J</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y-J</given-names></name><etal/></person-group>. <article-title>Immunobiology of dendritic cells</article-title>. <source>Annu Rev Immunol</source> (<year>2000</year>) <volume>18</volume>:<fpage>767</fpage>&#8211;<lpage>811</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.767</pub-id><pub-id pub-id-type="pmid">10837075</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name><name name-style="western"><surname>Sathe</surname><given-names>P</given-names></name><name name-style="western"><surname>Helft</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><name name-style="western"><surname>Mortha</surname><given-names>A</given-names></name></person-group>. <article-title>The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>:<fpage>563</fpage>&#8211;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-074950</pub-id><pub-id pub-id-type="pmid">23516985</pub-id><pub-id pub-id-type="pmcid">PMC3853342</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Castell-Rodr&#237;guez</surname><given-names>A</given-names></name><name name-style="western"><surname>Pi&#241;&#243;n-Z&#225;rate</surname><given-names>G</given-names></name><name name-style="western"><surname>Herrera-Enr&#237;quez</surname><given-names>M</given-names></name><name name-style="western"><surname>Jarqu&#237;n-Y&#225;&#241;ez</surname><given-names>K</given-names></name><name name-style="western"><surname>Medina-Solares</surname><given-names>I</given-names></name></person-group>. <article-title>Dendritic cells: location, function, and clinical implications</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name></person-group>, editor. <source>Biology of Myelomonocytic Cells</source>. (<publisher-loc>London, UK</publisher-loc>: <publisher-name>InTech</publisher-name>) (<year>2017</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.intechopen.com/books/biology-of-myelomonocytic-cells/dendritic-cells-location-function-and-clinical-implications">http://www.intechopen.com/books/biology-of-myelomonocytic-cells/dendritic-cells-location-function-and-clinical-implications</uri>.</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macri</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Patton</surname><given-names>T</given-names></name><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>M</given-names></name></person-group>. <article-title>Dendritic cell subsets</article-title>. <source>Semin Cell Dev Biol</source> (<year>2018</year>) <volume>84</volume>:<fpage>11</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semcdb.2017.12.009</pub-id><pub-id pub-id-type="pmid">29246859</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>PF</given-names></name><name name-style="western"><surname>Tussiwand</surname><given-names>R</given-names></name></person-group>. <article-title>Novel concepts in plasmacytoid dendritic cell (pDC) development and differentiation</article-title>. <source>Mol Immunol</source> (<year>2020</year>) <volume>126</volume>:<fpage>25</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2020.07.006</pub-id><pub-id pub-id-type="pmid">32739721</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epelman</surname><given-names>S</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>GJ</given-names></name></person-group>. <article-title>Origin and functions of tissue macrophages</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>:<fpage>21</fpage>&#8211;<lpage>35</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.013</pub-id><pub-id pub-id-type="pmid">25035951</pub-id><pub-id pub-id-type="pmcid">PMC4470379</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>C</given-names></name><name name-style="western"><surname>Brinck-Jensen</surname><given-names>N-S</given-names></name><name name-style="western"><surname>Zang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name></person-group>. <article-title>Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases</article-title>. <source>Int J Infect Diseases</source> (<year>2014</year>) <volume>19</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2013.09.023</pub-id><pub-id pub-id-type="pmid">24216295</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langlet</surname><given-names>C</given-names></name><name name-style="western"><surname>Tamoutounour</surname><given-names>S</given-names></name><name name-style="western"><surname>Henri</surname><given-names>S</given-names></name><name name-style="western"><surname>Luche</surname><given-names>H</given-names></name><name name-style="western"><surname>Ardouin</surname><given-names>L</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<page-range>1751&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1102744</pub-id><pub-id pub-id-type="pmid">22262658</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>KV</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>RM</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lew</surname><given-names>AM</given-names></name></person-group>. <article-title>Heterogeneity, functional specialization and differentiation of monocyte-derived dendritic cells</article-title>. <source>Immunol Cell Biol</source> (<year>2017</year>) <volume>95</volume>:<page-range>244&#8211;51</page-range>. doi: <pub-id pub-id-type="doi">10.1038/icb.2016.104</pub-id><pub-id pub-id-type="pmid">27748730</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>E</given-names></name><name name-style="western"><surname>Touzot</surname><given-names>M</given-names></name><name name-style="western"><surname>Bohineust</surname><given-names>A</given-names></name><name name-style="western"><surname>Cappuccio</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiocchia</surname><given-names>G</given-names></name><name name-style="western"><surname>HosMalin</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Human inflammatory dendritic cells induce Th17 cell differentiation</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>38</volume>:<page-range>336&#8211;48</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.018</pub-id><pub-id pub-id-type="pmid">23352235</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musumeci</surname><given-names>A</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>K</given-names></name><name name-style="western"><surname>Winheim</surname><given-names>E</given-names></name><name name-style="western"><surname>Krug</surname><given-names>AB</given-names></name></person-group>. <article-title>What makes a pDC: recent advances in understanding plasmacytoid DC development and heterogeneity</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1222</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01222</pub-id><pub-id pub-id-type="pmid">31191558</pub-id><pub-id pub-id-type="pmcid">PMC6548821</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collin</surname><given-names>M</given-names></name><name name-style="western"><surname>Bigley</surname><given-names>V</given-names></name></person-group>. <article-title>Human dendritic cell subsets: an update</article-title>. <source>Immunology</source> (<year>2018</year>) <volume>154</volume>:<fpage>3</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1111/imm.12888</pub-id><pub-id pub-id-type="pmid">29313948</pub-id><pub-id pub-id-type="pmcid">PMC5904714</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swiecki</surname><given-names>M</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M</given-names></name></person-group>. <article-title>The multifaceted biology of plasmacytoid dendritic cells</article-title>. <source>Nat Rev Immunol</source> (<year>2015</year>) <volume>15</volume>:<page-range>471&#8211;85</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3865</pub-id><pub-id pub-id-type="pmcid">PMC4808588</pub-id><pub-id pub-id-type="pmid">26160613</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sichien</surname><given-names>D</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>BN</given-names></name><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Scott</surname><given-names>CL</given-names></name></person-group>. <article-title>Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues</article-title>. <source>Mucosal Immunol</source> (<year>2017</year>) <volume>10</volume>:<page-range>831&#8211;44</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2017.8</pub-id><pub-id pub-id-type="pmid">28198365</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adler</surname><given-names>LN</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Bhamidipati</surname><given-names>K</given-names></name><name name-style="western"><surname>Millican</surname><given-names>M</given-names></name><name name-style="western"><surname>Macaubas</surname><given-names>C</given-names></name><name name-style="western"><surname>Hung</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The other function: class II-restricted antigen presentation by B cells</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>319</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00319</pub-id><pub-id pub-id-type="pmid">28386257</pub-id><pub-id pub-id-type="pmcid">PMC5362600</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z-G</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G-F</given-names></name></person-group>. <article-title>DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice</article-title>. <source>Int J Clin Exp Med</source> (<year>2015</year>) <volume>8</volume>:<page-range>17565&#8211;77</page-range>.<pub-id pub-id-type="pmcid">PMC4694247</pub-id><pub-id pub-id-type="pmid">26770347</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Broekhoven</surname><given-names>CL</given-names></name><name name-style="western"><surname>Parish</surname><given-names>CR</given-names></name><name name-style="western"><surname>Demangel</surname><given-names>C</given-names></name><name name-style="western"><surname>Britton</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Altin</surname><given-names>JG</given-names></name></person-group>. <article-title>Targeting dendritic cells with antigen-containing liposomes</article-title>. <source>Cancer Res</source> (<year>2004</year>) <volume>64</volume>:<page-range>4357&#8211;65</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0138</pub-id><pub-id pub-id-type="pmid">15205352</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Zaveri</surname><given-names>TD</given-names></name><name name-style="western"><surname>Crooks</surname><given-names>CP</given-names></name><name name-style="western"><surname>Keselowsky</surname><given-names>BG</given-names></name></person-group>. <article-title>Microparticle surface modifications targeting dendritic cells for non-activating applications</article-title>. <source>Biomaterials</source> (<year>2012</year>) <volume>33</volume>:<page-range>7221&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.06.049</pub-id><pub-id pub-id-type="pmcid">PMC3428206</pub-id><pub-id pub-id-type="pmid">22796161</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sangji</surname><given-names>MH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>SD</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy</article-title>. <source>Adv Funct Mater</source> (<year>2019</year>) <volume>29</volume>:<fpage>1904399</fpage>. doi: <pub-id pub-id-type="doi">10.1002/adfm.201904399</pub-id><pub-id pub-id-type="pmid">34335131</pub-id><pub-id pub-id-type="pmcid">PMC8320590</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Dendritic cell targeting peptide-based nanovaccines for enhanced cancer immunotherapy</article-title>. <source>ACS Appl Bio Mater</source> (<year>2019</year>) <volume>2</volume>:<page-range>1241&#8211;54</page-range>. doi: <pub-id pub-id-type="doi">10.1021/acsabm.8b00811</pub-id><pub-id pub-id-type="pmid">35021373</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puth</surname><given-names>S</given-names></name><name name-style="western"><surname>Verma</surname><given-names>V</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SH</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SE</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>JH</given-names></name></person-group>. <article-title>An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation</article-title>. <source>Biomaterials</source> (<year>2022</year>) <volume>286</volume>:<fpage>121542</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121542</pub-id><pub-id pub-id-type="pmid">35594837</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kleinovink</surname><given-names>JW</given-names></name><name name-style="western"><surname>Rueda</surname><given-names>F</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>CWGM</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F</given-names></name></person-group>. <article-title>Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8<sup>+</sup> T cell response: A comparative study</article-title>. <source>J Control Release</source> (<year>2014</year>) <volume>192</volume>:<page-range>209&#8211;18</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.07.040</pub-id><pub-id pub-id-type="pmid">25068703</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro</surname><given-names>FVV</given-names></name><name name-style="western"><surname>Tutt</surname><given-names>AL</given-names></name><name name-style="western"><surname>White</surname><given-names>AL</given-names></name><name name-style="western"><surname>Teeling</surname><given-names>JL</given-names></name><name name-style="western"><surname>James</surname><given-names>S</given-names></name><name name-style="western"><surname>French</surname><given-names>RR</given-names></name><etal/></person-group>. <article-title>CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses</article-title>. <source>Eur J Immunol</source> (<year>2008</year>) <volume>38</volume>:<page-range>2263&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.200838302</pub-id><pub-id pub-id-type="pmid">18651710</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>MN</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ghazal</surname><given-names>P</given-names></name></person-group>. <article-title>Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2000</year>) <volume>97</volume>:<page-range>847&#8211;52</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.97.2.847</pub-id><pub-id pub-id-type="pmcid">PMC15419</pub-id><pub-id pub-id-type="pmid">10639168</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkelberger</surname><given-names>JR</given-names></name><name name-style="western"><surname>Song</surname><given-names>W-C</given-names></name></person-group>. <article-title>Complement and its role in innate and adaptive immune responses</article-title>. <source>Cell Res</source> (<year>2010</year>) <volume>20</volume>:<fpage>34</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1038/cr.2009.139</pub-id><pub-id pub-id-type="pmid">20010915</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugholm</surname><given-names>LH</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>LR</given-names></name><name name-style="western"><surname>S&#248;ndergaard</surname><given-names>EKL</given-names></name><name name-style="western"><surname>Varming</surname><given-names>K</given-names></name><name name-style="western"><surname>Agger</surname><given-names>R</given-names></name></person-group>. <article-title>Enhanced humoral responses induced by targeting of antigen to murine dendritic cells</article-title>. <source>Scand J Immunol</source> (<year>2015</year>) <volume>82</volume>:<page-range>515&#8211;22</page-range>. doi: <pub-id pub-id-type="doi">10.1111/sji.12387</pub-id><pub-id pub-id-type="pmid">26346906</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braathen</surname><given-names>R</given-names></name><name name-style="western"><surname>Sp&#229;ng</surname><given-names>HCL</given-names></name><name name-style="western"><surname>Lindeberg</surname><given-names>MM</given-names></name><name name-style="western"><surname>Fossum</surname><given-names>E</given-names></name><name name-style="western"><surname>Gr&#248;deland</surname><given-names>G</given-names></name><name name-style="western"><surname>Fredriksen</surname><given-names>AB</given-names></name><etal/></person-group>. <article-title>The magnitude and IgG subclass of antibodies elicited by targeted DNA vaccines are influenced by specificity for APC surface molecules</article-title>. <source>Immunohorizons</source> (<year>2018</year>) <volume>2</volume>:<fpage>38</fpage>&#8211;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.4049/immunohorizons.1700038</pub-id><pub-id pub-id-type="pmid">31022690</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tutt</surname><given-names>AL</given-names></name><name name-style="western"><surname>James</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Castro</surname><given-names>FVV</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>SV</given-names></name><etal/></person-group>. <article-title>Ligation of CD11c during vaccination promotes germinal centreinduction and robust humoral responses without adjuvant</article-title>. <source>Immunology</source> (<year>2010</year>) <volume>131</volume>:<fpage>141</fpage>&#8211;<lpage>51</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2567.2010.03285.x</pub-id><pub-id pub-id-type="pmid">20465572</pub-id><pub-id pub-id-type="pmcid">PMC2966766</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mountford</surname><given-names>AP</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>A</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RA</given-names></name></person-group>. <article-title>The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni</article-title>. <source>Parasite Immunol</source> (<year>1994</year>) <volume>16</volume>:<page-range>521&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-3024.1994.tb00306.x</pub-id><pub-id pub-id-type="pmid">7870462</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zani</surname><given-names>I</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>S</given-names></name><name name-style="western"><surname>Mughal</surname><given-names>N</given-names></name><name name-style="western"><surname>Russell</surname><given-names>D</given-names></name><name name-style="western"><surname>Homer-Vanniasinkam</surname><given-names>S</given-names></name><name name-style="western"><surname>Wheatcroft</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Scavenger receptor structure and function in health and disease</article-title>. <source>Cells</source> (<year>2015</year>) <volume>4</volume>:<fpage>178</fpage>&#8211;<lpage>201</lpage>. doi: <pub-id pub-id-type="doi">10.3390/cells4020178</pub-id><pub-id pub-id-type="pmid">26010753</pub-id><pub-id pub-id-type="pmcid">PMC4493455</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallusto</surname><given-names>F</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M</given-names></name><name name-style="western"><surname>Danieli</surname><given-names>C</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group>. <article-title>Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products</article-title>. <source>J Exp Med</source> (<year>1995</year>) <volume>182</volume>:<fpage>389</fpage>&#8211;<lpage>400</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.182.2.389</pub-id><pub-id pub-id-type="pmid">7629501</pub-id><pub-id pub-id-type="pmcid">PMC2192110</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Lukacs-Kornek</surname><given-names>V</given-names></name><name name-style="western"><surname>Kurts</surname><given-names>C</given-names></name></person-group>. <article-title>The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>:<page-range>6770&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.176.11.6770</pub-id><pub-id pub-id-type="pmid">16709836</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Smed-S&#246;rensen</surname><given-names>A</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>L</given-names></name><name name-style="western"><surname>Chalouni</surname><given-names>C</given-names></name><name name-style="western"><surname>Vandlen</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B-C</given-names></name><etal/></person-group>. <article-title>Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>:<page-range>2011&#8211;20</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-01-402370</pub-id><pub-id pub-id-type="pmid">22791285</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L-Z</given-names></name><name name-style="western"><surname>Weidlick</surname><given-names>J</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>C</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>HC</given-names></name><name name-style="western"><surname>Keler</surname><given-names>T</given-names></name></person-group>. <article-title>Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine</article-title>. <source>Cell Mol Immunol</source> (<year>2015</year>) <volume>12</volume>:<page-range>719&#8211;28</page-range>. doi: <pub-id pub-id-type="doi">10.1038/cmi.2014.100</pub-id><pub-id pub-id-type="pmcid">PMC4716615</pub-id><pub-id pub-id-type="pmid">25345808</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>DS</given-names></name><name name-style="western"><surname>Hirosue</surname><given-names>S</given-names></name><name name-style="western"><surname>Raczy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bonilla-Ramirez</surname><given-names>L</given-names></name><name name-style="western"><surname>Jeanbart</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity</article-title>. <source>Nat Mater</source> (<year>2019</year>) <volume>18</volume>:<page-range>175&#8211;85</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41563-018-0256-5</pub-id><pub-id pub-id-type="pmid">30643235</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>SK</given-names></name><name name-style="western"><surname>Streng-Ouwehand</surname><given-names>I</given-names></name><name name-style="western"><surname>Litjens</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H</given-names></name><name name-style="western"><surname>Burgdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Saeland</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>:<page-range>916&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201040762</pub-id><pub-id pub-id-type="pmid">21400496</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L-Z</given-names></name><name name-style="western"><surname>Crocker</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Mendoza-Ramirez</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X-T</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Antigenic targeting of the human mannose receptor induces tumor immunity</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>:<page-range>6259&#8211;67</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6259</pub-id><pub-id pub-id-type="pmid">17475854</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>KPA</given-names></name><name name-style="western"><surname>Munster</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Dzionek</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>J</given-names></name><name name-style="western"><surname>Hart</surname><given-names>DNJ</given-names></name></person-group>. <article-title>Characterization of human blood dendritic cell subsets</article-title>. <source>Blood</source> (<year>2002</year>) <volume>100</volume>:<page-range>4512&#8211;20</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2001-11-0097</pub-id><pub-id pub-id-type="pmid">12393628</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mnich</surname><given-names>ME</given-names></name><name name-style="western"><surname>van Dalen</surname><given-names>R</given-names></name><name name-style="western"><surname>van Sorge</surname><given-names>NM</given-names></name></person-group>. <article-title>C-type lectin receptors in host defense against bacterial pathogens</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>309</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2020.00309</pub-id><pub-id pub-id-type="pmid">32733813</pub-id><pub-id pub-id-type="pmcid">PMC7358460</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>E</given-names></name><name name-style="western"><surname>Valladeau-Guilemond</surname><given-names>J</given-names></name><name name-style="western"><surname>Donnadieu</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Sastre-Garau</surname><given-names>X</given-names></name><name name-style="western"><surname>Soumelis</surname><given-names>V</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S</given-names></name></person-group>. <article-title>Characterization of resident and migratory dendritic cells in human lymph nodes</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>:<page-range>653&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20111457</pub-id><pub-id pub-id-type="pmcid">PMC3328358</pub-id><pub-id pub-id-type="pmid">22430490</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askew</surname><given-names>D</given-names></name><name name-style="western"><surname>Harding</surname><given-names>CV</given-names></name></person-group>. <article-title>Antigen processing and CD24 expression determine antigen presentation by splenic CD4<sup>+</sup> and CD8<sup>+</sup> dendritic cells</article-title>. <source>Immunology</source> (<year>2008</year>) <volume>123</volume>:<page-range>447&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02711.x</pub-id><pub-id pub-id-type="pmcid">PMC2433328</pub-id><pub-id pub-id-type="pmid">17949418</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hongo</surname><given-names>D</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>S</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>RD</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>E</given-names></name><name name-style="western"><surname>Engleman</surname><given-names>EG</given-names></name><etal/></person-group>. <article-title>Identification of two subsets of murine DC1 dendritic cells that differ by surface phenotype, gene expression, and function</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>746469</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.746469</pub-id><pub-id pub-id-type="pmid">34777358</pub-id><pub-id pub-id-type="pmcid">PMC8589020</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>CD24: from A to Z</article-title>. <source>Cell Mol Immunol</source> (<year>2010</year>) <volume>7</volume>:<page-range>100&#8211;3</page-range>. doi: <pub-id pub-id-type="doi">10.1038/cmi.2009.119</pub-id><pub-id pub-id-type="pmcid">PMC4001892</pub-id><pub-id pub-id-type="pmid">20154703</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Dutertre</surname><given-names>C-A</given-names></name><name name-style="western"><surname>Scott</surname><given-names>CL</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>N</given-names></name><name name-style="western"><surname>Sichien</surname><given-names>D</given-names></name><name name-style="western"><surname>Chakarov</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>:<page-range>669&#8211;84</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.015</pub-id><pub-id pub-id-type="pmcid">PMC5040826</pub-id><pub-id pub-id-type="pmid">27637149</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinbrecher</surname><given-names>A</given-names></name><name name-style="western"><surname>Reinhold</surname><given-names>D</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>L</given-names></name><name name-style="western"><surname>Gado</surname><given-names>A</given-names></name><name name-style="western"><surname>Tresser</surname><given-names>N</given-names></name><name name-style="western"><surname>Izikson</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-&#946;1 secretion <italic toggle="yes">in vivo</italic>
</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>:<page-range>2041&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.166.3.2041</pub-id><pub-id pub-id-type="pmid">11160254</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohnuma</surname><given-names>K</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>R</given-names></name><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Inhibition of middle east respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody</article-title>. <source>J Virol</source> (<year>2013</year>) <volume>87</volume>:<page-range>13892&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02448-13</pub-id><pub-id pub-id-type="pmcid">PMC3838260</pub-id><pub-id pub-id-type="pmid">24067970</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salnikov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Bretz</surname><given-names>NP</given-names></name><name name-style="western"><surname>Perne</surname><given-names>C</given-names></name><name name-style="western"><surname>Hazin</surname><given-names>J</given-names></name><name name-style="western"><surname>Keller</surname><given-names>S</given-names></name><name name-style="western"><surname>Fogel</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas</article-title>. <source>Br J Cancer</source> (<year>2013</year>) <volume>108</volume>:<page-range>1449&#8211;59</page-range>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2013.102</pub-id><pub-id pub-id-type="pmcid">PMC3629417</pub-id><pub-id pub-id-type="pmid">23511563</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy</article-title>. <source>J Cancer Res Clin Oncol</source> (<year>2019</year>) <volume>145</volume>:<page-range>1179&#8211;90</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00432-019-02865-8</pub-id><pub-id pub-id-type="pmcid">PMC11810302</pub-id><pub-id pub-id-type="pmid">30778749</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosteels</surname><given-names>C</given-names></name><name name-style="western"><surname>Neyt</surname><given-names>K</given-names></name><name name-style="western"><surname>Vanheerswynghels</surname><given-names>M</given-names></name><name name-style="western"><surname>van Helden</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sichien</surname><given-names>D</given-names></name><name name-style="western"><surname>Debeuf</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>52</volume>:<fpage>1039</fpage>&#8211;<lpage>1056.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.005</pub-id><pub-id pub-id-type="pmid">32392463</pub-id><pub-id pub-id-type="pmcid">PMC7207120</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villani</surname><given-names>A-C</given-names></name><name name-style="western"><surname>Satija</surname><given-names>R</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>G</given-names></name><name name-style="western"><surname>Sarkizova</surname><given-names>S</given-names></name><name name-style="western"><surname>Shekhar</surname><given-names>K</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors</article-title>. <source>Science</source> (<year>2017</year>) <volume>356</volume>:<elocation-id>eaah4573</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.aah4573</pub-id><pub-id pub-id-type="pmid">28428369</pub-id><pub-id pub-id-type="pmcid">PMC5775029</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name></person-group>. <article-title>Expanding dendritic cell nomenclature in the single-cell era</article-title>. <source>Nat Rev Immunol</source> (<year>2022</year>) <volume>22</volume>:<page-range>67&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41577-022-00675-7</pub-id><pub-id pub-id-type="pmid">35027741</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durai</surname><given-names>V</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name></person-group>. <article-title>Functions of murine dendritic cells</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>:<page-range>719&#8211;36</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2016.10.010</pub-id><pub-id pub-id-type="pmcid">PMC5145312</pub-id><pub-id pub-id-type="pmid">27760337</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>DA</given-names></name><name name-style="western"><surname>Dutertre</surname><given-names>C-A</given-names></name><name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name></person-group>. <article-title>Genetic models of human and mouse dendritic cell development and function</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>:<page-range>101&#8211;15</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41577-020-00413-x</pub-id><pub-id pub-id-type="pmcid">PMC10955724</pub-id><pub-id pub-id-type="pmid">32908299</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C-L</given-names></name></person-group>. <article-title>A recently described type 2 conventional dendritic cell (cDC2) subset mediates inflammation</article-title>. <source>Cell Mol Immunol</source> (<year>2020</year>) <volume>17</volume>:<page-range>1215&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41423-020-0511-y</pub-id><pub-id pub-id-type="pmcid">PMC7785008</pub-id><pub-id pub-id-type="pmid">32732988</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnaswamy</surname><given-names>JK</given-names></name><name name-style="western"><surname>Gowthaman</surname><given-names>U</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Szeponik</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Migratory CD11b<sup>+</sup> conventional dendritic cells induce T follicular helper cell&#8211;dependent antibody responses</article-title>. <source>Sci Immunol</source> (<year>2017</year>) <volume>2</volume>:<elocation-id>eaam9169</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.aam9169</pub-id><pub-id pub-id-type="pmid">29196450</pub-id><pub-id pub-id-type="pmcid">PMC7847246</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>CI</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C</given-names></name><name name-style="western"><surname>Metang</surname><given-names>P</given-names></name><name name-style="western"><surname>Marches</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Toshiyuki</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Human CD141<sup>+</sup> Dendritic cells induce CD4<sup>+</sup> T cells to produce type 2 cytokines</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>193</volume>:<page-range>4335&#8211;43</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1401159</pub-id><pub-id pub-id-type="pmcid">PMC4201960</pub-id><pub-id pub-id-type="pmid">25246496</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourdely</surname><given-names>P</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>G</given-names></name><name name-style="western"><surname>Vaivode</surname><given-names>K</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>RN</given-names></name><name name-style="western"><surname>Missolo-Koussou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Transcriptional and functional analysis of CD1c+ Human dendritic cells identifies a CD163+ Subset priming CD8+CD103+ T cells</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>53</volume>:<fpage>335</fpage>&#8211;<lpage>352.e8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.002</pub-id><pub-id pub-id-type="pmid">32610077</pub-id><pub-id pub-id-type="pmcid">PMC7445430</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabeza-Cabrerizo</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>A</given-names></name><name name-style="western"><surname>Minutti</surname><given-names>CM</given-names></name><name name-style="western"><surname>Pereira da Costa</surname><given-names>M</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group>. <article-title>Dendritic cells revisited</article-title>. <source>Annu Rev Immunol</source> (<year>2021</year>) <volume>39</volume>:<page-range>131&#8211;66</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-061020-053707</pub-id><pub-id pub-id-type="pmid">33481643</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifaz</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bonnyay</surname><given-names>DP</given-names></name><name name-style="western"><surname>Charalambous</surname><given-names>A</given-names></name><name name-style="western"><surname>Darguste</surname><given-names>DI</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S-I</given-names></name><name name-style="western"><surname>Soares</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">In vivo</italic> targeting of antigens to maturing dendritic cells <italic toggle="yes">via</italic> the DEC-205 receptor improves T cell vaccination</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>:<page-range>815&#8211;24</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20032220</pub-id><pub-id pub-id-type="pmcid">PMC2212731</pub-id><pub-id pub-id-type="pmid">15024047</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name><name name-style="western"><surname>Idoyaga</surname><given-names>J</given-names></name><name name-style="western"><surname>Suda</surname><given-names>K</given-names></name><name name-style="western"><surname>Suda</surname><given-names>N</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>K</given-names></name><name name-style="western"><surname>Noda</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A new triggering receptor expressed on myeloid cells (Trem) family member, Trem-like 4, binds to dead cells and is a DNAX activation protein 12-linked marker for subsets of mouse macrophages and dendritic cells</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>:<page-range>1278&#8211;86</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.182.3.1278</pub-id><pub-id pub-id-type="pmcid">PMC2843158</pub-id><pub-id pub-id-type="pmid">19155473</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Matos</surname><given-names>I</given-names></name><name name-style="western"><surname>Fiorese</surname><given-names>C</given-names></name><name name-style="western"><surname>Lubkin</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells <italic toggle="yes">in vivo</italic>, including protective immunity to HER2 protein</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<page-range>1147&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1102541</pub-id><pub-id pub-id-type="pmcid">PMC3262937</pub-id><pub-id pub-id-type="pmid">22210914</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Idoyaga</surname><given-names>J</given-names></name><name name-style="western"><surname>Fiorese</surname><given-names>C</given-names></name><name name-style="western"><surname>Zbytnuik</surname><given-names>L</given-names></name><name name-style="western"><surname>Lubkin</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Specialized role of migratory dendritic cells in peripheral tolerance induction</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>:<page-range>844&#8211;54</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI65260</pub-id><pub-id pub-id-type="pmcid">PMC3561796</pub-id><pub-id pub-id-type="pmid">23298832</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedeva</surname><given-names>C</given-names></name><name name-style="western"><surname>Menassa</surname><given-names>J</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Doerflinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Kueh</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>TREML4 receptor regulates inflammation and innate immune cell death during polymicrobial sepsis</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>21</volume>:<page-range>1585&#8211;96</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-020-0789-z</pub-id><pub-id pub-id-type="pmid">33020659</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fossum</surname><given-names>E</given-names></name><name name-style="western"><surname>Tesfaye</surname><given-names>DY</given-names></name><name name-style="western"><surname>Bobic</surname><given-names>S</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Braathen</surname><given-names>R</given-names></name><name name-style="western"><surname>Lahoud</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Targeting antigens to different receptors on conventional type 1 dendritic cells impacts the immune response</article-title>. <source>J Immunol</source> (<year>2020</year>) <volume>205</volume>:<page-range>661&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1901119</pub-id><pub-id pub-id-type="pmid">32591401</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifaz</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonnyay</surname><given-names>D</given-names></name><name name-style="western"><surname>Mahnke</surname><given-names>K</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>M</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name></person-group>. <article-title>Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8<sup>+</sup> T cell tolerance</article-title>. <source>J Exp Med</source> (<year>2002</year>) <volume>196</volume>:<page-range>1627&#8211;38</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20021598</pub-id><pub-id pub-id-type="pmcid">PMC2196060</pub-id><pub-id pub-id-type="pmid">12486105</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahoud</surname><given-names>MH</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Kitsoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Wan</surname><given-names>SS</given-names></name><name name-style="western"><surname>Vremec</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C-N</given-names></name><etal/></person-group>. <article-title>Targeting Antigen to Mouse Dendritic Cells <italic toggle="yes">via</italic> Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<page-range>842&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1101176</pub-id><pub-id pub-id-type="pmid">21677141</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masterman</surname><given-names>K-A</given-names></name><name name-style="western"><surname>Haigh</surname><given-names>OL</given-names></name><name name-style="western"><surname>Tullett</surname><given-names>KM</given-names></name><name name-style="western"><surname>Leal-Rojas</surname><given-names>IM</given-names></name><name name-style="western"><surname>Walpole</surname><given-names>C</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>FE</given-names></name><etal/></person-group>. <article-title>Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141<sup>+</sup> dendritic cells to activate na&#239;ve and memory NY-ESO-1-specific CD8<sup>+</sup> T cells</article-title>. <source>J Immunother Cancer</source> (<year>2020</year>) <volume>8</volume>:<elocation-id>e000691</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/jitc-2020-000691</pub-id><pub-id pub-id-type="pmid">32737142</pub-id><pub-id pub-id-type="pmcid">PMC7394304</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahoud</surname><given-names>MH</given-names></name><name name-style="western"><surname>Proietto</surname><given-names>AI</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Kitsoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Eidsmo</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>:<page-range>7587&#8211;94</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0900464</pub-id><pub-id pub-id-type="pmid">19494282</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagliani</surname><given-names>E</given-names></name><name name-style="western"><surname>Guermonprez</surname><given-names>P</given-names></name><name name-style="western"><surname>Sep&#250;lveda</surname><given-names>J</given-names></name><name name-style="western"><surname>L&#243;pez-Bravo</surname><given-names>M</given-names></name><name name-style="western"><surname>Ardav&#237;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8&#945;<sup>+</sup> Dendritic cells</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>:<page-range>3201&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.180.5.3201</pub-id><pub-id pub-id-type="pmid">18292544</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudjonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Lys&#233;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Balan</surname><given-names>S</given-names></name><name name-style="western"><surname>Sundvold-Gjerstad</surname><given-names>V</given-names></name><name name-style="western"><surname>Arnold-Schrauf</surname><given-names>C</given-names></name><name name-style="western"><surname>Richter</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Targeting influenza virus hemagglutinin to Xcr1<sup>+</sup> Dendritic cells in the absence of receptor-mediated endocytosis enhances protective antibody responses</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>:<page-range>2785&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1601881</pub-id><pub-id pub-id-type="pmid">28228559</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fossum</surname><given-names>E</given-names></name><name name-style="western"><surname>Gr&#248;deland</surname><given-names>G</given-names></name><name name-style="western"><surname>Terhorst</surname><given-names>D</given-names></name><name name-style="western"><surname>Tveita</surname><given-names>AA</given-names></name><name name-style="western"><surname>Vikse</surname><given-names>E</given-names></name><name name-style="western"><surname>Mjaaland</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8<sup>+</sup> T-cell responses against influenza virus: New technology</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>:<page-range>624&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201445080</pub-id><pub-id pub-id-type="pmid">25410055</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flinsenberg</surname><given-names>TWH</given-names></name><name name-style="western"><surname>Compeer</surname><given-names>EB</given-names></name><name name-style="western"><surname>Koning</surname><given-names>D</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M</given-names></name><name name-style="western"><surname>Amelung</surname><given-names>FJ</given-names></name><name name-style="western"><surname>van Baarle</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Fc&#947; receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3<sup>+</sup> dendritic cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>:<page-range>5163&#8211;72</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-06-434498</pub-id><pub-id pub-id-type="pmid">23093620</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delneste</surname><given-names>Y</given-names></name><name name-style="western"><surname>Magistrelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Gauchat</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Haeuw</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>:<page-range>353&#8211;62</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(02)00388-6</pub-id><pub-id pub-id-type="pmid">12354387</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>:<page-range>2306&#8211;13</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0903214</pub-id><pub-id pub-id-type="pmid">20631313</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Romain</surname><given-names>G</given-names></name><name name-style="western"><surname>Flamar</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Duluc</surname><given-names>D</given-names></name><name name-style="western"><surname>Dullaers</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>X-H</given-names></name><etal/></person-group>. <article-title>Targeting self- and foreign antigens to dendritic cells <italic toggle="yes">via</italic> DC-ASGPR generates IL-10&#8211;producing suppressive CD4<sup>+</sup> T cells</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>:<page-range>109&#8211;21</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20110399</pub-id><pub-id pub-id-type="pmcid">PMC3260876</pub-id><pub-id pub-id-type="pmid">22213806</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>CHK</given-names></name><name name-style="western"><surname>Baranska</surname><given-names>A</given-names></name><name name-style="western"><surname>Heidkamp</surname><given-names>GF</given-names></name><name name-style="western"><surname>Heger</surname><given-names>L</given-names></name><name name-style="western"><surname>Neubert</surname><given-names>K</given-names></name><name name-style="western"><surname>L&#252;hr</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>DC subset&#8211;specific induction of T cell responses upon antigen uptake <italic toggle="yes">via</italic> Fc&#947; receptors <italic toggle="yes">in vivo</italic>
</article-title>. <source>J Exp Med</source> (<year>2017</year>) <volume>214</volume>:<page-range>1509&#8211;28</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20160951</pub-id><pub-id pub-id-type="pmcid">PMC5413326</pub-id><pub-id pub-id-type="pmid">28389502</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorner</surname><given-names>BG</given-names></name><name name-style="western"><surname>Dorner</surname><given-names>MB</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Opitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Mora</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#252;ttler</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8<sup>+</sup> T cells</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>31</volume>:<page-range>823&#8211;33</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.027</pub-id><pub-id pub-id-type="pmid">19913446</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesfaye</surname><given-names>DY</given-names></name><name name-style="western"><surname>Bobic</surname><given-names>S</given-names></name><name name-style="western"><surname>Lys&#233;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Huszthy</surname><given-names>PC</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Braathen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Targeting xcr1 on dendritic cells rapidly induce th1-associated immune responses that contribute to protection against influenza infection</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>752714</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.752714</pub-id><pub-id pub-id-type="pmid">35296089</pub-id><pub-id pub-id-type="pmcid">PMC8918470</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>J</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>MP</given-names></name><name name-style="western"><surname>Ramakrishna</surname><given-names>V</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>L-Z</given-names></name><etal/></person-group>. <article-title>Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 <italic toggle="yes">in vitro</italic> elicits dual human CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses with broad antigen specificity</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<page-range>1218&#8211;27</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1000808</pub-id><pub-id pub-id-type="pmid">21149605</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meixlsperger</surname><given-names>S</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CS</given-names></name><name name-style="western"><surname>R&#228;mer</surname><given-names>PC</given-names></name><name name-style="western"><surname>Pack</surname><given-names>M</given-names></name><name name-style="western"><surname>Vanoaica</surname><given-names>LD</given-names></name><name name-style="western"><surname>Breton</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>CD141<sup>+</sup> dendritic cells produce prominent amounts of IFN-&#945; after dsRNA recognition and can be targeted <italic toggle="yes">via</italic> DEC-205 in humanized mice</article-title>. <source>Blood</source> (<year>2013</year>) <volume>121</volume>:<page-range>5034&#8211;44</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-12-473413</pub-id><pub-id pub-id-type="pmcid">PMC3689250</pub-id><pub-id pub-id-type="pmid">23482932</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhodapkar</surname><given-names>MV</given-names></name><name name-style="western"><surname>Sznol</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Carvajal</surname><given-names>RD</given-names></name><name name-style="western"><surname>Keohan</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205</article-title>. <source>Sci Transl Med</source> (<year>2014</year>) <volume>6</volume>:<fpage>232</fpage>&#8211;<lpage>52</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3008068</pub-id><pub-id pub-id-type="pmcid">PMC6151129</pub-id><pub-id pub-id-type="pmid">24739759</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>Proietto</surname><given-names>AI</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Kitsoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin Teh</surname><given-names>J</given-names></name><name name-style="western"><surname>Lo</surname><given-names>JCY</given-names></name><etal/></person-group>. <article-title>The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>:<page-range>3264&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2008-05-155176</pub-id><pub-id pub-id-type="pmcid">PMC2569177</pub-id><pub-id pub-id-type="pmid">18669894</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sancho</surname><given-names>D</given-names></name><name name-style="western"><surname>Mour&#227;o-S&#225;</surname><given-names>D</given-names></name><name name-style="western"><surname>Joffre</surname><given-names>OP</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>O</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>NC</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Tumor therapy in mice <italic toggle="yes">via</italic> antigen targeting to a novel, DC-restricted C-type lectin</article-title>. <source>J Clin Invest</source> (<year>2008</year>) <volume>118</volume>:<page-range>2098&#8211;110</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI34584</pub-id><pub-id pub-id-type="pmcid">PMC2391066</pub-id><pub-id pub-id-type="pmid">18497879</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canton</surname><given-names>J</given-names></name><name name-style="western"><surname>Blees</surname><given-names>H</given-names></name><name name-style="western"><surname>Henry</surname><given-names>CM</given-names></name><name name-style="western"><surname>Buck</surname><given-names>MD</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>O</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>NC</given-names></name><etal/></person-group>. <article-title>The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens</article-title>. <source>Nat Immunol</source> (<year>2021</year>) <volume>22</volume>:<page-range>140&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-020-00824-x</pub-id><pub-id pub-id-type="pmcid">PMC7116638</pub-id><pub-id pub-id-type="pmid">33349708</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>LC</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>AG</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>De Rose</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates: Immunomodulation</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>:<page-range>854&#8211;64</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201445127</pub-id><pub-id pub-id-type="pmid">25487143</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffre</surname><given-names>OP</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D</given-names></name><name name-style="western"><surname>Zelenay</surname><given-names>S</given-names></name><name name-style="western"><surname>Keller</surname><given-names>AM</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group>. <article-title>Efficient and versatile manipulation of the peripheral CD4<sup>+</sup> T-cell compartment by antigen targeting to DNGR-1/CLEC9A</article-title>. <source>Eur J Immunol</source> (<year>2010</year>) <volume>40</volume>:<page-range>1255&#8211;65</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201040419</pub-id><pub-id pub-id-type="pmcid">PMC3064981</pub-id><pub-id pub-id-type="pmid">20333625</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Davey</surname><given-names>GM</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>SN</given-names></name><name name-style="western"><surname>Nutt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Zotos</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Targeting antigen to clec9A primes follicular Th cell memory responses capable of robust recall</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>:<page-range>1006&#8211;14</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1500767</pub-id><pub-id pub-id-type="pmid">26101322</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>TM</given-names></name><name name-style="western"><surname>Park</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Hitchcock</surname><given-names>RO</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Hor</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Display of native antigen on cDC1 that have spatial access to both T and B cells underlies efficient humoral vaccination</article-title>. <source>J Immunol</source> (<year>2020</year>) <volume>205</volume>:<page-range>1842&#8211;56</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.2000549</pub-id><pub-id pub-id-type="pmcid">PMC7504891</pub-id><pub-id pub-id-type="pmid">32839238</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parlato</surname><given-names>S</given-names></name><name name-style="western"><surname>Romagnoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Spadaro</surname><given-names>F</given-names></name><name name-style="western"><surname>Canini</surname><given-names>I</given-names></name><name name-style="western"><surname>Sirabella</surname><given-names>P</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>LOX-1 as a natural IFN-&#945;&#8211;mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells</article-title>. <source>Blood</source> (<year>2010</year>) <volume>115</volume>:<page-range>1554&#8211;63</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2009-07-234468</pub-id><pub-id pub-id-type="pmid">20009034</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junker</surname><given-names>F</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>O</given-names></name></person-group>. <article-title>Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1393</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01393</pub-id><pub-id pub-id-type="pmid">32719679</pub-id><pub-id pub-id-type="pmcid">PMC7350606</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcaide</surname><given-names>EG</given-names></name><name name-style="western"><surname>Krishnarajah</surname><given-names>S</given-names></name><name name-style="western"><surname>Junker</surname><given-names>F</given-names></name></person-group>. <article-title>Dendritic cell tumor vaccination <italic toggle="yes">via</italic> fc gamma receptor targeting: lessons learned from pre-clinical and translational studies</article-title>. <source>Vaccines</source> (<year>2021</year>) <volume>9</volume>:<fpage>409</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9040409</pub-id><pub-id pub-id-type="pmid">33924183</pub-id><pub-id pub-id-type="pmcid">PMC8074394</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruhns</surname><given-names>P</given-names></name></person-group>. <article-title>Properties of mouse and human IgG receptors and their contribution to disease models</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>:<page-range>5640&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-01-380121</pub-id><pub-id pub-id-type="pmid">22535666</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruhns</surname><given-names>P</given-names></name><name name-style="western"><surname>Iannascoli</surname><given-names>B</given-names></name><name name-style="western"><surname>England</surname><given-names>P</given-names></name><name name-style="western"><surname>Mancardi</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>N</given-names></name><name name-style="western"><surname>Jorieux</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Specificity and affinity of human Fc&#947; receptors and their polymorphic variants for human IgG subclasses</article-title>. <source>Blood</source> (<year>2009</year>) <volume>113</volume>:<page-range>3716&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2008-09-179754</pub-id><pub-id pub-id-type="pmid">19018092</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroczek</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>E</given-names></name><name name-style="western"><surname>Gurka</surname><given-names>S</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M</given-names></name><name name-style="western"><surname>Reeg</surname><given-names>N</given-names></name><name name-style="western"><surname>Mages</surname><given-names>HW</given-names></name><etal/></person-group>. <article-title>Structure-function relationship of XCL1 used for in <italic toggle="yes">vivo</italic> targeting of antigen into XCR1+ Dendritic cells</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2806</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02806</pub-id><pub-id pub-id-type="pmid">30619244</pub-id><pub-id pub-id-type="pmcid">PMC6300513</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harshyne</surname><given-names>LA</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>SC</given-names></name><name name-style="western"><surname>Gambotto</surname><given-names>A</given-names></name><name name-style="western"><surname>Barratt-Boyes</surname><given-names>SM</given-names></name></person-group>. <article-title>Dendritic cells acquire antigens from live cells for cross-presentation to CTL</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>:<page-range>3717&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.166.6.3717</pub-id><pub-id pub-id-type="pmid">11238612</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudziak</surname><given-names>D</given-names></name><name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></name><name name-style="western"><surname>Heidkamp</surname><given-names>GF</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>VR</given-names></name><name name-style="western"><surname>Trumpfheller</surname><given-names>C</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Differential antigen processing by dendritic cell subsets in vivo</article-title>. <source>Science</source> (<year>2007</year>) <volume>315</volume>:<page-range>107&#8211;11</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1136080</pub-id><pub-id pub-id-type="pmid">17204652</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chappell</surname><given-names>CP</given-names></name><name name-style="western"><surname>Draves</surname><given-names>KE</given-names></name><name name-style="western"><surname>Giltiay</surname><given-names>NV</given-names></name><name name-style="western"><surname>Clark</surname><given-names>EA</given-names></name></person-group>. <article-title>Extrafollicular B cell activation by marginal zone dendritic cells drives T cell&#8211;dependent antibody responses</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>:<page-range>1825&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20120774</pub-id><pub-id pub-id-type="pmcid">PMC3457737</pub-id><pub-id pub-id-type="pmid">22966002</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uto</surname><given-names>T</given-names></name><name name-style="western"><surname>Fukaya</surname><given-names>T</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>H</given-names></name><name name-style="western"><surname>Arimura</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity</article-title>. <source>Nat Commun</source> (<year>2016</year>) <volume>7</volume>:<fpage>11273</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms11273</pub-id><pub-id pub-id-type="pmid">27068492</pub-id><pub-id pub-id-type="pmcid">PMC4832068</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neubert</surname><given-names>K</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>CHK</given-names></name><name name-style="western"><surname>Heger</surname><given-names>L</given-names></name><name name-style="western"><surname>Baranska</surname><given-names>A</given-names></name><name name-style="western"><surname>Staedtler</surname><given-names>AM</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>VR</given-names></name><etal/></person-group>. <article-title>Antigen delivery to CD11c<sup>+</sup> CD8<sup>&#8211;</sup> dendritic cells induces protective immune responses against experimental melanoma in mice <italic toggle="yes">in vivo</italic>
</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>:<page-range>5830&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1300975</pub-id><pub-id pub-id-type="pmid">24829411</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lys&#233;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Braathen</surname><given-names>R</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Tesfaye</surname><given-names>DY</given-names></name><name name-style="western"><surname>Bogen</surname><given-names>B</given-names></name><name name-style="western"><surname>Fossum</surname><given-names>E</given-names></name></person-group>. <article-title>Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>:<fpage>1820</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-38080-7</pub-id><pub-id pub-id-type="pmid">30755656</pub-id><pub-id pub-id-type="pmcid">PMC6372594</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></name><name name-style="western"><surname>Guermonprez</surname><given-names>P</given-names></name><name name-style="western"><surname>Dudziak</surname><given-names>D</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>:<page-range>3426&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1001205</pub-id><pub-id pub-id-type="pmcid">PMC3013633</pub-id><pub-id pub-id-type="pmid">20729332</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>RW</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C</given-names></name><name name-style="western"><surname>Reid</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SYC</given-names></name><name name-style="western"><surname>Tough</surname><given-names>DF</given-names></name></person-group>. <article-title>Preferential induction of CD4<sup>+</sup> T cell responses through <italic toggle="yes">in vivo</italic> targeting of antigen to dendritic cell-associated C-type lectin-1</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>177</volume>:<page-range>2276&#8211;84</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.177.4.2276</pub-id><pub-id pub-id-type="pmid">16887988</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>RW</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C</given-names></name><name name-style="western"><surname>Reid</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SYC</given-names></name><name name-style="western"><surname>Tough</surname><given-names>DF</given-names></name></person-group>. <article-title>Induction of CD8<sup>+</sup> T cell responses through targeting of antigen to Dectin-2</article-title>. <source>Cell Immunol</source> (<year>2006</year>) <volume>239</volume>:<fpage>87</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cellimm.2006.05.001</pub-id><pub-id pub-id-type="pmid">16781694</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>BS</given-names></name><name name-style="western"><surname>Brady</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wright</surname><given-names>MD</given-names></name><name name-style="western"><surname>Mottram</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>Antigen delivery <italic toggle="yes">via</italic> two molecules on the CD8<sup>-</sup> dendritic cell subset induces humoral immunity in the absence of conventional &#8220;danger&#8221;</article-title>. <source>Eur J Immunol</source> (<year>2005</year>) <volume>35</volume>:<page-range>2815&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.200526100</pub-id><pub-id pub-id-type="pmid">16143986</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schetters</surname><given-names>STT</given-names></name><name name-style="western"><surname>Kruijssen</surname><given-names>LJW</given-names></name><name name-style="western"><surname>Crommentuijn</surname><given-names>MHW</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H</given-names></name><name name-style="western"><surname>Ochando</surname><given-names>J</given-names></name><name name-style="western"><surname>den Haan</surname><given-names>JMM</given-names></name><etal/></person-group>. <article-title>Mouse DC-SIGN/CD209a as target for antigen delivery and adaptive immunity</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>990</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.00990</pub-id><pub-id pub-id-type="pmid">29867967</pub-id><pub-id pub-id-type="pmcid">PMC5949514</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papaioannou</surname><given-names>NE</given-names></name><name name-style="western"><surname>Salei</surname><given-names>N</given-names></name><name name-style="western"><surname>Rambichler</surname><given-names>S</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>K</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>J</given-names></name><name name-style="western"><surname>K&#252;ntzel</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Environmental signals rather than layered ontogeny imprint the function of type 2 conventional dendritic cells in young and adult mice</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>464</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-020-20659-2</pub-id><pub-id pub-id-type="pmid">33469015</pub-id><pub-id pub-id-type="pmcid">PMC7815729</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castenmiller</surname><given-names>C</given-names></name><name name-style="western"><surname>Keumatio-Doungtsop</surname><given-names>B-C</given-names></name><name name-style="western"><surname>Van Ree</surname><given-names>R</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>EC</given-names></name><name name-style="western"><surname>Van Kooyk</surname><given-names>Y</given-names></name></person-group>. <article-title>Tolerogenic immunotherapy: targeting DC surface receptors to induce antigen-specific tolerance</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>643240</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.643240</pub-id><pub-id pub-id-type="pmid">33679806</pub-id><pub-id pub-id-type="pmcid">PMC7933040</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kaifu</surname><given-names>T</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y</given-names></name></person-group>. <article-title>Dendritic cell immunoreceptor (DCIR): an ITIM-harboring C-type lectin receptor</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Yamasaki</surname><given-names>S</given-names></name></person-group>, editor. <source>C-type lectin receptors in immunity</source>. <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Springer Japan</publisher-name> (<year>2016</year>). p. <page-range>101&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-4-431-56015-9_7</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerscher</surname><given-names>B</given-names></name><name name-style="western"><surname>Willment</surname><given-names>JA</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name></person-group>. <article-title>The Dectin-2 family of C-type lectin-like receptors: an update</article-title>. <source>Int Immunol</source> (<year>2013</year>) <volume>25</volume>:<page-range>271&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxt006</pub-id><pub-id pub-id-type="pmcid">PMC3631001</pub-id><pub-id pub-id-type="pmid">23606632</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klechevsky</surname><given-names>E</given-names></name><name name-style="western"><surname>Flamar</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Blanck</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Bar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cross-priming CD8<sup>+</sup> T cells by targeting antigens to human dendritic cells through DCIR</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>:<page-range>1685&#8211;97</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-01-264960</pub-id><pub-id pub-id-type="pmcid">PMC2947393</pub-id><pub-id pub-id-type="pmid">20530286</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanriver</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ratnasothy</surname><given-names>K</given-names></name><name name-style="western"><surname>Bucy</surname><given-names>RP</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Lechler</surname><given-names>R</given-names></name></person-group>. <article-title>Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<page-range>1757&#8211;64</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0902987</pub-id><pub-id pub-id-type="pmid">20083658</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabansky</surname><given-names>I</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Watts</surname><given-names>D</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>C</given-names></name><name name-style="western"><surname>Funaro</surname><given-names>M</given-names></name><name name-style="western"><surname>Sands</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Targeting DEC-205&#8211;DCIR2<sup>+</sup> dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis</article-title>. <source>Mol Med</source> (<year>2018</year>) <volume>24</volume>:<fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s10020-018-0017-6</pub-id><pub-id pub-id-type="pmid">30134798</pub-id><pub-id pub-id-type="pmcid">PMC6016871</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Jakubzick</surname><given-names>C</given-names></name><name name-style="western"><surname>Naik</surname><given-names>SH</given-names></name><name name-style="western"><surname>Onai</surname><given-names>N</given-names></name><name name-style="western"><surname>Schraml</surname><given-names>BU</given-names></name><etal/></person-group>. <article-title>Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<page-range>571&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3712</pub-id><pub-id pub-id-type="pmcid">PMC4638219</pub-id><pub-id pub-id-type="pmid">25033907</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lew</surname><given-names>AM</given-names></name><name name-style="western"><surname>Naik</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kershaw</surname><given-names>MH</given-names></name></person-group>. <article-title>Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>179</volume>:<page-range>7577&#8211;84</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7577</pub-id><pub-id pub-id-type="pmid">18025203</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>N</given-names></name><name name-style="western"><surname>Motoi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Karuppuchamy</surname><given-names>T</given-names></name><name name-style="western"><surname>Izawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>PRAT4A-dependent expression of cell surface TLR5 on neutrophils, classical monocytes and dendritic cells</article-title>. <source>Int Immunol</source> (<year>2012</year>) <volume>24</volume>:<page-range>613&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxs068</pub-id><pub-id pub-id-type="pmid">22836022</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group>. <article-title>Toll-like receptors and dendritic cells: for whom the bug tolls</article-title>. <source>Semin Immunol</source> (<year>2004</year>) <volume>16</volume>:<fpage>27</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.smim.2003.10.004</pub-id><pub-id pub-id-type="pmid">14751761</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ariizumi</surname><given-names>K</given-names></name><name name-style="western"><surname>Shen</surname><given-names>G-L</given-names></name><name name-style="western"><surname>Shikano</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumamoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning</article-title>. <source>J Biol Chem</source> (<year>2000</year>) <volume>275</volume>:<page-range>20157&#8211;67</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M909512199</pub-id><pub-id pub-id-type="pmid">10779524</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundberg</surname><given-names>K</given-names></name><name name-style="western"><surname>Rydnert</surname><given-names>F</given-names></name><name name-style="western"><surname>Greiff</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindstedt</surname><given-names>M</given-names></name></person-group>. <article-title>Human blood dendritic cell subsets exhibit discriminative pattern recognition receptor profiles</article-title>. <source>Immunology</source> (<year>2014</year>) <volume>142</volume>:<page-range>279&#8211;88</page-range>. doi: <pub-id pub-id-type="doi">10.1111/imm.12252</pub-id><pub-id pub-id-type="pmcid">PMC4008235</pub-id><pub-id pub-id-type="pmid">24444310</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacken</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ginter</surname><given-names>W</given-names></name><name name-style="western"><surname>Berod</surname><given-names>L</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>B</given-names></name><name name-style="western"><surname>Sparwasser</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Targeting DC-SIGN <italic toggle="yes">via</italic> its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation</article-title>. <source>Blood</source> (<year>2011</year>) <volume>118</volume>:<page-range>4111&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2011-04-346957</pub-id><pub-id pub-id-type="pmid">21860028</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geijtenbeek</surname><given-names>TBH</given-names></name><name name-style="western"><surname>Torensma</surname><given-names>R</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>SJ</given-names></name><name name-style="western"><surname>van Duijnhoven</surname><given-names>GCF</given-names></name><name name-style="western"><surname>Adema</surname><given-names>GJ</given-names></name><name name-style="western"><surname>van Kooyk</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Identification of DC-SIGN, a novel dendritic cell&#8211;specific ICAM-3 receptor that supports primary immune responses</article-title>. <source>Cell</source> (<year>2000</year>) <volume>100</volume>:<page-range>575&#8211;85</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80693-5</pub-id><pub-id pub-id-type="pmid">10721994</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>KM</given-names></name><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hochrein</surname><given-names>H</given-names></name><name name-style="western"><surname>La&#226;bi</surname><given-names>Y</given-names></name><name name-style="western"><surname>K&#246;ntgen</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Molecular cloning of F4/80-like-receptor, a seven-span membrane protein expressed differentially by dendritic cell and monocyte-macrophage subpopulations</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>167</volume>:<page-range>3570&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.167.7.3570</pub-id><pub-id pub-id-type="pmid">11564768</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Vliet</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bay</surname><given-names>S</given-names></name><name name-style="western"><surname>Vuist</surname><given-names>IM</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H</given-names></name><name name-style="western"><surname>Garc&#237;a-Vallejo</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-&#945; secretion</article-title>. <source>J Leukocyte Biol</source> (<year>2013</year>) <volume>94</volume>:<page-range>315&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1189/jlb.1012520</pub-id><pub-id pub-id-type="pmid">23744646</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilarregui</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kooij</surname><given-names>G</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>E</given-names></name><name name-style="western"><surname>van der Pol</surname><given-names>SMA</given-names></name><name name-style="western"><surname>Koning</surname><given-names>N</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation</article-title>. <source>J Neuroinflammation</source> (<year>2019</year>) <volume>16</volume>:<fpage>130</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-019-1522-4</pub-id><pub-id pub-id-type="pmid">31248427</pub-id><pub-id pub-id-type="pmcid">PMC6598247</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heger</surname><given-names>L</given-names></name><name name-style="western"><surname>Balk</surname><given-names>S</given-names></name><name name-style="western"><surname>L&#252;hr</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Heidkamp</surname><given-names>GF</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>CHK</given-names></name><name name-style="western"><surname>Hatscher</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>CLEC10A is a specific marker for human CD1c+ Dendritic cells and enhances their toll-like receptor 7/8-induced cytokine secretion</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>744</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.00744</pub-id><pub-id pub-id-type="pmid">29755453</pub-id><pub-id pub-id-type="pmcid">PMC5934495</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denda-Nagai</surname><given-names>K</given-names></name><name name-style="western"><surname>Aida</surname><given-names>S</given-names></name><name name-style="western"><surname>Saba</surname><given-names>K</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Oo-puthinan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b)</article-title>. <source>J Biol Chem</source> (<year>2010</year>) <volume>285</volume>:<page-range>19193&#8211;204</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M110.113613</pub-id><pub-id pub-id-type="pmcid">PMC2885198</pub-id><pub-id pub-id-type="pmid">20304916</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggink</surname><given-names>LL</given-names></name><name name-style="western"><surname>Roby</surname><given-names>KF</given-names></name><name name-style="western"><surname>Cote</surname><given-names>R</given-names></name><name name-style="western"><surname>Kenneth Hoober</surname><given-names>J</given-names></name></person-group>. <article-title>An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides</article-title>. <source>J Immunother Cancer</source> (<year>2018</year>) <volume>6</volume>:<fpage>28</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40425-018-0339-5</pub-id><pub-id pub-id-type="pmid">29665849</pub-id><pub-id pub-id-type="pmcid">PMC5905120</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitoh</surname><given-names>S-I</given-names></name><name name-style="western"><surname>Abe</surname><given-names>F</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>A</given-names></name><name name-style="western"><surname>Tanimura</surname><given-names>N</given-names></name><name name-style="western"><surname>Mori Saitoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>:<fpage>1592</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-017-01687-x</pub-id><pub-id pub-id-type="pmid">29150602</pub-id><pub-id pub-id-type="pmcid">PMC5693993</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benitez-Ribas</surname><given-names>D</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>P</given-names></name><name name-style="western"><surname>Punt</surname><given-names>CJA</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>IJM</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name></person-group>. <article-title>Activation of human plasmacytoid dendritic cells by TLR9 impairs fc&#947;RII-mediated uptake of immune complexes and presentation by MHC class II</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<page-range>5219&#8211;24</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5219</pub-id><pub-id pub-id-type="pmid">18832675</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tel</surname><given-names>J</given-names></name><name name-style="western"><surname>Sittig</surname><given-names>SP</given-names></name><name name-style="western"><surname>Blom</surname><given-names>RAM</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Schreibelt</surname><given-names>G</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>:<page-range>5005&#8211;12</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1300787</pub-id><pub-id pub-id-type="pmid">24127556</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer-Wentrup</surname><given-names>F</given-names></name><name name-style="western"><surname>Benitez-Ribas</surname><given-names>D</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Punt</surname><given-names>CJA</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>IJM</given-names></name><etal/></person-group>. <article-title>Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-&#945; production</article-title>. <source>Blood</source> (<year>2008</year>) <volume>111</volume>:<page-range>4245&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2007-03-081398</pub-id><pub-id pub-id-type="pmid">18258799</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>RL</given-names></name><name name-style="western"><surname>Corinaldesi</surname><given-names>C</given-names></name><name name-style="western"><surname>Migneco</surname><given-names>G</given-names></name><name name-style="western"><surname>Carr</surname><given-names>IM</given-names></name><name name-style="western"><surname>Antanaviciute</surname><given-names>A</given-names></name><name name-style="western"><surname>Wasson</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma</article-title>. <source>Ann Rheum Dis</source> (<year>2021</year>) <volume>80</volume>:<page-range>920&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-218439</pub-id><pub-id pub-id-type="pmcid">PMC8237203</pub-id><pub-id pub-id-type="pmid">33542104</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepulveda-Toepfer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pichler</surname><given-names>J</given-names></name><name name-style="western"><surname>Fink</surname><given-names>K</given-names></name><name name-style="western"><surname>Sevo</surname><given-names>M</given-names></name><name name-style="western"><surname>Wildburger</surname><given-names>S</given-names></name><name name-style="western"><surname>Mudde-Boer</surname><given-names>LC</given-names></name><etal/></person-group>. <article-title>TLR9-mediated activation of dendritic cells by CD32 targeting for the generation of highly immunostimulatory vaccines</article-title>. <source>Hum Vaccines Immunotherapeutics</source> (<year>2019</year>) <volume>15</volume>:<page-range>179&#8211;88</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2018.1514223</pub-id><pub-id pub-id-type="pmcid">PMC6363151</pub-id><pub-id pub-id-type="pmid">30156957</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Raper</surname><given-names>A</given-names></name><name name-style="western"><surname>Sugita</surname><given-names>N</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>R</given-names></name><name name-style="western"><surname>Salio</surname><given-names>M</given-names></name><name name-style="western"><surname>Palmowski</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors</article-title>. <source>Blood</source> (<year>2006</year>) <volume>107</volume>:<page-range>3600&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2005-09-3842</pub-id><pub-id pub-id-type="pmid">16397130</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loschko</surname><given-names>J</given-names></name><name name-style="western"><surname>Heink</surname><given-names>S</given-names></name><name name-style="western"><surname>Hackl</surname><given-names>D</given-names></name><name name-style="western"><surname>Dudziak</surname><given-names>D</given-names></name><name name-style="western"><surname>Reindl</surname><given-names>W</given-names></name><name name-style="western"><surname>Korn</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Antigen targeting to plasmacytoid dendritic cells <italic toggle="yes">via</italic> siglec-H inhibits Th cell-dependent autoimmunity</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<page-range>6346&#8211;56</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1102307</pub-id><pub-id pub-id-type="pmid">22079988</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loschko</surname><given-names>J</given-names></name><name name-style="western"><surname>Schlitzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Dudziak</surname><given-names>D</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>I</given-names></name><name name-style="western"><surname>Sandholzer</surname><given-names>N</given-names></name><name name-style="western"><surname>Bourquin</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Antigen delivery to plasmacytoid dendritic cells <italic toggle="yes">via</italic> BST2 induces protective T cell-mediated immunity</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<page-range>6718&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1004029</pub-id><pub-id pub-id-type="pmid">21555533</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watarai</surname><given-names>H</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>E</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Kaisho</surname><given-names>T</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>M</given-names></name></person-group>. <article-title>PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2008</year>) <volume>105</volume>:<page-range>2993&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0710351105</pub-id><pub-id pub-id-type="pmcid">PMC2268573</pub-id><pub-id pub-id-type="pmid">18287072</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Tortorec</surname><given-names>A</given-names></name><name name-style="western"><surname>Willey</surname><given-names>S</given-names></name><name name-style="western"><surname>Neil</surname><given-names>SJD</given-names></name></person-group>. <article-title>Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction</article-title>. <source>Viruses</source> (<year>2011</year>) <volume>3</volume>:<page-range>520&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.3390/v3050520</pub-id><pub-id pub-id-type="pmcid">PMC3185764</pub-id><pub-id pub-id-type="pmid">21994744</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasius</surname><given-names>AL</given-names></name><name name-style="western"><surname>Giurisato</surname><given-names>E</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>AS</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M</given-names></name></person-group>. <article-title>Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>177</volume>:<page-range>3260&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.177.5.3260</pub-id><pub-id pub-id-type="pmid">16920966</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>P</given-names></name><name name-style="western"><surname>Loschko</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L</given-names></name><name name-style="western"><surname>Pham</surname><given-names>P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2020</year>) <volume>117</volume>:<page-range>23730&#8211;41</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2002345117</pub-id><pub-id pub-id-type="pmcid">PMC7519282</pub-id><pub-id pub-id-type="pmid">32879009</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balan</surname><given-names>S</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group>. <article-title>Dendritic cell subsets and locations</article-title>. <source>Int Rev Cell Mol Biol</source> (<year>2019</year>) <volume>348</volume>:<fpage>1</fpage>&#8211;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1016/bs.ircmb.2019.07.004</pub-id><pub-id pub-id-type="pmid">31810551</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Persson</surname><given-names>EK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>CL</given-names></name><name name-style="western"><surname>McI. Mowat</surname><given-names>A</given-names></name><name name-style="western"><surname>Agace</surname><given-names>WW</given-names></name></person-group>. <article-title>Dendritic cell subsets in the intestinal lamina propria: Ontogeny and function</article-title>. <source>Eur J Immunol</source> (<year>2013</year>) <volume>43</volume>:<page-range>3098&#8211;107</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.201343740</pub-id><pub-id pub-id-type="pmcid">PMC3933733</pub-id><pub-id pub-id-type="pmid">23966272</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stagg</surname><given-names>AJ</given-names></name></person-group>. <article-title>Intestinal dendritic cells in health and gut inflammation</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2883</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02883</pub-id><pub-id pub-id-type="pmid">30574151</pub-id><pub-id pub-id-type="pmcid">PMC6291504</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>BN</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H</given-names></name></person-group>. <article-title>Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections</article-title>. <source>Mucosal Immunol</source> (<year>2013</year>) <volume>6</volume>:<page-range>464&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2013.14</pub-id><pub-id pub-id-type="pmid">23549447</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semmrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Plantinga</surname><given-names>M</given-names></name><name name-style="western"><surname>Svensson-Frej</surname><given-names>M</given-names></name><name name-style="western"><surname>Uronen-Hansson</surname><given-names>H</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Mowat</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Directed antigen targeting in <italic toggle="yes">vivo</italic> identifies a role for CD103<sup>+</sup> dendritic cells in both tolerogenic and immunogenic T-cell responses</article-title>. <source>Mucosal Immunol</source> (<year>2012</year>) <volume>5</volume>:<page-range>150&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2011.61</pub-id><pub-id pub-id-type="pmcid">PMC3282433</pub-id><pub-id pub-id-type="pmid">22166938</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>El-Asady</surname><given-names>R</given-names></name><name name-style="western"><surname>Farber</surname><given-names>DL</given-names></name><name name-style="western"><surname>Gress</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>Regulation of CD103 expression by CD8<sup>+</sup> T cells responding to renal allografts</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>172</volume>:<page-range>214&#8211;21</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.172.1.214</pub-id><pub-id pub-id-type="pmid">14688328</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Carey</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>Genetic vaccines to potentiate the effective CD103<sup>+</sup> Dendritic cell&#8211;mediated cross-priming of antitumor immunity</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>:<page-range>5937&#8211;47</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1500089</pub-id><pub-id pub-id-type="pmcid">PMC4458448</pub-id><pub-id pub-id-type="pmid">25972487</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name><name name-style="western"><surname>van Kooyk</surname><given-names>Y</given-names></name><name name-style="western"><surname>Adema</surname><given-names>GJ</given-names></name></person-group>. <article-title>C-type lectin receptors on dendritic cells and langerhans cells</article-title>. <source>Nat Rev Immunol</source> (<year>2002</year>) <volume>2</volume>:<fpage>77</fpage>&#8211;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri723</pub-id><pub-id pub-id-type="pmid">11910898</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ROmani</surname><given-names>N</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>BE</given-names></name><name name-style="western"><surname>Stoitzner</surname><given-names>P</given-names></name></person-group>. <article-title>Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin</article-title>. <source>Immunol Rev</source> (<year>2010</year>) <volume>234</volume>:<page-range>120&#8211;41</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.0105-2896.2009.00886.x</pub-id><pub-id pub-id-type="pmcid">PMC2907488</pub-id><pub-id pub-id-type="pmid">20193016</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name><name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Collin</surname><given-names>M</given-names></name></person-group>. <article-title>Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>:<page-range>935&#8211;47</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri2455</pub-id><pub-id pub-id-type="pmid">19029989</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>HC</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>CL</given-names></name></person-group>. <article-title>Redefining the role of langerhans cells as immune regulators within the skin</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>8</volume>:<elocation-id>1941</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2017.01941</pub-id><pub-id pub-id-type="pmid">29379502</pub-id><pub-id pub-id-type="pmcid">PMC5770803</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>DH</given-names></name></person-group>. <article-title>Ontogeny and function of murine epidermal Langerhans cells</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>:<page-range>1068&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.3815</pub-id><pub-id pub-id-type="pmcid">PMC6422157</pub-id><pub-id pub-id-type="pmid">28926543</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satpathy</surname><given-names>AT</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Albring</surname><given-names>JC</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name></person-group>. <article-title>Re(de)fining the dendritic cell lineage</article-title>. <source>Nat Immunol</source> (<year>2012</year>) <volume>13</volume>:<page-range>1145&#8211;54</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.2467</pub-id><pub-id pub-id-type="pmcid">PMC3644874</pub-id><pub-id pub-id-type="pmid">23160217</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romani</surname><given-names>N</given-names></name><name name-style="western"><surname>Thurnher</surname><given-names>M</given-names></name><name name-style="western"><surname>Idoyaga</surname><given-names>J</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Flacher</surname><given-names>V</given-names></name></person-group>. <article-title>Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy</article-title>. <source>Immunol Cell Biol</source> (<year>2010</year>) <volume>88</volume>:<page-range>424&#8211;30</page-range>. doi: <pub-id pub-id-type="doi">10.1038/icb.2010.39</pub-id><pub-id pub-id-type="pmcid">PMC2907485</pub-id><pub-id pub-id-type="pmid">20368713</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R-JE</given-names></name><name name-style="western"><surname>Hogervorst</surname><given-names>TP</given-names></name><name name-style="western"><surname>Achilli</surname><given-names>S</given-names></name><name name-style="western"><surname>Bruijns</surname><given-names>SCM</given-names></name><name name-style="western"><surname>Spiekstra</surname><given-names>S</given-names></name><name name-style="western"><surname>Viv&#232;s</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Targeting of the C-type lectin receptor langerin using bifunctional mannosylated antigens</article-title>. <source>Front Cell Dev Biol</source> (<year>2020</year>) <volume>8</volume>:<elocation-id>556</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2020.00556</pub-id><pub-id pub-id-type="pmid">32760719</pub-id><pub-id pub-id-type="pmcid">PMC7371993</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellmann</surname><given-names>L</given-names></name><name name-style="western"><surname>Strandt</surname><given-names>H</given-names></name><name name-style="western"><surname>Zelle-Rieser</surname><given-names>C</given-names></name><name name-style="western"><surname>Ortner</surname><given-names>D</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>CH</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Targeted delivery of a vaccine protein to Langerhans cells in the human skin <italic toggle="yes">via</italic> the C-type lectin receptor Langerin</article-title>. <source>Eur J Immunol</source> (<year>2022</year>) <volume>52</volume>:<page-range>1829&#8211;41</page-range>. doi: <pub-id pub-id-type="doi">10.1002/eji.202149670</pub-id><pub-id pub-id-type="pmcid">PMC9788233</pub-id><pub-id pub-id-type="pmid">34932821</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukunaga</surname><given-names>A</given-names></name><name name-style="western"><surname>Khaskhely</surname><given-names>NM</given-names></name><name name-style="western"><surname>Sreevidya</surname><given-names>CS</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>SN</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>SE</given-names></name></person-group>. <article-title>Dermal dendritic cells, and not langerhans cells, play an essential role in inducing an immune response</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>:<page-range>3057&#8211;64</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.180.5.3057</pub-id><pub-id pub-id-type="pmcid">PMC2408377</pub-id><pub-id pub-id-type="pmid">18292528</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mair</surname><given-names>F</given-names></name><name name-style="western"><surname>Liechti</surname><given-names>T</given-names></name></person-group>. <article-title>Comprehensive phenotyping of human dendritic cells and monocytes</article-title>. <source>Cytometry</source> (<year>2021</year>) <volume>99</volume>:<page-range>231&#8211;42</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cyto.a.24269</pub-id><pub-id pub-id-type="pmid">33200508</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutertre</surname><given-names>C-A</given-names></name><name name-style="western"><surname>Becht</surname><given-names>E</given-names></name><name name-style="western"><surname>Irac</surname><given-names>SE</given-names></name><name name-style="western"><surname>Khalilnezhad</surname><given-names>A</given-names></name><name name-style="western"><surname>Narang</surname><given-names>V</given-names></name><name name-style="western"><surname>Khalilnezhad</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells</article-title>. <source>Immunity</source> (<year>2019</year>) <volume>51</volume>:<fpage>573</fpage>&#8211;<lpage>589.e8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.08.008</pub-id><pub-id pub-id-type="pmid">31474513</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gibbings</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tewari</surname><given-names>AD</given-names></name><name name-style="western"><surname>Atif</surname><given-names>SM</given-names></name><name name-style="western"><surname>Vestal</surname><given-names>B</given-names></name><name name-style="western"><surname>Danhorn</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Human and mouse transcriptome profiling identifies cross-species homology in pulmonary and lymph node mononuclear phagocytes</article-title>. <source>Cell Rep</source> (<year>2020</year>) <volume>33</volume>:<fpage>108337</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108337</pub-id><pub-id pub-id-type="pmid">33147458</pub-id><pub-id pub-id-type="pmcid">PMC7673261</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>H</given-names></name><name name-style="western"><surname>Moran</surname><given-names>TP</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>K</given-names></name><name name-style="western"><surname>Gerrish</surname><given-names>KE</given-names></name><name name-style="western"><surname>Bortner</surname><given-names>CD</given-names></name><name name-style="western"><surname>Cook</surname><given-names>DN</given-names></name></person-group>. <article-title>Complement receptor C5aR1/CD88 and dipeptidyl peptidase-4/CD26 define distinct hematopoietic lineages of dendritic cells</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>:<page-range>3808&#8211;19</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1402195</pub-id><pub-id pub-id-type="pmcid">PMC4390500</pub-id><pub-id pub-id-type="pmid">25769922</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>M-N</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>LT</given-names></name><name name-style="western"><surname>Batich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kopin</surname><given-names>D</given-names></name><name name-style="western"><surname>Wellford</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses</article-title>. <source>J Clin Invest</source> (<year>2020</year>) <volume>130</volume>:<page-range>774&#8211;88</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI128267</pub-id><pub-id pub-id-type="pmcid">PMC6994156</pub-id><pub-id pub-id-type="pmid">31661470</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Park</surname><given-names>OK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K</given-names></name><name name-style="western"><surname>Pack</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Deep tumor penetration of drug-loaded nanoparticles by click reaction-assisted immune cell targeting strategy</article-title>. <source>J Am Chem Soc</source> (<year>2019</year>) <volume>141</volume>:<page-range>13829&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.1021/jacs.9b04621</pub-id><pub-id pub-id-type="pmid">31382746</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veiga</surname><given-names>N</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M</given-names></name><name name-style="western"><surname>Granot</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>D</given-names></name><name name-style="western"><surname>Dammes</surname><given-names>N</given-names></name><name name-style="western"><surname>Kedmi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>:<fpage>4493</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-06936-1</pub-id><pub-id pub-id-type="pmid">30374059</pub-id><pub-id pub-id-type="pmcid">PMC6206083</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Slight</surname><given-names>SR</given-names></name><name name-style="western"><surname>Khader</surname><given-names>SA</given-names></name></person-group>. <article-title>Th17 cytokines and vaccine-induced immunity</article-title>. <source>Semin Immunopathol</source> (<year>2010</year>) <volume>32</volume>:<fpage>79</fpage>&#8211;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00281-009-0191-2</pub-id><pub-id pub-id-type="pmid">20112107</pub-id><pub-id pub-id-type="pmcid">PMC2855296</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reith</surname><given-names>W</given-names></name><name name-style="western"><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Waldburger</surname><given-names>J-M</given-names></name></person-group>. <article-title>Regulation of MHC class II gene expression by the class II transactivator</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>:<fpage>793</fpage>&#8211;<lpage>806</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri1708</pub-id><pub-id pub-id-type="pmid">16200082</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buxad&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Huerga Encabo</surname><given-names>H</given-names></name><name name-style="western"><surname>Riera-Borrull</surname><given-names>M</given-names></name><name name-style="western"><surname>Quintana-Gallardo</surname><given-names>L</given-names></name><name name-style="western"><surname>L&#243;pez-Cotarelo</surname><given-names>P</given-names></name><name name-style="western"><surname>Tellechea</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5</article-title>. <source>J Exp Med</source> (<year>2018</year>) <volume>215</volume>:<page-range>2901&#8211;18</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20180314</pub-id><pub-id pub-id-type="pmcid">PMC6219740</pub-id><pub-id pub-id-type="pmid">30327417</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muntjewerff</surname><given-names>EM</given-names></name><name name-style="western"><surname>Meesters</surname><given-names>LD</given-names></name><name name-style="western"><surname>van den Bogaart</surname><given-names>G</given-names></name></person-group>. <article-title>Antigen cross-Presentation by macrophages</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1276</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01276</pub-id><pub-id pub-id-type="pmid">32733446</pub-id><pub-id pub-id-type="pmcid">PMC7360722</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>TA</given-names></name></person-group>. <article-title>Protective and pathogenic functions of macrophage subsets</article-title>. <source>Nat Rev Immunol</source> (<year>2011</year>) <volume>11</volume>:<page-range>723&#8211;37</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3073</pub-id><pub-id pub-id-type="pmcid">PMC3422549</pub-id><pub-id pub-id-type="pmid">21997792</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>A</given-names></name><name name-style="western"><surname>Alex</surname><given-names>L</given-names></name><name name-style="western"><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group>. <article-title>Identification of macrophages in normal and injured mouse tissues using reporter lines and antibodies</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>:<fpage>4542</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-08278-x</pub-id><pub-id pub-id-type="pmid">35296717</pub-id><pub-id pub-id-type="pmcid">PMC8927419</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name></person-group>. <article-title>Targeting macrophages in cancer immunotherapy</article-title>. <source>Sig Transduct Target Ther</source> (<year>2021</year>) <volume>6</volume>:<fpage>127</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00506-6</pub-id><pub-id pub-id-type="pmcid">PMC7994399</pub-id><pub-id pub-id-type="pmid">33767177</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>B-Z</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>JW</given-names></name></person-group>. <article-title>Macrophage diversity enhances tumor progression and metastasis</article-title>. <source>Cell</source> (<year>2010</year>) <volume>141</volume>:<fpage>39</fpage>&#8211;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2010.03.014</pub-id><pub-id pub-id-type="pmid">20371344</pub-id><pub-id pub-id-type="pmcid">PMC4994190</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>PR</given-names></name></person-group>. <article-title>Tissue-resident macrophages</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>:<page-range>986&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.2705</pub-id><pub-id pub-id-type="pmcid">PMC4045180</pub-id><pub-id pub-id-type="pmid">24048120</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geissmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Manz</surname><given-names>MG</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S</given-names></name><name name-style="western"><surname>Sieweke</surname><given-names>MH</given-names></name><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name><name name-style="western"><surname>Ley</surname><given-names>K</given-names></name></person-group>. <article-title>Development of monocytes, macrophages, and dendritic cells</article-title>. <source>Science</source> (<year>2010</year>) <volume>327</volume>:<page-range>656&#8211;61</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1178331</pub-id><pub-id pub-id-type="pmcid">PMC2887389</pub-id><pub-id pub-id-type="pmid">20133564</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngambenjawong</surname><given-names>C</given-names></name><name name-style="western"><surname>Gustafson</surname><given-names>HH</given-names></name><name name-style="western"><surname>Pun</surname><given-names>SH</given-names></name></person-group>. <article-title>Progress in tumor-associated macrophage (TAM)-targeted therapeutics</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2017</year>) <volume>114</volume>:<page-range>206&#8211;21</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.addr.2017.04.010</pub-id><pub-id pub-id-type="pmcid">PMC5581987</pub-id><pub-id pub-id-type="pmid">28449873</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colino</surname><given-names>CI</given-names></name><name name-style="western"><surname>Lanao</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gutierrez-Millan</surname><given-names>C</given-names></name></person-group>. <article-title>Targeting of hepatic macrophages by therapeutic nanoparticles</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>218</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.00218</pub-id><pub-id pub-id-type="pmid">32194546</pub-id><pub-id pub-id-type="pmcid">PMC7065596</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hossainy</surname><given-names>S</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Esser-Kahn</surname><given-names>AP</given-names></name></person-group>. <article-title>Immunostimulatory polymers as adjuvants, immunotherapies, and delivery systems</article-title>. <source>Macromolecules</source> (<year>2022</year>) <volume>55</volume>:<page-range>6913&#8211;37</page-range>. doi: <pub-id pub-id-type="doi">10.1021/acs.macromol.2c00854</pub-id><pub-id pub-id-type="pmcid">PMC9404695</pub-id><pub-id pub-id-type="pmid">36034324</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laroui</surname><given-names>H</given-names></name><name name-style="western"><surname>Viennois</surname><given-names>E</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>B</given-names></name><name name-style="western"><surname>Canup</surname><given-names>BSB</given-names></name><name name-style="western"><surname>Geem</surname><given-names>D</given-names></name><name name-style="western"><surname>Denning</surname><given-names>TL</given-names></name><etal/></person-group>. <article-title>Fab&#8217;-bearing siRNA TNF&#945;-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis</article-title>. <source>J Controlled Release</source> (<year>2014</year>) <volume>186</volume>:<fpage>41</fpage>&#8211;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.04.046</pub-id><pub-id pub-id-type="pmcid">PMC4100604</pub-id><pub-id pub-id-type="pmid">24810114</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#225;vez-Gal&#225;n</surname><given-names>L</given-names></name><name name-style="western"><surname>Olleros</surname><given-names>ML</given-names></name><name name-style="western"><surname>Vesin</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>I</given-names></name></person-group>. <article-title>Much More than M1 and M2 Macrophages, There are also CD169<sup>+</sup> and TCR<sup>+</sup> Macrophages</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>6</volume>:<elocation-id>263</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2015.00263</pub-id><pub-id pub-id-type="pmid">26074923</pub-id><pub-id pub-id-type="pmcid">PMC4443739</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ericsson</surname><given-names>AC</given-names></name></person-group>. <article-title>Function of macrophages in disease: current understanding on molecular mechanisms</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>620510</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.620510</pub-id><pub-id pub-id-type="pmid">33763066</pub-id><pub-id pub-id-type="pmcid">PMC7982479</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1998</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01998</pub-id><pub-id pub-id-type="pmid">31497026</pub-id><pub-id pub-id-type="pmcid">PMC6712945</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cieslewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><name name-style="western"><surname>Zavaljevski</surname><given-names>M</given-names></name><name name-style="western"><surname>Motoyama</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2013</year>) <volume>110</volume>:<page-range>15919&#8211;24</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1312197110</pub-id><pub-id pub-id-type="pmcid">PMC3791765</pub-id><pub-id pub-id-type="pmid">24046373</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T-H</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>M</given-names></name></person-group>. <article-title>Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis</article-title>. <source>Biomaterials</source> (<year>2015</year>) <volume>61</volume>:<page-range>162&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.05.028</pub-id><pub-id pub-id-type="pmcid">PMC4464978</pub-id><pub-id pub-id-type="pmid">26004232</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-Shavit</surname><given-names>Z</given-names></name><name name-style="western"><surname>Terry</surname><given-names>S</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>R</given-names></name></person-group>. <article-title>Neurotensin &#8212; macrophage interaction: Specific binding and augmentation of phagocytosis</article-title>. <source>Neuropeptides</source> (<year>1982</year>) <volume>2</volume>:<page-range>325&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0143-4179(82)90070-1</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farajzadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Zarghami</surname><given-names>N</given-names></name><name name-style="western"><surname>Serati-Nouri</surname><given-names>H</given-names></name><name name-style="western"><surname>Momeni-Javid</surname><given-names>Z</given-names></name><name name-style="western"><surname>Farajzadeh</surname><given-names>T</given-names></name><name name-style="western"><surname>Jalilzadeh-Tabrizi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Macrophage repolarization using CD44-targeting hyaluronic acid&#8211;polylactide nanoparticles containing curcumin</article-title>. <source>Artif Cells Nanomedicine Biotechnol</source> (<year>2017</year>) <volume>46</volume>(<issue>8</issue>):<fpage>2013</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21691401.2017.1408116</pub-id><pub-id pub-id-type="pmid">29183161</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>T-H</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>R</given-names></name><name name-style="western"><surname>Shelke</surname><given-names>J</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>MM</given-names></name></person-group>. <article-title>Modulation of macrophage functional polarity towards anti-inflammatory phenotype with plasmid DNA delivery in CD44 targeting hyaluronic acid nanoparticles</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<fpage>16632</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep16632</pub-id><pub-id pub-id-type="pmid">26577684</pub-id><pub-id pub-id-type="pmcid">PMC4649614</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarado-Vazquez</surname><given-names>PA</given-names></name><name name-style="western"><surname>Bernal</surname><given-names>L</given-names></name><name name-style="western"><surname>Paige</surname><given-names>CA</given-names></name><name name-style="western"><surname>Grosick</surname><given-names>RL</given-names></name><name name-style="western"><surname>Moracho Vilrriales</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions</article-title>. <source>Immunobiology</source> (<year>2017</year>) <volume>222</volume>:<page-range>900&#8211;12</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.imbio.2017.05.011</pub-id><pub-id pub-id-type="pmcid">PMC5718187</pub-id><pub-id pub-id-type="pmid">28545809</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Mary</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name></person-group>. <article-title>Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles</article-title>. <source>Mol Pharmaceutics.</source> (<year>2013</year>) <volume>10</volume>:<page-range>3525&#8211;30</page-range>. doi: <pub-id pub-id-type="doi">10.1021/mp400216r</pub-id><pub-id pub-id-type="pmcid">PMC3946577</pub-id><pub-id pub-id-type="pmid">23901887</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aouadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tencerova</surname><given-names>M</given-names></name><name name-style="western"><surname>Vangala</surname><given-names>P</given-names></name><name name-style="western"><surname>Yawe</surname><given-names>JC</given-names></name><name name-style="western"><surname>Nicoloro</surname><given-names>SM</given-names></name><name name-style="western"><surname>Amano</surname><given-names>SU</given-names></name><etal/></person-group>. <article-title>Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2013</year>) <volume>110</volume>:<page-range>8278&#8211;83</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1300492110</pub-id><pub-id pub-id-type="pmcid">PMC3657808</pub-id><pub-id pub-id-type="pmid">23630254</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aouadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tesz</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Nicoloro</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chouinard</surname><given-names>M</given-names></name><name name-style="western"><surname>Soto</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation</article-title>. <source>Nature</source> (<year>2009</year>) <volume>458</volume>:<page-range>1180&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature07774</pub-id><pub-id pub-id-type="pmcid">PMC2879154</pub-id><pub-id pub-id-type="pmid">19407801</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngambenjawong</surname><given-names>C</given-names></name><name name-style="western"><surname>Cieslewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Schellinger</surname><given-names>JG</given-names></name><name name-style="western"><surname>Pun</surname><given-names>SH</given-names></name></person-group>. <article-title>Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages</article-title>. <source>J Controlled Release</source> (<year>2016</year>) <volume>224</volume>:<page-range>103&#8211;11</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.057</pub-id><pub-id pub-id-type="pmcid">PMC4747818</pub-id><pub-id pub-id-type="pmid">26772876</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S-JS</given-names></name><name name-style="western"><surname>Joo</surname><given-names>H</given-names></name><name name-style="western"><surname>Bae</surname><given-names>H</given-names></name></person-group>. <article-title>Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>:<page-range>54951&#8211;65</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.18627</pub-id><pub-id pub-id-type="pmcid">PMC5589633</pub-id><pub-id pub-id-type="pmid">28903394</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H</given-names></name><name name-style="western"><surname>Bae</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide</article-title>. <source>J immunotherapy Cancer</source> (<year>2019</year>) <volume>7</volume>:<fpage>147</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40425-019-0610-4</pub-id><pub-id pub-id-type="pmcid">PMC6555931</pub-id><pub-id pub-id-type="pmid">31174610</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puig-Kr&#246;ger</surname><given-names>A</given-names></name><name name-style="western"><surname>Sierra-Filardi</surname><given-names>E</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Soto</surname><given-names>A</given-names></name><name name-style="western"><surname>Samaniego</surname><given-names>R</given-names></name><name name-style="western"><surname>Corcuera</surname><given-names>MT</given-names></name><name name-style="western"><surname>G&#243;mez-Aguado</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Folate receptor &#946; Is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>:<page-range>9395&#8211;403</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2050</pub-id><pub-id pub-id-type="pmid">19951991</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hattori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>J</given-names></name><name name-style="western"><surname>Sakaida</surname><given-names>C</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>K</given-names></name><name name-style="western"><surname>Yonemochi</surname><given-names>E</given-names></name></person-group>. <article-title>Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages</article-title>. <source>J Liposome Res</source> (<year>2015</year>) <volume>25</volume>:<page-range>131&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.3109/08982104.2014.954128</pub-id><pub-id pub-id-type="pmid">25203609</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shao</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Targeting folate receptor &#946; positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex</article-title>. <source>Sig Transduct Target Ther</source> (<year>2020</year>) <volume>5</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-020-0115-0</pub-id><pub-id pub-id-type="pmcid">PMC6976681</pub-id><pub-id pub-id-type="pmid">32296026</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagai</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsuneyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Michie</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hasui</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor &#946;</article-title>. <source>Cancer Immunol Immunother</source> (<year>2009</year>) <volume>58</volume>:<page-range>1577&#8211;86</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00262-009-0667-x</pub-id><pub-id pub-id-type="pmcid">PMC11030051</pub-id><pub-id pub-id-type="pmid">19238383</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocker</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S</given-names></name></person-group>. <article-title>Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages</article-title>. <source>J Exp Med</source> (<year>1986</year>) <volume>164</volume>:<page-range>1862&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.164.6.1862</pub-id><pub-id pub-id-type="pmcid">PMC2188478</pub-id><pub-id pub-id-type="pmid">3783087</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phan</surname><given-names>TG</given-names></name><name name-style="western"><surname>Grigorova</surname><given-names>I</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells</article-title>. <source>Nat Immunol</source> (<year>2007</year>) <volume>8</volume>:<fpage>992</fpage>&#8211;<lpage>1000</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ni1494</pub-id><pub-id pub-id-type="pmid">17660822</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junt</surname><given-names>T</given-names></name><name name-style="western"><surname>Moseman</surname><given-names>EA</given-names></name><name name-style="western"><surname>Iannacone</surname><given-names>M</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Lang</surname><given-names>PA</given-names></name><name name-style="western"><surname>Boes</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells</article-title>. <source>Nature</source> (<year>2007</year>) <volume>450</volume>:<page-range>110&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature06287</pub-id><pub-id pub-id-type="pmid">17934446</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dinther</surname><given-names>D</given-names></name><name name-style="western"><surname>Veninga</surname><given-names>H</given-names></name><name name-style="western"><surname>Iborra</surname><given-names>S</given-names></name><name name-style="western"><surname>Borg</surname><given-names>EGF</given-names></name><name name-style="western"><surname>Hoogterp</surname><given-names>L</given-names></name><name name-style="western"><surname>Olesek</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Functional CD169 on macrophages mediates interaction with dendritic cells for CD8<sup>+</sup> T cell cross-priming</article-title>. <source>Cell Rep</source> (<year>2018</year>) <volume>22</volume>:<page-range>1484&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.021</pub-id><pub-id pub-id-type="pmid">29425504</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dinther</surname><given-names>D</given-names></name><name name-style="western"><surname>Veninga</surname><given-names>H</given-names></name><name name-style="western"><surname>Revet</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoogterp</surname><given-names>L</given-names></name><name name-style="western"><surname>Olesek</surname><given-names>K</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Comparison of protein and peptide targeting for the development of a CD169-based vaccination strategy against melanoma</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1997</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.01997</pub-id><pub-id pub-id-type="pmid">30237798</pub-id><pub-id pub-id-type="pmcid">PMC6135888</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nijen Twilhaar</surname><given-names>MK</given-names></name><name name-style="western"><surname>Czentner</surname><given-names>L</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>J</given-names></name><name name-style="western"><surname>Affandi</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lau</surname><given-names>CYJ</given-names></name><name name-style="western"><surname>Olesek</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Optimization of liposomes for antigen targeting to splenic CD169<sup>+</sup> Macrophages</article-title>. <source>Pharmaceutics</source> (<year>2020</year>) <volume>12</volume>:<fpage>1138</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics12121138</pub-id><pub-id pub-id-type="pmid">33255564</pub-id><pub-id pub-id-type="pmcid">PMC7760819</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>N</given-names></name><name name-style="western"><surname>Vela</surname><given-names>JL</given-names></name><name name-style="western"><surname>Nycholat</surname><given-names>CM</given-names></name><name name-style="western"><surname>Rademacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Khurana</surname><given-names>A</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Targeted delivery of lipid antigen to macrophages <italic toggle="yes">via</italic> the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2013</year>) <volume>110</volume>:<page-range>7826&#8211;31</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1219888110</pub-id><pub-id pub-id-type="pmcid">PMC3651435</pub-id><pub-id pub-id-type="pmid">23610394</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edgar</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>N</given-names></name><name name-style="western"><surname>Nycholat</surname><given-names>CM</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>JC</given-names></name></person-group>. <article-title>Targeted delivery of antigen to activated CD169<sup>+</sup> Macrophages induces bias for expansion of CD8<sup>+</sup> T cells</article-title>. <source>Cell Chem Biol</source> (<year>2019</year>) <volume>26</volume>:<fpage>131</fpage>&#8211;<lpage>136.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chembiol.2018.10.006</pub-id><pub-id pub-id-type="pmid">30393066</pub-id><pub-id pub-id-type="pmcid">PMC6338492</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisk</surname><given-names>C</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>R</given-names></name><name name-style="western"><surname>Kuniholm</surname><given-names>J</given-names></name><name name-style="western"><surname>Antos</surname><given-names>D</given-names></name><name name-style="western"><surname>Reiser</surname><given-names>ML</given-names></name><name name-style="western"><surname>Wetzler</surname><given-names>LM</given-names></name></person-group>. <article-title>CD169<sup>+</sup> Subcapsular macrophage role in antigen adjuvant activity</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>624197</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.624197</pub-id><pub-id pub-id-type="pmid">33815376</pub-id><pub-id pub-id-type="pmcid">PMC8012505</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>T</given-names></name><name name-style="western"><surname>Rothenberg</surname><given-names>ME</given-names></name></person-group>. <article-title>The regulatory function of eosinophils</article-title>. <source>Microbiol Spectr</source> (<year>2016</year>) <volume>4</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1128/microbiolspec.MCHD-0020-2015</pub-id><pub-id pub-id-type="pmcid">PMC5088784</pub-id><pub-id pub-id-type="pmid">27780017</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddur</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kaveri</surname><given-names>SV</given-names></name><name name-style="western"><surname>Bayry</surname><given-names>J</given-names></name></person-group>. <article-title>Basophils as antigen presenting cells</article-title>. <source>Trends Immunol</source> (<year>2010</year>) <volume>31</volume>:<page-range>45&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2009.12.004</pub-id><pub-id pub-id-type="pmid">20060781</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Gaudenzio</surname><given-names>N</given-names></name></person-group>. <article-title>Human mast cells as antigen-presenting cells: When is this role important <italic toggle="yes">in vivo</italic>
</article-title>? <source>J Allergy Clin Immunol</source> (<year>2018</year>) <volume>141</volume>:<page-range>92&#8211;3</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2017.05.029</pub-id><pub-id pub-id-type="pmid">28624609</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kambayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>TM</given-names></name></person-group>. <article-title>Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell</article-title>? <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<page-range>719&#8211;30</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3754</pub-id><pub-id pub-id-type="pmid">25324123</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abi Abdallah</surname><given-names>DS</given-names></name><name name-style="western"><surname>Egan</surname><given-names>CE</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>BA</given-names></name><name name-style="western"><surname>Denkers</surname><given-names>EY</given-names></name></person-group>. <article-title>Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation</article-title>. <source>Int Immunol</source> (<year>2011</year>) <volume>23</volume>:<page-range>317&#8211;26</page-range>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxr007</pub-id><pub-id pub-id-type="pmcid">PMC3082529</pub-id><pub-id pub-id-type="pmid">21422151</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trentini</surname><given-names>MM</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>FM</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>A</given-names></name><name name-style="western"><surname>Junqueira-Kipnis</surname><given-names>AP</given-names></name></person-group>. <article-title>The Role of Neutrophils in the Induction of Specific Th1 and Th17 during Vaccination against Tuberculosis</article-title>. <source>Front Microbiol</source> (<year>2016</year>) <volume>7</volume>:<elocation-id>898</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2016.00898</pub-id><pub-id pub-id-type="pmid">27375607</pub-id><pub-id pub-id-type="pmcid">PMC4901074</pub-id></mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartneck</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group>. <article-title>Therapeutic targeting of neutrophil granulocytes in inflammatory liver disease</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2257</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02257</pub-id><pub-id pub-id-type="pmid">31616430</pub-id><pub-id pub-id-type="pmcid">PMC6764082</pub-id></mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filep</surname><given-names>JG</given-names></name></person-group>. <article-title>Targeting neutrophils for promoting the resolution of inflammation</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>866747</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.866747</pub-id><pub-id pub-id-type="pmid">35371088</pub-id><pub-id pub-id-type="pmcid">PMC8966391</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J</given-names></name><name name-style="western"><surname>Malik</surname><given-names>AB</given-names></name></person-group>. <article-title>Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils</article-title>. <source>Nat Nanotech.</source> (<year>2014</year>) <volume>9</volume>:<page-range>204&#8211;10</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nnano.2014.17</pub-id><pub-id pub-id-type="pmcid">PMC4100792</pub-id><pub-id pub-id-type="pmid">24561355</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group>. <article-title>Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke</article-title>. <source>Sci Adv</source> (<year>2019</year>) <volume>5</volume>:<elocation-id>eaax7964</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.aax7964</pub-id><pub-id pub-id-type="pmid">31723603</pub-id><pub-id pub-id-type="pmcid">PMC6834394</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vij</surname><given-names>N</given-names></name><name name-style="western"><surname>Min</surname><given-names>T</given-names></name><name name-style="western"><surname>Bodas</surname><given-names>M</given-names></name><name name-style="western"><surname>Gorde</surname><given-names>A</given-names></name><name name-style="western"><surname>Roy</surname><given-names>I</given-names></name></person-group>. <article-title>Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases</article-title>. <source>Nanomedicine: Nanotechnology Biol Med</source> (<year>2016</year>) <volume>12</volume>:<page-range>2415&#8211;27</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.nano.2016.06.008</pub-id><pub-id pub-id-type="pmid">27381067</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bohinc</surname><given-names>D</given-names></name><name name-style="western"><surname>Andraska</surname><given-names>EA</given-names></name><name name-style="western"><surname>Alvikas</surname><given-names>J</given-names></name><name name-style="western"><surname>Raghunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Masters</surname><given-names>NA</given-names></name><etal/></person-group>. <article-title>Nanomedicine platform for targeting activated neutrophils and neutrophil&#8211;platelet complexes using an &#945;1-antitrypsin-derived peptide motif</article-title>. <source>Nat Nanotechnol</source> (<year>2022</year>) <volume>17</volume>:<page-range>1004&#8211;14</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41565-022-01161-w</pub-id><pub-id pub-id-type="pmcid">PMC9909445</pub-id><pub-id pub-id-type="pmid">35851383</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsyth</surname><given-names>S</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>A</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>P</given-names></name></person-group>. <article-title>A review and comparison of the murine &#945;1-antitrypsin and &#945;1-antichymotrypsin multigene clusters with the human clade A serpins</article-title>. <source>Genomics</source> (<year>2003</year>) <volume>81</volume>:<page-range>336&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0888-7543(02)00041-1</pub-id><pub-id pub-id-type="pmid">12659817</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#246;ls</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaisar-Iluz</surname><given-names>N</given-names></name><name name-style="western"><surname>Shaul</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ryvkin</surname><given-names>A</given-names></name><name name-style="western"><surname>Ashkenazy</surname><given-names>H</given-names></name><name name-style="western"><surname>Yehuda</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Targeted nanoparticles modify neutrophil function <italic toggle="yes">in vivo</italic>
</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1003871</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.1003871</pub-id><pub-id pub-id-type="pmid">36275643</pub-id><pub-id pub-id-type="pmcid">PMC9580275</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos Dias</surname><given-names>L</given-names></name><name name-style="western"><surname>Silva</surname><given-names>LBR</given-names></name><name name-style="western"><surname>Nosanchuk</surname><given-names>JD</given-names></name><name name-style="western"><surname>Taborda</surname><given-names>CP</given-names></name></person-group>. <article-title>Neutrophil cells are essential for the efficacy of a therapeutic vaccine against paracoccidioidomycosis</article-title>. <source>J Fungi (Basel).</source> (<year>2021</year>) <volume>7</volume>:<fpage>416</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jof7060416</pub-id><pub-id pub-id-type="pmid">34073466</pub-id><pub-id pub-id-type="pmcid">PMC8226764</pub-id></mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabro</surname><given-names>S</given-names></name><name name-style="western"><surname>Tortoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>BC</given-names></name><name name-style="western"><surname>Pacitto</surname><given-names>A</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><etal/></person-group>. <article-title>Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>1812&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.090</pub-id><pub-id pub-id-type="pmid">21215831</pub-id></mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogan</surname><given-names>SP</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>HF</given-names></name><name name-style="western"><surname>Moqbel</surname><given-names>R</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>S</given-names></name><name name-style="western"><surname>Foster</surname><given-names>PS</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Eosinophils: biological properties and role in health and disease</article-title>. <source>Clin Exp Allergy</source> (<year>2008</year>) <volume>38</volume>:<page-range>709&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2222.2008.02958.x</pub-id><pub-id pub-id-type="pmid">18384431</pub-id></mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arinobu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Gurish</surname><given-names>MF</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>S</given-names></name><name name-style="western"><surname>Shigematsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2005</year>) <volume>102</volume>:<page-range>18105&#8211;10</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0509148102</pub-id><pub-id pub-id-type="pmcid">PMC1312421</pub-id><pub-id pub-id-type="pmid">16330751</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piliponsky</surname><given-names>AM</given-names></name><name name-style="western"><surname>Shubin</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Lahiri</surname><given-names>AK</given-names></name><name name-style="western"><surname>Truong</surname><given-names>P</given-names></name><name name-style="western"><surname>Clauson</surname><given-names>M</given-names></name><name name-style="western"><surname>Niino</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice</article-title>. <source>Nat Immunol</source> (<year>2019</year>) <volume>20</volume>:<page-range>129&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-018-0288-7</pub-id><pub-id pub-id-type="pmcid">PMC6352314</pub-id><pub-id pub-id-type="pmid">30664762</pub-id></mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dellon</surname><given-names>ES</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Murray</surname><given-names>JA</given-names></name><name name-style="western"><surname>Falk</surname><given-names>GW</given-names></name><name name-style="western"><surname>Gonsalves</surname><given-names>N</given-names></name><name name-style="western"><surname>Chehade</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Anti&#8211;siglec-8 antibody for eosinophilic gastritis and duodenitis</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>383</volume>:<page-range>1624&#8211;34</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2012047</pub-id><pub-id pub-id-type="pmcid">PMC7600443</pub-id><pub-id pub-id-type="pmid">33085861</pub-id></mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nycholat</surname><given-names>CM</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S</given-names></name><name name-style="western"><surname>Knuplez</surname><given-names>E</given-names></name><name name-style="western"><surname>Worth</surname><given-names>C</given-names></name><name name-style="western"><surname>Elich</surname><given-names>M</given-names></name><name name-style="western"><surname>Yao</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A sulfonamide sialoside analogue for targeting siglec-8 and -F on immune cells</article-title>. <source>J Am Chem Soc</source> (<year>2019</year>) <volume>141</volume>:<page-range>14032&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1021/jacs.9b05769</pub-id><pub-id pub-id-type="pmcid">PMC6861165</pub-id><pub-id pub-id-type="pmid">31460762</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiwamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>N</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bochner</surname><given-names>BS</given-names></name></person-group>. <article-title>Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions</article-title>. <source>Pharmacol Ther</source> (<year>2012</year>) <volume>135</volume>:<page-range>327&#8211;36</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.06.005</pub-id><pub-id pub-id-type="pmcid">PMC3587973</pub-id><pub-id pub-id-type="pmid">22749793</pub-id></mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rillahan</surname><given-names>CD</given-names></name><name name-style="western"><surname>Macauley</surname><given-names>MS</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>E</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>McBride</surname><given-names>R</given-names></name><name name-style="western"><surname>Arlian</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas</article-title>. <source>Chem Sci</source> (<year>2014</year>) <volume>5</volume>:<fpage>2398</fpage>. doi: <pub-id pub-id-type="doi">10.1039/c4sc00451e</pub-id><pub-id pub-id-type="pmid">24921038</pub-id><pub-id pub-id-type="pmcid">PMC4048721</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>S</given-names></name><name name-style="western"><surname>Koziol-White</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Jester</surname><given-names>WF</given-names></name><name name-style="western"><surname>Nycholat</surname><given-names>CM</given-names></name><name name-style="western"><surname>Macauley</surname><given-names>MS</given-names></name><name name-style="western"><surname>Panettieri</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen</article-title>. <source>J Clin Invest</source> (<year>2019</year>) <volume>129</volume>:<page-range>1387&#8211;401</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI125456</pub-id><pub-id pub-id-type="pmcid">PMC6391081</pub-id><pub-id pub-id-type="pmid">30645205</pub-id></mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbs</surname><given-names>BF</given-names></name><name name-style="western"><surname>Yasinska</surname><given-names>IM</given-names></name><name name-style="western"><surname>Calzolai</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilliland</surname><given-names>D</given-names></name><name name-style="western"><surname>Sumbayev</surname><given-names>VV</given-names></name></person-group>. <article-title>Highly specific targeting of human leukocytes using gold nanoparticle-based biologically active conjugates</article-title>. <source>J Biomed Nanotechnology</source> (<year>2014</year>) <volume>10</volume>:<page-range>1259&#8211;66</page-range>. doi: <pub-id pub-id-type="doi">10.1166/jbn.2014.1807</pub-id><pub-id pub-id-type="pmid">24804546</pub-id></mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasinska</surname><given-names>IM</given-names></name><name name-style="western"><surname>Calzolai</surname><given-names>L</given-names></name><name name-style="western"><surname>Raap</surname><given-names>U</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>R</given-names></name><name name-style="western"><surname>Siligardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Sumbayev</surname><given-names>VV</given-names></name><etal/></person-group>. <article-title>Targeting of basophil and mast cell pro-allergic reactivity using functionalised gold nanoparticles</article-title>. <source>Front Pharmacol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>333</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2019.00333</pub-id><pub-id pub-id-type="pmid">30984005</pub-id><pub-id pub-id-type="pmcid">PMC6449467</pub-id></mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Read</surname><given-names>BJ</given-names></name></person-group>. <article-title>Shaping humoral immunity to vaccines through antigen-displaying nanoparticles</article-title>. <source>Curr Opin Immunol</source> (<year>2020</year>) <volume>65</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coi.2020.01.007</pub-id><pub-id pub-id-type="pmid">32200132</pub-id><pub-id pub-id-type="pmcid">PMC7501207</pub-id></mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group>. <article-title>Lymph node targeting strategies to improve vaccination efficacy</article-title>. <source>J Controlled Release</source> (<year>2017</year>) <volume>267</volume>:<fpage>47</fpage>&#8211;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.08.009</pub-id><pub-id pub-id-type="pmid">28818619</pub-id></mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdallah</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#252;llertz</surname><given-names>OO</given-names></name><name name-style="western"><surname>Styles</surname><given-names>IK</given-names></name><name name-style="western"><surname>M&#246;rsdorf</surname><given-names>A</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>JF</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>Lymphatic targeting by albumin-hitchhiking: Applications and optimisation</article-title>. <source>J Controlled Release</source> (<year>2020</year>) <volume>327</volume>:<page-range>117&#8211;28</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.046</pub-id><pub-id pub-id-type="pmid">32771478</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>ST</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>JA</given-names></name></person-group>. <article-title>Targeting dendritic cells with biomaterials: developing the next generation of vaccines</article-title>. <source>Trends Immunol</source> (<year>2006</year>) <volume>27</volume>:<page-range>573&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2006.10.005</pub-id><pub-id pub-id-type="pmid">17049307</pub-id></mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCright</surname><given-names>J</given-names></name><name name-style="western"><surname>Naiknavare</surname><given-names>R</given-names></name><name name-style="western"><surname>Yarmovsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Maisel</surname><given-names>K</given-names></name></person-group>. <article-title>Targeting lymphatics for nanoparticle drug delivery</article-title>. <source>Front Pharmacol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>887402</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.887402</pub-id><pub-id pub-id-type="pmid">35721179</pub-id><pub-id pub-id-type="pmcid">PMC9203826</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swartz</surname><given-names>M</given-names></name></person-group>. <article-title>The physiology of the lymphatic system</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2001</year>) <volume>50</volume>:<fpage>3</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0169-409X(01)00150-8</pub-id><pub-id pub-id-type="pmid">11489331</pub-id></mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name></person-group>. <article-title>Eliciting B cell immunity against infectious diseases using nanovaccines</article-title>. <source>Nat Nanotechnol.</source> (<year>2021</year>) <volume>16</volume>:<fpage>16</fpage>&#8211;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41565-020-00790-3</pub-id><pub-id pub-id-type="pmid">33199883</pub-id><pub-id pub-id-type="pmcid">PMC7855692</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Tenzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Storck</surname><given-names>W</given-names></name><name name-style="western"><surname>Hobernik</surname><given-names>D</given-names></name><name name-style="western"><surname>Raker</surname><given-names>VK</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Protein corona&#8211;mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses</article-title>. <source>J Allergy Clin Immunol</source> (<year>2018</year>) <volume>142</volume>:<page-range>1558&#8211;70</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2017.08.049</pub-id><pub-id pub-id-type="pmid">29382591</pub-id></mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>T</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>H</given-names></name></person-group>. <article-title>Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon</article-title>. <source>Immunobiology</source> (<year>2013</year>) <volume>218</volume>:<page-range>725&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.imbio.2012.08.274</pub-id><pub-id pub-id-type="pmid">22995937</pub-id></mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Mima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ukawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ando</surname><given-names>H</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells</article-title>. <source>Immunobiology</source> (<year>2015</year>) <volume>220</volume>:<page-range>1151&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.imbio.2015.06.005</pub-id><pub-id pub-id-type="pmid">26095176</pub-id></mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Abu Lila</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimazaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mima</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A novel platform for cancer vaccines: antigen-selective delivery to splenic marginal zone B cells <italic toggle="yes">via</italic> repeated injections of PEGylated liposomes</article-title>. <source>J Immunol</source> (<year>2018</year>) <volume>201</volume>:<page-range>2969&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1701351</pub-id><pub-id pub-id-type="pmid">30333124</pub-id></mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Awata</surname><given-names>M</given-names></name><name name-style="western"><surname>Abu Lila</surname><given-names>AS</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>C</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ando</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes</article-title>. <source>J Controlled Release.</source> (<year>2021</year>) <volume>329</volume>:<page-range>1046&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.033</pub-id><pub-id pub-id-type="pmid">33080272</pub-id></mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temchura</surname><given-names>VV</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>D</given-names></name><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>&#220;berla</surname><given-names>K</given-names></name><name name-style="western"><surname>Epple</surname><given-names>M</given-names></name></person-group>. <article-title>Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen</article-title>. <source>Biomaterials</source> (<year>2014</year>) <volume>35</volume>:<page-range>6098&#8211;105</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.010</pub-id><pub-id pub-id-type="pmid">24776487</pub-id></mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zilker</surname><given-names>C</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>D</given-names></name><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Epple</surname><given-names>M</given-names></name><name name-style="western"><surname>&#220;berla</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Nanoparticle-based B-cell targeting vaccines: Tailoring of humoral immune responses by functionalization with different TLR-ligands</article-title>. <source>Nanomedicine: Nanotechnology Biol Med</source> (<year>2017</year>) <volume>13</volume>:<page-range>173&#8211;82</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.nano.2016.08.028</pub-id><pub-id pub-id-type="pmid">27593489</pub-id></mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JYH</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Watson</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Engineered immunogen binding to alum adjuvant enhances humoral immunity</article-title>. <source>Nat Med</source> (<year>2020</year>) <volume>26</volume>:<page-range>430&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41591-020-0753-3</pub-id><pub-id pub-id-type="pmcid">PMC7069805</pub-id><pub-id pub-id-type="pmid">32066977</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>RH</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>DT</given-names></name></person-group>. <article-title>CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes</article-title>. <source>Science</source> (<year>1992</year>) <volume>256</volume>:<page-range>105&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1373518</pub-id><pub-id pub-id-type="pmid">1373518</pub-id></mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fearon</surname><given-names>DT</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>MC</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>MC</given-names></name></person-group>. <article-title>Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex</article-title>. <source>Annu Rev Immunol</source> (<year>2000</year>) <volume>18</volume>:<fpage>393</fpage>&#8211;<lpage>422</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.393</pub-id><pub-id pub-id-type="pmid">10837064</pub-id></mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Unternaehrer</surname><given-names>J</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I</given-names></name><name name-style="western"><surname>Mamula</surname><given-names>MJ</given-names></name></person-group>. <article-title>Targeting antigen to CD19 on B cells efficiently activates T cells</article-title>. <source>Int Immunol</source> (<year>2005</year>) <volume>17</volume>:<page-range>869&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxh266</pub-id><pub-id pub-id-type="pmid">15967786</pub-id></mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Targeting of antigens to B lymphocytes <italic toggle="yes">via</italic> CD19 as a means for tumor vaccine development</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>190</volume>:<page-range>5588&#8211;99</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1203216</pub-id><pub-id pub-id-type="pmcid">PMC3660458</pub-id><pub-id pub-id-type="pmid">23630363</pub-id></mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Marroquin</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name></person-group>. <article-title>Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>:<page-range>2817&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2008-05-157396</pub-id><pub-id pub-id-type="pmcid">PMC2556617</pub-id><pub-id pub-id-type="pmid">18669871</pub-id></mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>TK</given-names></name><name name-style="western"><surname>Huszthy</surname><given-names>PC</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>RP</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Fauskanger</surname><given-names>M</given-names></name><name name-style="western"><surname>Tveita</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules</article-title>. <source>NPJ Vaccines</source> (<year>2019</year>) <volume>4</volume>:<fpage>9</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-019-0101-0</pub-id><pub-id pub-id-type="pmid">30775000</pub-id><pub-id pub-id-type="pmcid">PMC6370881</pub-id></mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinke</surname><given-names>DM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>TK</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>RP</given-names></name><name name-style="western"><surname>Skullerud</surname><given-names>LM</given-names></name><name name-style="western"><surname>Werninghaus</surname><given-names>IC</given-names></name><name name-style="western"><surname>Gr&#248;deland</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses</article-title>. <source>Cell Rep</source> (<year>2022</year>) <volume>39</volume>:<fpage>110901</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2022.110901</pub-id><pub-id pub-id-type="pmid">35649357</pub-id></mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Nierop</surname><given-names>K</given-names></name></person-group>. <article-title>Human follicular dendritic cells: function, origin and development</article-title>. <source>Semin Immunol</source> (<year>2002</year>) <volume>14</volume>:<page-range>251&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1044-5323(02)00057-X</pub-id><pub-id pub-id-type="pmid">12163300</pub-id></mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranich</surname><given-names>J</given-names></name><name name-style="western"><surname>Krautler</surname><given-names>NJ</given-names></name></person-group>. <article-title>How follicular dendritic cells shape the B-cell antigenome</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<elocation-id>225</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00225</pub-id><pub-id pub-id-type="pmid">27446069</pub-id><pub-id pub-id-type="pmcid">PMC4914831</pub-id></mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>BA</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-A</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>SF</given-names></name><name name-style="western"><surname>Kuligowski</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kirchhausen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>38</volume>:<page-range>1164&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.023</pub-id><pub-id pub-id-type="pmcid">PMC3773956</pub-id><pub-id pub-id-type="pmid">23770227</pub-id></mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>BA</given-names></name><name name-style="western"><surname>Myers</surname><given-names>RC</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>MC</given-names></name></person-group>. <article-title>Follicular dendritic cells: dynamic antigen libraries</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<fpage>495</fpage>&#8211;<lpage>504</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3689</pub-id><pub-id pub-id-type="pmid">24948364</pub-id></mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y-N</given-names></name><name name-style="western"><surname>Lazarovits</surname><given-names>J</given-names></name><name name-style="western"><surname>Poon</surname><given-names>W</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>B</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>LNM</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity</article-title>. <source>Nano Lett</source> (<year>2019</year>) <volume>19</volume>:<page-range>7226&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1021/acs.nanolett.9b02834</pub-id><pub-id pub-id-type="pmid">31508968</pub-id></mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Yrlid</surname><given-names>U</given-names></name><name name-style="western"><surname>Stensson</surname><given-names>A</given-names></name><name name-style="western"><surname>Sch&#246;n</surname><given-names>K</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MCI</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>JV</given-names></name><etal/></person-group>. <article-title>Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<page-range>3641&#8211;52</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1101107</pub-id><pub-id pub-id-type="pmid">21880985</pub-id></mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schussek</surname><given-names>S</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>V</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>UA</given-names></name><name name-style="western"><surname>Str&#246;mberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Gribonika</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization</article-title>. <source>Mucosal Immunol</source> (<year>2020</year>) <volume>13</volume>:<page-range>545&#8211;57</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41385-020-0253-2</pub-id><pub-id pub-id-type="pmcid">PMC7223721</pub-id><pub-id pub-id-type="pmid">31959882</pub-id></mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aung</surname><given-names>A</given-names></name><name name-style="western"><surname>Cui</surname><given-names>A</given-names></name><name name-style="western"><surname>Maiorino</surname><given-names>L</given-names></name><name name-style="western"><surname>Amini</surname><given-names>AP</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>JR</given-names></name><name name-style="western"><surname>BuKenya</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Low protease activity in B cell follicles promotes retention of intact antigens after immunization</article-title>. <source>Science</source> (<year>2023</year>) <volume>379</volume>:<elocation-id>eabn8934</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/science.abn8934</pub-id><pub-id pub-id-type="pmid">36701450</pub-id><pub-id pub-id-type="pmcid">PMC10041875</pub-id></mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamburini</surname><given-names>BA</given-names></name><name name-style="western"><surname>Burchill</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kedl</surname><given-names>RM</given-names></name></person-group>. <article-title>Antigen capture and archiving by lymphatic endothelial cells following vaccination or viral infection</article-title>. <source>Nat Commun</source> (<year>2014</year>) <volume>5</volume>:<fpage>3989</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms4989</pub-id><pub-id pub-id-type="pmid">24905362</pub-id><pub-id pub-id-type="pmcid">PMC4073648</pub-id></mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedl</surname><given-names>RM</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>RS</given-names></name><name name-style="western"><surname>Finlon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>ED</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Tamburini</surname><given-names>BAJ</given-names></name></person-group>. <article-title>Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction</article-title>. <source>Nat Commun</source> (<year>2017</year>) <volume>8</volume>:<fpage>2034</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-017-02247-z</pub-id><pub-id pub-id-type="pmid">29229919</pub-id><pub-id pub-id-type="pmcid">PMC5725486</pub-id></mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>RM</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>ED</given-names></name><name name-style="western"><surname>Doan</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ware</surname><given-names>BC</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Molecular tracking devices quantify antigen distribution and archiving in the murine lymph node</article-title>. <source>eLife</source> (<year>2021</year>) <volume>10</volume>:<elocation-id>e62781</elocation-id>. doi: <pub-id pub-id-type="doi">10.7554/eLife.62781</pub-id><pub-id pub-id-type="pmid">33843587</pub-id><pub-id pub-id-type="pmcid">PMC8116055</pub-id></mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vokali</surname><given-names>E</given-names></name><name name-style="western"><surname>Yu</surname><given-names>SS</given-names></name><name name-style="western"><surname>Hirosue</surname><given-names>S</given-names></name><name name-style="western"><surname>Rin&#231;on-Restrepo</surname><given-names>M</given-names></name><name name-style="western"><surname>Duraes</surname><given-names>FV</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lymphatic endothelial cells prime na&#239;ve CD8<sup>+</sup> T cells into memory cells under steady-state conditions</article-title>. <source>Nat Commun</source> (<year>2020</year>) <volume>11</volume>:<fpage>538</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-019-14127-9</pub-id><pub-id pub-id-type="pmid">31988323</pub-id><pub-id pub-id-type="pmcid">PMC6985113</pub-id></mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tewalt</surname><given-names>EF</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JN</given-names></name><name name-style="western"><surname>Rouhani</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Fahl</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Lymphatic endothelial cells induce tolerance <italic toggle="yes">via</italic> PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>:<page-range>4772&#8211;82</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-04-427013</pub-id><pub-id pub-id-type="pmcid">PMC3520619</pub-id><pub-id pub-id-type="pmid">22993390</pub-id></mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouhani</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Eccles</surname><given-names>JD</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>P</given-names></name><name name-style="western"><surname>Peske</surname><given-names>JD</given-names></name><name name-style="western"><surname>Tewalt</surname><given-names>EF</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JN</given-names></name><etal/></person-group>. <article-title>Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>6771</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms7771</pub-id><pub-id pub-id-type="pmid">25857745</pub-id><pub-id pub-id-type="pmcid">PMC4403767</pub-id></mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubrot</surname><given-names>J</given-names></name><name name-style="western"><surname>Duraes</surname><given-names>FV</given-names></name><name name-style="western"><surname>Potin</surname><given-names>L</given-names></name><name name-style="western"><surname>Capotosti</surname><given-names>F</given-names></name><name name-style="western"><surname>Brighouse</surname><given-names>D</given-names></name><name name-style="western"><surname>Suter</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Lymph node stromal cells acquire peptide&#8211;MHCII complexes from dendritic cells and induce antigen-specific CD4<sup>+</sup> T cell tolerance</article-title>. <source>J Exp Med</source> (<year>2014</year>) <volume>211</volume>:<page-range>1153&#8211;66</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20132000</pub-id><pub-id pub-id-type="pmcid">PMC4042642</pub-id><pub-id pub-id-type="pmid">24842370</pub-id></mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humbert</surname><given-names>M</given-names></name><name name-style="western"><surname>Hugues</surname><given-names>S</given-names></name><name name-style="western"><surname>Dubrot</surname><given-names>J</given-names></name></person-group>. <article-title>Shaping of peripheral T cell responses by lymphatic endothelial cells</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>684</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00684</pub-id><pub-id pub-id-type="pmid">28127298</pub-id><pub-id pub-id-type="pmcid">PMC5226940</pub-id></mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurty</surname><given-names>AT</given-names></name><name name-style="western"><surname>Turley</surname><given-names>SJ</given-names></name></person-group>. <article-title>Lymph node stromal cells: cartographers of the immune system</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>21</volume>:<page-range>369&#8211;80</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-020-0635-3</pub-id><pub-id pub-id-type="pmid">32205888</pub-id></mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Pierie</surname><given-names>C</given-names></name><name name-style="western"><surname>Mebius</surname><given-names>RE</given-names></name><name name-style="western"><surname>van Baarsen</surname><given-names>LGM</given-names></name></person-group>. <article-title>Lymph node stromal cells: subsets and functions in health and disease</article-title>. <source>Trends Immunol</source> (<year>2021</year>) <volume>42</volume>:<page-range>920&#8211;36</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2021.08.009</pub-id><pub-id pub-id-type="pmid">34521601</pub-id></mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Ke</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Ke</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Yi</given-names></name></person-group>. <article-title>Mouse lymphatic endothelial cell targeted probes: anti-LYVE-1 antibody-based magnetic nanoparticles</article-title>. <source>Int J Nanomed 2273</source> (<year>2013</year>) <volume>8</volume>:<fpage>2273</fpage>&#8211;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IJN.S45817</pub-id><pub-id pub-id-type="pmcid">PMC3693816</pub-id><pub-id pub-id-type="pmid">23818783</pub-id></mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>A dual targeting magnetic nanoparticle for human cancer detection</article-title>. <source>Nanoscale Res Lett</source> (<year>2019</year>) <volume>14</volume>:<fpage>228</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s11671-019-3049-0</pub-id><pub-id pub-id-type="pmid">31289961</pub-id><pub-id pub-id-type="pmcid">PMC6616609</pub-id></mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>M</given-names></name><name name-style="western"><surname>Nadler</surname><given-names>SG</given-names></name></person-group>. <article-title>Immunogenicity to biotherapeutics &#8211; the role of anti-drug immune complexes</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<elocation-id>21</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00021</pub-id><pub-id pub-id-type="pmid">26870037</pub-id><pub-id pub-id-type="pmcid">PMC4735944</pub-id></mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaisman-Mentesh</surname><given-names>A</given-names></name><name name-style="western"><surname>Gutierrez-Gonzalez</surname><given-names>M</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Wine</surname><given-names>Y</given-names></name></person-group>. <article-title>The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1951</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01951</pub-id><pub-id pub-id-type="pmid">33013848</pub-id><pub-id pub-id-type="pmcid">PMC7461797</pub-id></mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansel</surname><given-names>TT</given-names></name><name name-style="western"><surname>Kropshofer</surname><given-names>H</given-names></name><name name-style="western"><surname>Singer</surname><given-names>T</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>JA</given-names></name><name name-style="western"><surname>George</surname><given-names>AJT</given-names></name></person-group>. <article-title>The safety and side effects of monoclonal antibodies</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2010</year>) <volume>9</volume>:<page-range>325&#8211;38</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrd3003</pub-id><pub-id pub-id-type="pmid">20305665</pub-id></mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolbink</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Aarden</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dijkmans</surname><given-names>B</given-names></name></person-group>. <article-title>Dealing with immunogenicity of biologicals: assessment and clinical relevance</article-title>. <source>Curr Opin Rheumatol</source> (<year>2009</year>) <volume>21</volume>:<page-range>211&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.1097/BOR.0b013e328329ed8b</pub-id><pub-id pub-id-type="pmid">19399992</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>